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Chapter 1 
General Introduction 
 
Lipids exert a wide variety of biological functions, like storing energy and signaling.  Since the membrane of 
cell, which is the basic unit of all organs, is consisted of lipid bilayer, the importance of lipids admits of no 
doubt.  Recently, the gene arrangement of a large variety of organism have been revealed, and advancement of 
technology of proteomics
1,2
 enables us to understand the functions, structures and interactions of proteins.  On 
the other hand, lipids still remain largely unknown, therefore they receive a lot of attention and many studies 
are performed to investigate their functions and biological roles.  The difficulties of studying lipids would 
come from their low solubility to water and low stability of their natural ligands to light and oxygen.  
Therefore the establishment of new synthetic method that is efficient and flexible to synthesize natural ligands 
and their analogues, and development of stable ligands are necessary to promote lipids research and understand 
the biological and pharmacological roles of lipids.  
Prostaglandins are one of the most well-known lipid mediators.  A fair amount of researches have been 
already reported relating to prostaglandins, one of the most important research was performed by Corey et al. in 
1969
3
. They established efficient, diverse and economical synthetic method of prostaglandins and his works 
made an enormous step forward of prostaglandin research.  Actually, PGF2, PGE2 and PGE1 were on the 
market in 1974 as labor induction agents or drugs for improvement of blood circulation.  Moreover, his 
synthetic strategy is still widely applied in prostaglandin research. 
Therefore the author aimed to develop new synthetic methods of lipid mediators and discover useful tool 
compounds for further development of lipid research.  In this thesis, the author will report discovery of G 
protein-biased and highly subtype selective novel EP2 receptor agonists and the first total syntheses of resolvin 
E2 and haterumalide NA methyl ester. 
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1) Discovery of G protein-biased EP2 agonists. 
Prostaglandin E2 is an oxygenated metabolite of arachidonic acid, which is a polyunsaturated ω-6 fatty acid, 
and exerts a wide variety of biological actions through four receptor subtypes, EP1-EP4, in various tissues.  
EPs are a family of prostanoid recepters of progtaglandin E type and belong to G protein-coupled recepter 
(GPCR) which are also known as seven taransmembrane receptors and control the biological action through G 
protein-mediated signaling. EP1-4 receptors have been already cloned and subtype selective ligands (agonists 
or anatgonists) of EPs have been developed and used to evaluate a biological role of each receptors.  EP2 
receptor has been characterized by a relaxation of blood vessels.
4
  Furthermore, EP2 receptor plays important 
roles in production of cytokines and bone metabolisms by the production of cyclic adenosine monophosphate 
(cAMP).
5,6
  A number of EP2 agonists have been previously reported.  PGE2 analogue, butaprost (1)
7
 is 
well-known as a selective EP2 agonist and widely utilized as a chemical tool compound in many studies for 
investigation of pharmacological activities mediated by EP2 receptor.  In the previous studies, ONO 
Pharmaceutical developed a highly selective and chemically stable EP2 agonist as 2
8
, which is also a good tool 
compound for EP2 receptor.  A number of non-prostanoid scaffolds of EP2 agonists were also reported to 
show potent EP2 agonist activities (i.e. PF-4217329 (3)
9
 and 4
10
) (Figure 1-1).   
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Figure 1-1. Reported EP2 agonists 
Up to the present time, however, there is no EP2 agonist that is approved for clinical use.  Although the true 
reasons of suspension of clinical trials of EP2 agonists were not clear, the author assume that variety biological 
actions induced by EP2 agonists cause crucial side effects for crinical use.  Therefore, the author focused on 
the biased ligand of GPCRs to develop the next generation EP2 agonists. 
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Recently, biased ligands receive a fair amount of attention in drug discovery,
11
 because they have a potential to 
remove on-target adverse effect and also enhance efficacy.  In addition to G protein signaling, GPCRs can also 
activate other distinct signaling pathways, like β arrestin-mediated signaling.  GPCR biased ligands are 
compounds that selectively engage some signals withour activation of other signals mediated by the same 
receptor. 
A number of studies were performed to understand biological roles of G protein- and β arrestin-mediated 
signalings of EP2 receptor.  In the brain, EP2 receptor modulates beneficial neuroprotective effects in acute 
models of excitoxicity though G protein-mediated cAMP-PKA signaling.
12-15
  On the other hand, the 
activation of β arrestin-mediated signaling of EP2 receptor led to deleterious effects, like tumorigenesis and 
angiogenesis.
16-18
  Therefore, the author supposed that G protein-biased ligands of EP2 receptor have a 
potential to be a new generation of EP2 agonists that particularly increase the efficacy and avoid deleterious 
effect of EP2 receptor. 
To identify G protein-biased and highly subtype-selective EP2 agonists, a series of bicyclic prostaglandin 
analogues were designed and synthesized.  Structural hybridization of EP2/4 dual agonist 5 and prostacyclin 
analog 6, followed by simplification of ω chain led the author to find novel EP2 agonists with a unique 
prostacyclin-like scaffold.  Further optimization of ω chain was performed to improve EP2 agonist activity 
and subtype selectivity.  Phenoxy derivative 7 showed potent agonist activity and excellent subtype selectivity, 
furthermore a series of compounds were identified as G protein-biased EP2 receptor agonists.  The discovery 
of novel G protein-biased EP2 agonists as well as structure functional selectivity relationship will be discussed 
in Chapter 2-1. 
N
O
S
S
N
OH
CO
2
H
O
CO
2
H
O
OHOH
O
OH
N
S
CO
2
H
O
+
5 6 7
function
hEP2 cAMP
hEP2 βarrestin
hEP1
hEP3
hEP4
hFP
hIP
13nM
>10000nM
>10000nM
>10000nM
>10000nM
>10000nM
>10000nM
  
Figure 1-2. Discovery of G protein-biased ligand 7 
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 Further optimization of novel G protein-biased EP2 agonist 7 was undertaken to improve G protein activity 
and investigate structure functional selectivity relationship (SFSR).  Optimization of substituents on the 
phenyl group, followed by modification of 11-OH led the author find 8 with 100-fold increase in G protein 
signaling without increase of β arrestin activity relative to 7.  Furthermore, SFSR studies revealed that the 
combination of meta and para substituents on the phenyl moiety was crucial to regulate its functional 
selectivity.  The synthesis of a series of these derivatives and detail structure-activity relationship and structure 
functional selectivity relationship will be also discussed in Chapter 2-2. 
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Figure 1-3. Optimization of G protein-biased ligands 
 
2) Total synthesis and bioactivity of Resolvin E2 
Prostaglandins derived from arachidonic acid (AA), ω-6 polyunsaturated fatty acids, are well-known as 
inflammatory mediators.  On the other hand, resolvins are new family of lipid mediators derived from ω-3 
polyunsaturated fatty acids, like eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and they are 
generated during the resolution phase of acute inflammation.
19
  A number of resolvins have been identified 
and they exert a wide variety of biological actions in various tissues.  Resolvin E1 is biosynthesized from EPA 
via cyclooxygenase (COX)-2- and 5-lipoxygenase-mediated conversion and has been shown to possess 
significant anti-inflammatory and proresolution properties, thereby protecting organs from collateral damage.
20
  
Another E series resolvin, namely, resolvin E2 (1), is formed via reduction of 5S-hydroperoxy-18R-hydroxy- 
EPE, an intermediate in the biosynthesis of resolvin E1, and exhibits potent anti-inflammatory properties in 
murine peritonitis.
21
  It has been hypothesized that these E series resolvins contribute to the beneficial actions 
6 
 
that have been attributed to EPA in certain human diseases, particularly those in which inflammation is 
suspected as a key component in pathogenesis.  Motivated by their therapeutic potential for new treatment of 
human disorders associated with aberrant inflammation, the author launched the synthetic studies of resolvins 
as well as other lipid mediators.  In Chapter3, the author will report an efficient total synthesis of resolvin E2 
by taking advantage of its intrinsic pseudoenantiomeric substructures and using a torquoselective thermal 
electrocyclic ring-opening reaction of cyclobutene aldehydes 4 and 5 for constructing the E,Z-olefins at C6 of 2 
and C17 of 3 (Figure 1-4).  The biological activities of synthetic resolving E2 will be also shown in this 
Chapter. 
 
Figure 1-4. Synthetic strategy of resolvin E2 
 
3) Enantioselective Synthesis of Haterumalide NA Methyl Ester and Revised Structure of Haterumalide 
NA.  
A number of bioactive natural products isolated from marine organisms have received a fair amount of 
attentions for drug discovery because of their potent and unique biological activities.  Recently, exploratory 
research using halichondrin B
22
, which was isolated from Halichondrail okadai, as a lead compound was 
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performed to discovery a new anti-cancer drug by Kishi et al. and Eisai Co.  Precise SAR studies of 
halichondrin B led to discovery of Halaven, which is used as anti-cancer agent in clinical from 2010.
23-25
   
 
            
Figure 1-5. Structure of halichondrin B and halaven 
 
The author focused on haterumalide NA
26
 which was isolated from the Okinawan sponge Ircinia sp.  
Haterumalide NA has a 14-membered macrolide moiety (long fatty acid derivative) and exerts moderate 
cytotoxicity to mouse P388 leukemia cell and acute toxicity to ddY mouse.  The structurally-related 
haterumalide B
27
 and oocydin A
28
 were isolated from an Okinawan ascidian and a South American epiphyte, 
respectively, and their stereostructures have not been fully established. 
 
  
Figure 1-6. Structure of haterumalide NA and oocydin A 
 
The author launched the synthetic study of haterumalide NA to identify the absolute stereochemistry and 
supply samples to perform further biological studies.  The enantioselective synthesis of haterumalide NA 
methyl ester by using the stereoselective construction of a chloroolefin unit and the intramolecular 
Reformatsky-type reaction will be discussed in Chapter 4.  
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Chapter 2-1 
Discovery of G protein-biased EP2 receptor agonists 
 
Abstract:  
To identify G protein-biased and highly subtype-selective EP2 receptor agonists, a series of bicyclic 
prostaglandin analogues were designed and synthesized.  Structural hybridization of EP2/4 dual agonist 5 and 
prostacyclin analog 6, followed by simplification of the ω chain enabled the author to discover novel EP2 
agonists with a unique prostacyclin-like scaffold. Further optimization of the ω chain was performed to improve 
EP2 agonist activity and subtype selectivity. Phenoxy derivative 27a showed potent agonist activity and 
excellent subtype selectivity.  Furthermore, a series of compounds were identified as G protein-biased EP2 
receptor agonists.  These are the first examples of biased ligands of prostanoid receptors. 
 
 
Figure 2-1-1. Outline of Chapter2-1 
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Introduction 
 
Prostaglandin E2 (PGE2) is an oxygenated metabolite of arachidonic acid that exerts a wide variety of 
biological actions through four receptor subtypes, EP1–EP4, in various tissues, which are G protein-coupled 
recepter (GPCR), in which their ligands induce signaling through G protein activation.  The EP2 receptor has 
been characterized by relaxation of blood vessels.
1
  Furthermore, EP2 receptor plays important roles in 
cytokine production and bone metabolism.
2,3
  It has also been reported that activation of EP2 receptor led to 
neuroprotective effects in ischemic stroke models.
4-8
  EP2 receptor receives a lot of attention as a therapeutic 
target for various diseases. 
 
 
Figure 2-1-2. Reported EP2 agonists 
 
A number of EP2 agonists have previously been reported.
9–15
  The PGE2 analogue, butaprost (1), is well 
known as a selective EP2 agonist, and is widely used as a chemical tool compound in many studies on 
pharmacological activities mediated by EP2 receptor.  In previous studies, ONO Pharmaceutical developed the 
highly selective and chemically stable EP2 agonist, 2,
10
 which is a good tool compound for EP2 receptor.  A 
number of non-prostanoid scaffolds of EP2 agonists have also been reported to show a potent EP2 agonist 
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activity (for example, PF-4217329 (3)
13
 and 4
15
).  In recent studies by Pfizer, PF-4217329 (3), an isopropyl 
ester, showed remarkable intraocular pressure-lowering effects in primary open-angle glaucoma and ocular 
hypertension.
16
    To date, however, there is no EP2 agonist that is approved for clinical use. Although the 
true reasons for the suspension of clinical trials of EP2 agonists are not clear, the author assumes that a variety 
of biological actions induced by EP2 agonists caused crucial side effects for clinical use. 
Recently, biased ligands have received a fair amount of attention in drug discovery,
17-22
 because they have the 
potential to suppress on-target adverse effects and enhance efficacy.  In addition to G protein signaling, G 
protein-coupled receptors (GPCRs) can activate other distinct signaling pathways, like β arrestin-mediated 
signaling.  GPCR-biased ligands are compounds that selectively engage some signals without activation of 
other signals mediated by the same receptor.  A number of studies have been performed to investigate the 
biological roles of G protein- and β arrestin-mediated EP2 receptor signaling.  In the brain, EP2 receptor 
modulates beneficial neuroprotective effects in acute models of excitotoxicity through G protein-mediated 
cAMP-PKA signaling.
4,5,23,24
  Conversely, activation of β arrestin-mediated EP2 receptor signaling led to 
deleterious effects, like tumorigenesis and angiogenesis.
25-27
  Therefore, the author hypothesized that G 
protein-biased ligands of EP2 receptor have the potential to be next generation EP2 agonists that will overcome 
the clinical problems of previously reported EP2 agonists.  To the best of the author’s knowledge, there is no 
report of biased ligands of prostanoid receptors.  Moreover, the author performed screening of in-house EP2 
agonists and failed to identify G protein-biased agonists. As the compounds the author evaluated have a similar 
structure to PGE2, the author aimed to discover G protein-biased EP2 agonists by design and investigation of a 
new scaffold. In this report, the author describes the discovery of novel, highly selective EP2 agonists with a 
unique bicyclic scaffold, which were identified as G protein-biased EP2 agonists.  The functional selectivity 
and signaling bias of the compounds are also discussed. 
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Results and discussion 
 
Identification of initial lead compound 
First, to identify novel subtype-selective EP2 agonists with a new scaffold, the author focused on EP2/EP4 
dual agonist 5.  In ONO’s previous study
28
, the thiazole group of 5 was one of the key substructures to 
increase EP2 agonist activity.  Introduction of a thiazole group into various reported scaffolds seemed to 
contribute to the development of novel and potent EP2 agonists.  Chemically stable prostacyclin analogue 6,
29
 
which has been reported by the Upjohn group in the 1970s, showed very weak EP2 agonist activity (EC50 = 
8900 nM).  The author designed and synthesized compound 7 with a bicyclic scaffold by hybridization of 6 
and the thiazole moiety of 5 (Figure 2-1-3).  The resulting 7 exhibited remarkably potent EP2 agonist activity 
as the author expected, however, it also showed potent agonist activity toward the other receptor subtypes, 
especially EP1 and EP3 (Table 2-1-1).  To increase the subtype selectivity, the author next focused on the ω 
chain of 7. 
Because all the natural prostanoids (for example, PGE2, PGI2, and PGF2) have a hydroxyl group at a 
particular position in the ω chain, which is supposed to be a crucial moiety for exerting agonist activity toward 
PG receptors.  However, a number of non-prostanoid scaffolds of EP2 agonists without a hydroxyl group have 
been reported to show potent EP2 agonist activity (for example, 3
13
 and 4
15
).  The author hypothesized that the 
removal of the 15-hydroxyl group from compound 7 would be effective for decreasing the agonist activity 
toward all of the receptor subtypes except for EP2.  As expected, the dehydroxylated derivative 8 dramatically 
improved the subtype selectivity without any loss of EP2 agonist activity.  As a result of the preliminary 
modification, compound 8 was identified as an initial lead compound that is a highly selective EP2 agonist. 
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Figure 2-1-3. Design of novel EP2 agonists with unique bicyclic scaffold 
 
cmpd 
EC50(nM)
a
 
hEP1 hEP2 hEP3 hEP4 hFP hIP 
5 N.T. 5.6 3000 0.5 N.T. N.T. 
6 N.T. 8900 N.T. 4600 N.T. 47 
7 1.4 7.9 0.8 33 32 11  
8 160 3.9 260 1900 380 2500 
a
 Assay protocols are provided in the Supporting Information. EC50 values represent the mean of at two 
experiments. 
Table 2-1-1. Subtype selectivity of initial lead compounds 
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Syntheses of bicyclic derivatives 
All test compounds in Tables 2-1-1, 2 and 3 were synthesized as outlined in Schemes 2-1-1, 2 amd 3. 
Synthesis of common intermediate 14 is outlined in Scheme 2-1-1.  The protected Corey lactone 9 was 
reduced to a lactol by DIBAL, Wittig olefination of which afforded the vinyl ether 10. The vinyl ether 10 was 
transformed to lactol 11 under acidic hydrolysis conditions.  The lactol 11 was treated with acetic anhydride, 
and the resulting diacetate was transformed to 12 by introducing a cyano group in the presence of Lewis acid 
catalyst as a diastereomeric mixture (β/α ratio = 5/1).  Thioamidation, condensation with bromopyruvate and 
cyclization by treatment with TFAA generated thiazole 13.  Deprotection of the silyl group with TBAF 
afforded the common intermediate 14.  
 
Reagents and conditions: (a) DIBAL, toluene, −78°C, (b) (methoxymethyl)(triphenyl)phosphonium chloride, 
KOtBu, THF, −78°C, 86% (2 steps), (c) AcOH, THF, H2O, 55°C, 63%, (d) Ac2O, Py, rt, (e) TMSCN, SnCl4, 
MeCN, (f) (NH4)2S, Py, 10°C, 55% (3 steps), (g) ethyl bromopyruvate, KHCO3, DME, −25°C, (h) TFAA, Py, 
−25°C, 97% (2 steps), (i) TBAF, AcOH, THF, rt, 84%. 
Scheme 2-1-1. Synthesis of common intermediate 14 
 
Julia-Kocienski reagent 17 was synthesized as outlined in Scheme 2-1-2.  Commercially available halide 15 
was treated with potassium carbonate and 1-phenyl-1H-tetrazole-5-thiol, and oxidation of the resulting sulfide 
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16 afforded compound 17.  Compounds 18 and 19 were synthesized in a similar manner using the 
corresponding halides.  
 
Reagents and conditions: (a) 1-phenyl-1H-tetrazole-5-thiol, K2CO3, acetone, 60°C, 94%, (b) 30%H2O2aq., 
Na2WO4 2H2O, PhPO(OH)2, (C8H17)3NMe HCl, rt, 71%  
Scheme 2-1-2. Synthesis of Julia-Kocienski reagents 17–19 
 
Syntheses of compounds 8, 21a and 21b are outlined in Scheme 2-1-3A.  Oxidation of the common 
intermediate 14, followed by the Julia-Kocienski reaction with reagent 17 and 18 gave compound 20a and 20b, 
respectively.  Hydrolysis of the both compounds provided compounds 8 and 21a.  Reduction of the double 
bond of 20b, followed by hydrolysis gave compound 21b. 
Syntheses of compounds 21c and 21d are outlined in Scheme 2-1-3B.  Oxidation of the common 
intermediate 14, followed by the Julia-Kocienski reaction using reagent 19 gave compound 22.  Deprotection 
of the TBS group, followed by the Mitsunobu reaction gave compound 23.  Hydrolysis provided compound 
21c.  Reduction of the double bond of 23 and hydrolysis gave compound 21d. 
Synthesis of compound 21e is outlined in Scheme 2-1-3C. Hydrolysis of 13, esterification and protection of 
the hydroxyl group by a THP moiety, followed by deprotection of the TBDPS gave alcohol 24. The resulting 
alcohol 24 was treated with Dess-Martin reagent to give an aldehyde, which was transformed to a vinyl ether by 
treatment with a phosphoylide.  Acidic hydrolysis of the vinyl ether gave compound 25.  Acetylation of the 
hydroxy group, followed by reduction of the aldehyde gave compound 26.  Introduction of a phenoxy group 
by the Mitsunobu reaction and hydrolysis provided compound 21e.  
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Syntheses of compounds 27a–n were started from commercially available phenols as outlined in Scheme 
2-1-3D.  Phenol was introduced into 14 by the Mitsunobu reaction, and the product was hydrolyzed under 
basic conditions to give 27a.  Compounds 27b–n were synthesized in a similar manner using the 
corresponding phenols. 
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20a(n=1)
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14
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13 24 25
26 21e
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14
21a(n=2)
20b(n=2)
 
Reagents and conditions: (a) Dess-Martin periodinane, CH2Cl2, 0°C, 77%, (b) 17, 18 or 19, KHMDS, DME, 
0°C, 37–66%, (c) 2 mol/L NaOHaq, DME, MeOH, 56–96%, (d) TsNHNH2, NaOAc, EtOH, H2O, 80°C, 55–
71%, (e) TBAF, THF, rt, 96% (f) DEAD, Ph3P, THF, rt, 82%, (g) i-PrI, K2CO3, DMF, rt, 54%, (h) PPTS, 
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CH2Cl2, DHP, (i) (methoxymethyl)triphenylphospine chrolide, KOtBu, THF, rt, 64%, (j) TsOH, acetone, H2O, 
rt, 78%, (k) Ac2O, Py, 82%, (l) NaBH4, THF, rt, 61% (m) phenol analogues, TMAD, Bu3P, THF, rt, 61–92% 
Scheme 2-1-3. Syntheses of compounds 8, 21a–e and 27a–n 
 
Optimization of omega chain and evaluation of functional selectivity 
Chemical modification of the ω chain was performed to further improve subtype selectivity of the initial lead 
compound 8.  As described in Table 2-1-2, 21a–e and 27a were synthesized to adjust the length between the 
cyclopentane scaffold and the phenoxy moiety, and to investigate the effect of the double bond of the ω chain. 
Compound 21a, which has a longer linker relative to 8, improved subtype selectivity to EP4 and FP receptors, 
while it showed a 3.3-fold decreased EP2 agonist activity.  Conversely, 21c with a shorter linker relative to 8 
showed potent EP2 agonist activity and improved subtype selectivity.  Reduction of the double bond of 21a 
and 21c gave 21b and 21d with 2.2 and 2.6-fold decreases in EP2 agonist activity, respectively.  Compound 
21e, with a shorter linker relative to 21c, showed the most potent EP2 agonist activity; however, it also had a 
potent EP1 agonist activity.  The shortest ω chain derivative 27a exhibited an excellent selectivity to all other 
receptor subtypes with favorable G protein activity. 
The author next investigated the functional selectivity of the newly identified EP2 agonists 8, 21a–e and 27a.  
The compounds were evaluated by the EP2-mediated β arrestin recruitment Path Hunter assay
30
 (DiscoveRX), 
to determine their functional selectivity.  Surprisingly, none of the compounds exerted full agonist activity 
toward β arrestin recruitment at 10 µM, that is, these compounds were identified as G protein-biased EP2 
agonists (see Table 2-1-2).  To the author’s knowledge, these are the first examples of biased ligands of 
prostanoid receptors. 
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a
Assay protocols are provided in the Supporting Information. EC50 values represent the mean of two 
experiments. 
Table 2-1-2. Optimization of the ω chain for functional and subtype selectivity. 
 
Structure functional selectivity relationship study of 27a 
To investigate the structure–functional selectivity relationship
19
 and improve G protein agonist activity, the 
author performed further optimization of compound 27a.  As demonstrated in Table 2-1-3 (27b–d), 
introduction of steric hindering substituents to the ortho position on the phenyl moiety improved the β arrestin 
activity, and the electron nature of the ortho substituents had a small effect on its functional selectivity.  
Introduction of 2-Cl substituent to the phenyl moiety afforded 27b, which showed a 3.9-fold increase in G 
protein activity, and it dramatically increased β arrestin recruitment.  Compound 27c, which has a 2-CF3 
substituent on the phenyl moiety, also increased the G protein activity and showed a more than 900-fold 
O
OH
R
N
S
CO
2
H
EC50(nM) Emax(%) EC50(nM) Emax(%)
8 3.9 98 >10,000 38 160 260 1900 2500 380
21a 13 91 >10,000 42 970 360 >10,000 >10,000 8600
21b 28 105 >10,000 35 N.T. N.T. N.T. N.T. N.T.
21c 3.8 96 >10,000 11 700 7600 >10,000 >10,000 >10,000
21d 10 107 >10,000 10 4200 5800 >10,000 >10,000 >10,000
21e 1.4 77 >10,000 22 97 1400 >10,000 >10,000 >10,000
27a 13 118 >10,000 28 >10,000 >10,000 >10,000 >10,000 >10,000
hEP1
EC50(nM)
hEP3
EC50(nM)
hEP4
EC50(nM)
hIP
EC50(nM)
hFP
EC50(nM)
cmpd R G protein (cAMP) β arrestin
hEP2
*
O
* O
* O
* O
* O
*
O
O*
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increase in β arrestin recruitment.  Conversely, compound 27d, which possesses a 2-F substituent, showed a 
partial G protein activity without any change in β arrestin recruitment. 
As shown in Table 2-1-3 (27e–h), introduction of meta substituents into the phenyl moiety generally improved 
G protein activity.  Additionally, steric hindrance of meta substituents on the phenyl moiety significantly 
affected the functional selectivity, that is, bulky substituents enhanced β arrestin recruitment.  Compound 27e, 
which possesses a 3-Me substituent on the phenyl moiety, was 3.6-fold more potent in G protein activity 
without an increase of β arrestin activity.  Introduction of a 3-Cl substituent gave 27f, which retained both G 
protein and β arrestin activity relative to 27a.  However, introduction of 3-OCF3 and 3-CF3 substituents gave 
27g and 27h, respectively, both of which showed a 14-fold increase in G protein activity compared with 27a.  
Additionally, 27g and 27h showed dramatically increased β arrestin activity (144-fold increase for 27g and 
1111-fold increase for 27h).  Compound 27i with a 3-F substituent retained both G protein and β arrestin 
activity relative to 27a. 
Introduction of para substituents into the phenyl moiety had little effect on the functional selectivity, namely, 
all four substituent derivatives were found to be G protein-biased EP2 agonists (see Table 2-1-3, 27j–n).  
Introduction of a 4-Me moiety (27j) slightly decreased G protein activity with no effect on β arrestin 
recruitment.  4-Cl derivative 27k showed a 3.3-fold more potent G protein activity without an increase in β 
arrestin activity.  Compound 27l, possessing bulky substituents (OCF3) at the para position, showed moderate 
G protein activity and very weak β arrestin recruitment.  In contrast to the ortho or meta position, introduction 
of a CF3 group into the para position of the phenyl moiety (27m) surprisingly lost the β arrestin activity.  
Compound 27n, possessing a less hindered fluoride at the para position, showed similar profiles to 27a 
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cmpd R1 R2 R3 
hEP2 
G protein (cAMP) β arrestin 
EC50(nM) Emax(%) EC50(nM) Emax(%) 
27a H H H 13 118 >10,000 28 
27b Cl H H 3.3 95 203 78 
27c CF3 H H 0.5 119 11 121 
27d F H H 23 59 >10,000 38 
27e H Me H 3.6 100 >10,000 38 
27f H Cl H 6.5 65 >10,000 27 
27g H OCF3 H 0.9 119 69 79 
27h H CF3 H 0.9 112 9 62 
27i H F H 5.4 94 >10,000 35 
27j H H Me 27 85 >10,000 20 
27k H H Cl 3.9 96 >10,000 12 
27l H H OCF3 14 110 4500 57 
27m H H CF3 13 103 >10,000 23 
27n H H F 7 99 >10,000 22 
a
Assay protocols are provided in the Supporting Information. EC50 values represent the mean of two 
experiments. 
Table 2-1-3. Structure functional selectivity relationship study of phenoxy derivatives 
 
Overall, steric hindrance of the ortho and meta positions on the phenyl moiety dramatically enhanced β 
arrestin recruitment and changed the functional selectivity, though the electron characteristics of the 
substituents did not show any significant difference in functional selectivity among the analogues.  These 
structure activity relationship studies suggest that the functional selectivity is easily controlled by small 
chemical modifications of the phenyl moiety. 
O
OH
N
S
CO
2
H
O
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 To confirm the G protein-biased agonism of our EP2 agonists, lead compound 27a and 27k which was the 
most potent G protein activity in para substituents derivatives were evaluated in an equimolar comparison
31 
of
  
G protein and  arrestin responses. Both compounds showed markedly less  arrestin activity with equivalent G 
protein activity relative to PGE2, this result indicates 27a and a series of compounds are G protein-biased 
agonists of EP2 receptor. 
 
Figure 2-1-4. Equimolar comparison of G protein and  arrestin responses of PGE2, 27a and 27k 
 
Figure 2-1-5. Concentration-response curves of PGE2, 27a and 27k 
In summary, the author designed a novel EP2 agonist 8 by hybridization of the thiazole moiety and the 
bicyclic scaffold mimicking prostacyclins.  Simplification of the ω chain enabled the author to discover the 
highly selective EP2 phenoxy derivative 27a, which was identified as a G protein-biased EP2 agonist.  The 
substituents on the phenyl group of 27a play an important role in modulating the functional selectivity.  
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Experimental Section 
 
General Experimental. 
Analytical samples were homogeneous as confirmed by TLC, and spectroscopic results were consistent with 
the assigned structures.  NMR spectra were recorded as designated on either a Varian Mercury 300 
spectrometer or INOVA-500 spectrometer using deuterated chloroform (CDCl3) or deuterated dimethyl 
sulfoxide (DMSO-d6) as the solvent.  Mass spectral analyses with fast atom bombardment (FABMS, HRMS) 
and electron ionization (EI) were performed on a JEOL JMS-DX303HF spectrometer.  Purity analysis was 
carried out by the following LC/MS system. LC/MS: Waters ACQUITY UPLC system fitted by with Waters 
Micromass ZQ-2000 spectrometer. Column; YMC Triart C18 (2.0 mm × 30 mm). Eluting over 1.5 min with 
5−95% acetonitrile( 0.1% TFA) in water (0.1%TFA), flow rate of 1.0 mL/min, column temperature of 30 °C, 
detection with UV (PDA) and ELSD.  Column chromatography was performed with silica gel [Merck Silica 
Gel 60 (0.063−0.200 μm), Wako gel C- 200, or Fuji Silysia PSQ-100B or Fuji Silysia FL60D].  Thin layer 
chromatography was performed with silica gel (Merck TLC or HPTLC plates, Silica Gel 60 F254). 
Medium-pressure preparative liquid chromatography was performed with a medium-pressure preparative liquid 
chromatograph W-prep 2XY (manufactured by Yamazen Corporation; column: main column size S-5L, inject 
column size SS-2L). 
 
Scheme 2-1-1  
(1S,2R,3S,4R)-2-(3-methoxy-2-propen-1-yl)-3-({[(2-methyl-2-propanyl)(diphenyl)silyl]oxy}methyl)-4-(tetr
ahydro-2H-pyran-2-yloxy)cyclopentanol (10) 
THPO
O
O
OTBDPS
THPO
OTBDPS
OH
O
CH
3
THPO
O
OH
OTBDPS
9 109-2  
To a solution of 9 (422 g, 853 mmol) in toluene (1.50 L) at –78 °C was added diisobutylaluminium hydride 
(1.00 M in toluene, 995 mL, 995 mmol).  After stirred at –78 °C for 1 h, potassium sodium tartrate (434 g, 
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1.54 mol) in H2O (650 mL) was added. The reaction mixture was stirred at room temperature for 20 h and 
extracted with tert-BuOMe. The organic layer was washed with H2O and brine and dried over Na2SO4.  
Concentration gave 9-2 (462 g, crude), which was directly used in the next reaction. 
To a suspension of 85% potassium tert-butoxide (298 g, 2.26 mol) in THF (2.30 L) was slowly added 
(methoxymethyl)triphenylphosphonium chloride (775 g, 2.26 mol).  After the mixture was stirred at 0 °C for 
30 min, 9-2 (456 g, crude) in THF (600 mL) was added. After stirred at 0 °C for 30 min, the reaction mixture 
was quenched with H2O and extracted with EtOAc.  The organic layer was washed with brine and dried over 
Na2SO4.  Concentration gave crude mixture (1100 g), which was purified by recrystallization from IPA (400 
mL) and hexane (400 mL) to remove triphenylphosphine oxide.  After filtration of the phosphine oxide, the 
filtrate was concentrated, and flash column chromatography (Fuji silicia PSQ-100B, hexane/EtOAc 
1:0-10:1-5:1-2:1) gave 10 (391 g) in 88% yield over 2 steps. 
1
H NMR (300 MHz, CDCl3)  7.69-7.60 (m, 4H), 7.46-7.35 (m, 6H), 6.33 (m, 0.7H), 5.90 (m, 0.3H), 4.73 (m, 
0.7H), 4.70-4.62 (m, 1H), 4.41 (m, 0.3H), 4.36-4.24 (m, 1H), 4.17-4.00 (m, 1H), 3.92-3.66 (m, 3H), 3.58 (s, 
0.45H), 3.57 (s, 0.45H), 3.55-3.44 (m, 1H), 3.43 (s, 1.05 H), 3.42 (s, 1.05 H), 2.39-2.20 (m, 2H), 2.03 (m, 1H), 
2.07-1.67 (m, 4H), 1.57-1.47 (m, 5H), 1.054 (s, 4.5H), 1.045 (s, 4.5H) (Peak of OH was not observed.). 
  
(4aR,5S,6R,7aS)-5-({[(2-methyl-2-propanyl)(diphenyl)silyl]oxy}methyl)octahydrocyclopenta[b]pyran-2,6-
diol (11) 
OH
OTBDPS
O
OH
THPO
OTBDPS
OH
O
CH
3
1110  
To a solution of 10 (410 g, 781 mmol) in THF (1.50 L) and H2O (600 mL) was added acetic acid (1.20 L).  
After stirred at 55 °C for 3 h, the reaction mixture was extracted with toluene. The organic layer was washed 
with H2O, 1.0 M hydrochloric acid and brine, dried over Na2SO4, and concentrated.  The crude product (372 g) 
was purified by flash column chromatography (Fuji silicia PSQ-100B, hexane/EtOAc 1:0-4:1-2:1-1:3) to give 
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11 (211 g) in 63% yield. 
1
H NMR (300 MHz, CDCl3)  7.67-7.62 (m, 4H), 7.43-7.35 (m, 6H), 5.27 (m, 0.4H), 4.90 (m, 0.6H), 4.65 (m, 
0.6H), 4.40 (m, 0.4H), 4.19-4.09 (m, 1H), 4.02 (m, 0.4H), 3.79 (dd, J = 9.9, 4.5 Hz, 1H), 3.65-3.60 (m, 1H), 
3.54 (m, 0.6H), 2.92 (d, J = 6.0 Hz, 0.6H), 2.81 (d, J = 9.6 Hz, 0.4H), 2.74 (d, J = 9.6 Hz, 0.6H), 2.66 (d, J = 
6.0 Hz, 0.4H), 2.15-2.00 (m, 3H), 1.87-1.72 (m, 3H), 1.63-1.46 (m, 1H), 1.05 (s, 9H). 
 
(2R,4aR,5S,6R,7aS)-2-cyano-5-({[(2-methyl-2-propanyl)(diphenyl)silyl]oxy}methyl)octahydrocyclopenta[
b]pyran-6-yl acetate (12) 
AcO
OTBDPS
O
NC
OH
OTBDPS
O
OH
AcO
OTBDPS
O
AcO
1211 11-2  
To a solution of 11 (211 g, 494 mmol) in pyridine (900 mL) at 0 °C was added acetic anhydride (182 g, 1.78 
mol).  After stirred at room temperature for 14 h, the reaction mixture was diluted with toluene (500 mL) and 
H2O (1.8 L) and extracted with toluene. The organic layer was washed with H2O, 1.0 M hydrochloric acid, 
saturated aqueous NaHCO3 and brine, successively, and dried over Na2SO4.  Concentration gave 11-2 (268 g 
crude), which was directly used in the next reaction. 
To a solution of 11-2 (268 g, crude) and trimethylsilyl cyanide (91.9 g, 889 mmol) in CH3CN (1.40 L) at 0 °C 
was added SnCl4 (1.0 M in CH2Cl2, 494 mL, 494 mmol).  After stirred at 0 °C for 40 min, the reaction mixture 
was poured into a mixture of saturated aqueous NaHCO3 and ice.  The mixture was extracted with EtOAc. The 
organic layer was dried over Na2SO4.  Concentration gave 12 (230 g) in 97% yield over 2 steps. 
1
H NMR (300 MHz, CDCl3)  7.64-7.60 (m, 4H), 7.45-7.35 (m, 6H), 5.17 (m, 1H), 4.80 (m, 1H), 4.26 (m, 1H), 
3.81 (dd, J = 10.8, 3.9 Hz, 1H), 3.63 (dd, J = 10.8, 4.2 Hz, 1H), 2.37 (m, 1H), 2.32 (m, 1H), 2.10-1.90 (m, 4H), 
2.04 (s, 3H), 1.74-1.63 (m, 2H), 1.04 (s, 9H). 
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(2R,4aR,5S,6R,7aS)-2-carbamothioyl-5-({[(2-methyl-2-propanyl)(diphenyl)silyl]oxy}methyl)octahydrocyc
lopenta[b]pyran-6-yl acetate (12-2) 
AcO
OTBDPS
O
NC
AcO
OTBDPS
O
S
NH
2
12 12-2  
To a solution of 12 (230 g, 482 mmol) in pyridine (1.20 L) at 0 °C was added S(NH4)2 (20% in aqueous 
solution, 163 g, 440 mmol).  After the mixture was stirred under 10 °C for 22 h, S(NH4)2 (20% in aqueous 
solution, 82 g, 240 mmol) was added, and the mixture stirred at 10 °C for 2 h.  Ice (300 g) and H2O (2.0 L) 
were added, and the mixture was extracted with toluene. The organic layer was washed with H2O and brine.  
Concentration and flash column chromatography (Fuji silicia PSQ-100B, hexane/EtOAc 9:1-5:1-4:1-3:1-2:1) 
gave 12-2 (86.5 g) in 34% yield and diastereomeric mixture (107 g).  12-2 (71.5 g) and its diastereomeric 
mixture (167 g) were synthesized in the same procedure using 12 (249 g, 523 mmol).  Further purification of 
diastereomeric mixtures (107 g and 167 g) by flash column chromatography (Fuji silicia PSQ-100B, 
hexane/EtOAc 9:1-5:1-4:1-3:1-2:1) gave 12-2 (124 g), total 12-2 (282g) in 55% yield.  
1
H NMR (300 MHz, CDCl3)  8.02 (m, 1H), 7.65-7.60 (m, 4H), 7.52 (m, 1H), 7.45-7.35 (m, 6H), 5.06 (m, 1H), 
4.42 (dd, J = 7.8, 4.8 Hz, 1H), 4.22 (m, 1H), 3.73 (dd, J = 10.2, 4.8 Hz, 1H), 3.63 (dd, J = 10.2, 4.2 Hz, 1H), 
2.38 (m, 1H), 2.26 (m, 1H), 2.09-2.01 (m, 2H), 2.03 (s, 3H), 1.96-1.84 (m, 4H), 1.05 (s, 9H). 
 
The stereochemistry of C5 position was determined by 2D NMR (ROESY).  
AcO
OTBDPS
O
S
NH
2
H
H
AcO
OTBDPS
O
S
NH
2
H
H
12-2
The diastereomer of 12-2 
ROESY
correlation
no correlation
5
9
5
9
 
The diastereomer of 12-2 showed ROESY correlation between H5 and H9. 
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Ethyl 2-[(2R,4aR,5S,6R,7aS)-6-acetoxy-5-({[(2-methyl-2-propanyl)(diphenyl)silyl] 
-oxy}methyl)octahydrocyclopenta[b]pyran-2-yl]-1,3-thiazole-4-carboxylate (13)  
AcO
OTBDPS
O
N
S
CO
2
Et
AcO
OTBDPS
O
S
NH
2
1312-2  
To a solution of 12-2 (129 g, 252 mmol) in 1,2-dimethoxyethane (1.10 L) at –25 °C was added KHCO3 (202 g, 
2.02 mol).  Ethyl bromopyruvate (164 g, 756 mmol) was added at –25 °C, and the mixture was stirred for 4 h.  
Then, pyridine (160 g, 2.02 mol) and trifluoroacetic anhydride (212 g, 1.01 mol) were added at –25 °C for 35 
min.  After stirred at –25 °C for 30 min, the mixture was quenched with H2O and extracted with EtOAc.  The 
organic layer was washed with H2O and brine and dried over Na2SO4.  Concentration and flash column 
chromatography (Fuji silicia BW-820MH, hexane/EtOAc 1:0-10:1-6:1-4:1-3:1) gave 13 (150 g) in 97% yield. 
1
H NMR (300 MHz, CDCl3)  8.16 (s, 1H), 7.65-7.60 (m, 4H), 7.45-7.31 (m, 6H), 5.14 (t, J = 5.7 Hz, 1H), 5.12 
(m, 1H), 4.41 (q, J = 7.2 Hz, 2H), 4.23 (m, 1H), 3.77 (dd, J = 10.2, 4.5 Hz, 1H), 3.65 (dd, J = 10.2, 4.8 Hz, 1H), 
2.37 (m, 1H), 2.25 (m, 1H), 2.13 (m, 2H), 2.04 (s, 3H), 1.96-1.82 (m, 3H), 1.62-1.50 (m, 1H), 1.40 (t, J = 7.2 
Hz, 3H), 1.04 (s, 9H). 
 
Ethyl 2-[(2R,4aR,5S,6R,7aS)-6-acetoxy-5-(hydroxymethyl)octahydrocyclopenta[b] 
-pyran-2-yl]-1,3-thiazole-4-carboxylate (14) 
AcO
OTBDPS
O
N
S
CO
2
Et
AcO
OH
O
N
S
CO
2
Et
13 14  
To a solution of 13 (150 g, 247 mmol) in THF (370 mL) and acetic acid (38.5 g, 642 mmol) at room 
temperature was added tetra-n-butylammonium fluoride (1.00 M in THF, 642 mL, 642 mmol).  After stirred at 
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44 °C for 2 h, the reaction mixture was quenched with saturated aqueous NaHCO3 and extracted with EtOAc. 
The organic layer was washed with H2O and brine and dried over Na2SO4.  Concentration and flash column 
chromatography (Fuji silicia BW-820MH, hexane / EtOAc 1:1-1:2) gave alcohol 14 (77.3 g) in 84% yield. 
1
H NMR (300 MHz, CDCl3)  8.18 (s, 1H), 5.18 (t, J = 5.4 Hz, 1H), 5.02 (dt, J = 8.7, 4.8 Hz, 1H), 4.41 (q, J = 
7.2 Hz, 2H), 4.23 (m, 1H), 3.70 (m, 1H), 3.61 (m, 1H), 2.70 (m, 1H), 2.35-2.14 (m, 3H), 2.12 (s, 3H), 2.06-1.98 
(m, 2H), 1.79-1.61 (m, 3H), 1.40 (t, J = 7.2 Hz, 3H).  
13
C NMR (75 MHz, CDCl3) δ 14.33, 20.79, 21.37, 24.84, 
37.14, 38.75, 50.63, 61.40, 62.63, 72.65, 73.49, 76.38, 128.07, 147.10, 161.42, 172.09, 173.52.  MS (FAB, 
Pos.) m/z 370 (M + H)
+
.  HRMS (FAB, Pos.) C17H24NO6S (M + H)
+
 calc. mass 370.1324, found 370.1331. 
 
Scheme 2-1-2 
5-[(4-phenoxybutyl)thio]-1-phenyl-1H-tetrazole (16) 
O
Br
NN
N
N S
O
15 16  
To a solution of 15 (3.00 g, 13.1 mmol) and 1-phenyl-1H-tetrazole-5-thiol (2.46 g, 13.8 mmol) in acetone (15.0 
mL) at room temperature was added K2CO3 (1.90 g, 13.8 mmol).  After stirred at 60 °C for 16 h, the reaction 
mixture was quenched with 1.0 M hydrochloric acid and extracted with EtOAc. The organic layer was washed 
with H2O and brine and dried over Na2SO4.  Concentration and a medium-pressure preparative liquid 
chromatography (Yamazen W-prep 2XY flash column chromatography L, hexane/EtOAc 9:1-2:1) gave 16 
(4.01 g) in 94% yield. 
1
H NMR (300 MHz, DMSO-d6) δ 7.60-7.53 (m, 5H), 7.28 (d, J = 7.2 Hz, 2H), 6.94 (t, J = 7.2 Hz, 1H), 6.87 (d, 
J = 7.2 Hz, 2H), 4.00 (t, J = 6.0 Hz, 2H), 3.49 (t, J = 7.2 Hz, 2H), 2.05 (m, 2H), 1.95 (m, 2H). 
 
5-[(4-phenoxybutyl)sulfonyl]-1-phenyl-1H-tetrazole (17) 
NN
N
N S
O
O
O
NN
N
N S
O
16 17
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To a solution of 16 (2.00 g, 6.13 mmol) in CH2Cl2 (15.0 mL) at 0 °C was added 3-chloroperoxybenzoic acid 
(3.21 g, 12.1 mmol).  After the mixture was stirred at room temperature for 2 h, 3-chloroperoxybenzoic acid 
(1.66 g, 6.1 mmol) was added. After stirred at room temperature for 2 h, the reaction mixture was quenched 
with saturated aqueous Na2SO3 and extracted with EtOAc.  The organic layer was washed with brine and dried 
over Na2SO4.  Concentration and flash column chromatography (Yamazen W-prep 2XY flash column 
chromatography L, hexane/EtOAc 9:1-2:1) gave 17 (1.55 g) in 71% yield. 
1
H NMR (300 MHz, DMSO-d6) δ 7.71-7.68 (m, 2H), 7.64-7.58 (m, 3H), 7.29 (d, J = 6.9 Hz, 2H), 6.96 (t, J = 
6.9 Hz, 1H), 6.87 (d, J = 6.9 Hz, 2H), 4.03 (t, J = 5.7 Hz, 2H), 3.87 (t, J = 6.0 Hz, 2H), 2.20 (m, 2H), 2.03 (m, 
2H). 
 
Scheme 2-1-3A 
Ethyl 2-[(2R,4aR,5R,6R,7aS)-6-acetoxy-5-formyloctahydrocyclopenta[b]pyran 
-2-yl]-1,3-thiazole-4-carboxylate (14-2)  
AcO
OH
O
N
S
CO
2
Et
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O
O
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S
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2
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H
14 14-2  
To a solution of 14 (3.00 g, 8.12 mmol) in CH2Cl2 (30 mL) at 0 °C was added Dess-Martin periodinane (4.00 g, 
9.43 mmol).  After stirred at room temperature for 2 h, the reaction mixture was quenched with saturated 
aqueous NaHCO3 and extracted with EtOAc. The organic layer was washed with H2O and brine and dried over 
Na2SO4.  Concentration and a medium-pressure preparative liquid chromatography (Yamazen W-prep 2XY 
flash column chromatography, hexane/EtOAc 1:1-0:1) gave 14-2 (2.30 g) in 77% yield. 
1
H NMR (300 MHz, CDCl3)  9.82 (d, J = 2.4 Hz, 1H), 8.17 (s, 1H), 5.29 (m, 1H), 5.18 (t, J = 5.1 Hz, 1H), 
4.41 (q, J = 7.2 Hz, 2H), 4.20 (m, 1H), 3.02 (m, 1H), 2.37 (m, 1H), 2.25 (m, 2H), 2.17 (m, 1H), 2.10 (s, 3H), 
2.10-2.00 (m, 2H), 1.72 (m, 1H), 1.40 (t, J = 7.2 Hz, 3H). 
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Ethyl 2-{(2R,4aR,5R,6R,7aS)-6-acetoxy-5-[(1E)-5-phenoxy-1-penten-1-yl] 
-octahydrocyclopenta[b]pyran-2-yl}-1,3-thiazole-4-carboxylate (20b) 
AcO
O
O
N
S
CO
2
Et
H
AcO
O
N
S
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2
Et
O
14-2 20b   
To a solution of 17 (143 mg, 0.389 mmol) in 1,2-dimethoxyethane (2.0 mL) at –60 °C was added potassium 
bis(trimethylsilyl)amide (0.50 M in toluene, 0.80 mL, 0.40 mmol).  After the mixture was stirred at –60 °C for 
10 min, 14-2 (73.4 mg, 0.20 mmol) in 1,2-dimethoxyethane (1.0 mL) was added.  After stirred at 0 °C for 30 
min, the reaction mixture was quenched with saturated aqueous NaHCO3 and extracted with EtOAc.  The 
organic layer was washed with brine and dried over Na2SO4.  Concentration and a medium-pressure 
preparative liquid chromatography (Yamazen W-prep 2XY flash column chromatography M, hexane/EtOAc 
9:1-3:1-7:3) gave 20b (66.0 mg) in 34% yield. 
1
H NMR (300 MHz, CDCl3)  8.17 (s, 1H), 7.31-7.24 (m, 2H), 6.93 (t, J = 7.2 Hz, 1H), 6.89 (d, J = 7.2 Hz, 2H), 
5.58 (dt, J = 15.6, 6.3 Hz, 1H), 5.31 (dd, J = 15.6, 8.4 Hz, 1H), 5.17 (t, J = 5.1 Hz, 1H), 4.84 (m, 1H), 4.41 (q, J 
= 6.9 Hz, 1H), 4.13 (m, 1H), 3.96 (t, J = 6.6 Hz, 2H), 2.79 (m, 1H), 2.49 (m, 4H), 2.21 (m, 4H), 2.05 (s, 3H), 
1.86 (m, 3H), 1.71 (m, 1H), 1.40 (t, J = 6.9 Hz, 3H). 
 
2-{(2R,4aR,5R,6R,7aS)-6-hydroxy-5-[(1E)-5-phenoxy-1-penten-1-yl]octahydrocyclopenta[b]pyran-2-yl}-1,
3-thiazole-4-carboxylic acid (21a) 
AcO
O
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S
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2
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To a solution of 20b (30 mg, 0.060 mmol) in 1,2-dimethoxyethane (0.50 mL) and ethanol (0.50 mL) at room 
temperature was added 1.0 M sodium hydroxide (0.50 mL, 0.50 mmol).  After stirred at room temperature for 
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3 h, the reaction mixture was extracted with tert-BuOMe. The aqueous layer was acidified by 1.0 M 
hydrochloric acid and extracted with EtOAc. The EtOAc layer was washed with brine and dried over MgSO 4.  
Concentration gave 21a (23.2 mg) in 90% yield. 
1
H NMR (300 MHz, CDCl3) δ 8.29 (s, 1H), 7.27 (t, J = 7.5 Hz, 2H), 6.92 (t, J = 7.5 Hz, 1H), 6.88 (d, J = 7.5 Hz, 
2H), 5.62 (dt, J = 15.0, 5.4 Hz, 1H), 5.30 (dd, J = 15.0, 8.4 Hz, 1H), 5.17 (t, J = 4.5 Hz, 1H), 4.13-4.08 (m, 1H), 
3.97 (t, J = 6.3 Hz, 2H), 3.92-3.86 (m, 1H), 2.61-2.51 (m, 1H), 2.32-2.19 (m, 5H), 1.92-1.85 (m, 3H), 1.83-1.76 
(m, 1H), 1.59-1.53 (m, 2H), (Peaks of OH and CO2H were not observed.).  LCMS (ELSD) RT = 0.94 min 
(97.3%).  MS (FAB, Pos.) m/z 430 (M + H)
+
.  HRMS (FAB, Pos.) C23H28NO5S (M + H)
+
 calc. mass 
430.1688, found 430.1691. 
 
Ethyl 2-[(2R,4aR,5R,6R,7aS)-6-acetoxy-5-(5-phenoxypentyl)octahydrocyclopenta 
-[b]pyran-2-yl]-1,3-thiazole-4-carboxylate (20c) 
AcO
O
N
S
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2
Et
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2
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20b 20c  
To a solution of 20b (32.0 mg, 0.064 mmol) and sodium acetate (105 mg, 1.28 mmol) in EtOH (0.50 mL) and 
H2O (1.00 mL) at room temperature was added p-toluenesulfonyl hydrazide (119 mg, 0.64 mmol).  After the 
mixture was stirred at 80 °C for 14.5 h, H2O was added and the reaction mixture was extracted with EtOAc.  
The organic layer was washed with saturated aqueous NaHCO3 and brine and dried over MgSO4.  
Concentration and preparative thin layer chromatography gave 20c (17.7 mg) in 55% yield. 
1
H NMR (300 MHz, CDCl3) δ 8.15 (s, 1H), 7.27 (t, J = 7.2 Hz, 2H), 6.92 (t, J = 7.2 Hz, 1H), 6.87 (d, J = 7.2 Hz, 
2H), 5.13 (t, J = 6.0 Hz, 1H), 4.80 (m, 1H), 4.40 (q, J = 6.9 Hz, 2H), 4.21 (m, 1H), 3.95 (t, J = 6.6 Hz, 2H), 2.39 
(m, 1H), 2.23 (m, 1H), 2.15-1.90 (m, 4H), 2.06 (s, 3H), 1.87-1.74 (m, 4H), 1.75-1.69 (m, 2H), 1.58-1.38 (m, 
4H), 1.40 (t, J = 6.9 Hz, 3H). 
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2-[(2R,4aR,5R,6R,7aS)-6-hydroxy-5-(5-phenoxypentyl)octahydrocyclopenta[b]pyran-2-yl]-1,3-thiazole-4-
carboxylic acid (21b)  
AcO
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2
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O
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O
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2
H
20c 21b  
To a solution of 20c (17.5 mg, 0.035 mmol) in 1,2-dimethoxyethane (0.50 mL) and EtOH (0.50 mL) at room 
temperature was added 1.0 M sodium hydroxide (0.50 mL, 0.50 mmol).  After stirred at room temperature for 
2 h, the reaction mixture was extracted with tert-BuOMe. The aqueous layer was acidified by 1.0 M 
hydrochloric acid and extracted with EtOAc. The EtOAc layer was washed with brine and dried over MgSO4.  
Concentration and column chromatography (Wakogel, chloroform/MeOH 1:0-95:5) gave 21b (8.4 mg) in 56% 
yield. 
1
H NMR (300 MHz, CDCl3) δ 8.30 (s, 1H), 7.26 (m, 2H), 6.92 (m, 1H), 6.88 (d, J = 7.8 Hz, 2H), 5.17 (t, J = 
5.1 Hz, 1H), 4.15 (m, 1H), 3.96 (t, J = 6.3 Hz, 2H), 3.91 (m, 1H), 2.28-2.21 (m, 2H), 2.06-1.91 (m, 4H), 1.81 
(m, 2H), 1.67 (m, 1H), 1.55-1.31 (m, 7H) (Peaks of OH and CO2H were not observed.).  LCMS (ELSD) RT = 
0.99 min (>98%).  MS (FAB, Neg.) m/z 430 (M - H)
-
.  HRMS (FAB, Neg.) C23H28NO5S (M - H)
-
 calc. mass 
430.1688, found 430.1691. 
 
8 was synthesized in a similar manner by using Julia Kocienski reagent 19. 
2-{(2R,4aR,5R,6R,7aS)-6-hydroxy-5-[(1E)-4-phenoxy-1-buten-1-yl]octahydrocyclopenta[b]pyran-2-yl}-1,3
-thiazole-4-carboxylic acid (8) 
1
H NMR (300 MHz, CDCl3) δ 8.30 (s, 1H), 7.27 (d, J = 7.2 Hz, 2H), 6.93 (t, J = 7.2 Hz, 1H), 6.87 (d, J = 7.2 
Hz, 2H), 5.66 (dt, J = 15.0, 6.9 Hz, 1H), 5.41 (dd, J = 15.0, 8.7 Hz, 1H), 5.18 (t, J = 4.8 Hz, 1H), 4.13 (m, 1H), 
4.00 (t, J = 6.9 Hz, 2H), 3.99 (m, 1H), 2.64-2.49 (m, 3H), 2.34-2.18 (m, 3H), 1.94 (m, 1H), 1.81 (m, 1H), 1.61 
(m, 2H) (Peaks of OH and CO2H were not observed.).  LCMS (ELSD) RT = 0.89 min (>98%).  MS (FAB, 
Pos.) m/z 416 (M + H)
+
.  HRMS (FAB, Pos.) C22H26NO5S (M + H)
+
 calc. mass 416.1532, found 416.1531. 
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Scheme 2-1-3B 
Ethyl 2-{(2R,4aR,5R,6R,7aS)-6-acetoxy-5-[(1E)-3-{[dimethyl(2-methyl-2-propanyl) 
-silyl]oxy}-1-propen-1-yl]octahydrocyclopenta[b]pyran-2-yl}-1,3-thiazole-4-carboxylate (22) 
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To a solution of 21 (501 mg, 1.36 mmol) and 14-2 (252 mg, 0.689 mmol) in 1,2-dimethoxyethane (6.8 mL) at –
60 °C was added potassium bis(trimethylsilyl)amide (0.50 M in toluene, 2.04 ml, 1.02 mmol) slowly.  After 
stirred at –60 °C to –30 °C for 1 h, the reaction mixture was quenched with saturated aqueous NaHCO3 and 
extracted with EtOAc. The organic layer was washed with brine and dried over Na2SO4.  Concentration and a 
medium-pressure preparative liquid chromatography (Yamazen W-prep 2XY flash column chromatography L, 
hexane/EtOAc 97:3-85:15-4:1) gave 22 (128 mg) in 18%. 
1
H NMR (300 MHz, CDCl3)  8.17 (s, 1H), 5.69 (dt, J = 15.3, 4.8 Hz, 1H), 5.51 (dd, J = 15.3, 8.7 Hz, 1H), 5.18 
(t, J = 5.1 Hz, 1H), 4.86 (m, 1H), 4.41 (q, J = 7.2 Hz, 2H), 4.17 (m, 2H), 2.86 (m, 1H), 2.52 (m, 1H), 2.24 (m, 
2H), 2.06 (s, 3H), 1.93 (m, 1H), 1.70 (m, 1H), 1.64-1.57 (m, 3H), 1.40 (t, J = 7.2 Hz, 3H), 0.90 (s, 9H), 0.07 (s, 
6H). 
 
Ethyl 2-{(2R,4aR,5R,6R,7aS)-6-acetoxy-5-[(1E)-3-phenoxy-1-propen-1-yl] 
-octahydrocyclopenta[b]pyran-2-yl}-1,3-thiazole-4-carboxylate (23) 
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To a solution of 22 (125 mg, 0.245 mmol) in THF (1.5 mL) at 0 °C was added tetra-n-butylammonium fluoride 
(1.0 M in THF, 0.38 mL, 0.38 mmol).  After stirred at room temperature for 2.5 h, the reaction mixture was 
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quenched with saturated aqueous NH4Cl and extracted with EtOAc.  The organic layer was washed with brine 
and dried over Na2SO4.  Concentration and flash a medium-pressure preparative liquid chromatography 
(Yamazen W-prep 2XY flash column chromatography M, hexane/EtOAc 1:1-3:7) gave 22-2, which was 
directly used in the next reaction. 
To a solution of 22-2, phenol (31.1 mg, 0.330 mmol) and triphenyl phosphine (86.6 mg, 0.430 mmol) in THF 
(1.0 mL) at room temperature was added diethyl azodicarboxylate (2.2 M in toluene, 150 μL, 0.430 mmol).  
After stirred at room temperature for 1 h, the reaction mixture was concentrated. A medium-pressure 
preparative liquid chromatography (Yamazen W-prep 2XY flash column chromatography M, hexane/EtOAc 
9:1-3:1-7:3) gave 23 (97.3 mg) in 84% yield. 
1
H NMR (300 MHz, CDCl3)  8.16 (s, 1H), 7.27-7.24 (m, 2H), 6.93 (t, J = 7.2 Hz, 1H), 6.89 (d, J = 7.2 Hz, 2H), 
5.81 (dt, J = 15.0, 5.4 Hz, 1H), 5.68 (dd, J = 15.0, 8.1 Hz, 1H), 5.18 (t, J = 5.1 Hz, 1H), 4.89 (m, 1H), 4.51 (d, J 
= 4.5 Hz, 2H), 4.40 (q, J = 6.9 Hz, 2H), 4.16 (m, 1H), 2.90 (m, 1H), 2.51 (m, 1H), 2.24 (m, 2H), 2.06 (s, 3H), 
1.94 (m, 1H), 1.72 (m, 1H), 1.66-1.54 (m, 2H), 1.40 (t, J = 6.9 Hz, 3H). 
 
2-{(2R,4aR,5R,6R,7aS)-6-hydroxy-5-[(1E)-3-phenoxy-1-propen-1-yl]octahydrocyclopenta[b]pyran-2-yl}-1
,3-thiazole-4-carboxylic acid (21c) 
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To a solution of 23 (95.0 mg, 0.201 mmol) in 1,2-dimethoxyethane (1.50 mL) and EtOH (1.50 mL) at room 
temperature was added 1.0 M sodium hydroxide (1.50 mL, 1.50 mmol).  After stirred at room temperature for 
2 h, the reaction mixture was extracted with tert-BuOMe. The aqueous layer was acidified by 1.0 M 
hydrochloric acid and extracted with EtOAc. The EtOAc layer was washed with brine and dried over MgSO 4.  
Concentration gave 21c (56.6 mg) in 70% yield. 
1
H NMR (300 MHz, CDCl3) δ 8.31 (s, 1H), 7.29 (m, 2H), 6.93 (m, 3H), 5.87 (dt, J = 15.3, 5.7 Hz, 1H), 5.70 
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(dd, J = 15.3, 8.4 Hz, 1H), 5.19 (t, J = 4.8 Hz, 1H), 4.54 (d, J = 4.5 Hz, 2H), 4.13 (m, 1H), 4.00 (m, 1H), 2.69 
(m, 1H), 2.31 (m, 1H), 2.26 (m, 2H), 1.95 (m, 1H), 1.85 (m, 1H), 1.69-1.58 (m, 2H) (Peaks of OH and CO2H 
were not observed.).  LCMS (ELSD) RT = 0.85 min (>98%).  MS (EI, Pos.) m/z 401 (M)
+
.  HRMS (EI, 
Pos.) C21H23NO5S (M)
+
 calc. mass 401.1297, found 401.1292. 
 
2-[(2R,4aR,5R,6R,7aS)-6-hydroxy-5-(3-phenoxypropyl)octahydrocyclopenta[b]pyran-2-yl]-1,3-thiazole-4-
carboxylic acid (21d) 
AcO
O
N
S
O
CO
2
Et
AcO
O
N
S
CO
2
Et
O
OH
O
N
S
O
CO
2
H
23 23-2 21d  
To a solution of 23 (75.0 mg, 0.159 mmol) and AcONa (262 mg, 3.20 mmol) in EtOH (1.0 mL) and H2O (2.0 
mL) at room temperature was added p-toluenesulphonyl hydrazine (298 mg, 1.60 mmol).  After the reaction 
mixture was stirred at 80 °C for 3 days, H2O was added and the reaction mixture was extracted with EtOAc.  
The organic layer was washed with saturated aqueous NaHCO3 and brine and dried over MgSO4.  
Concentration and a medium-pressure preparative liquid chromatography (Yamazen W-prep 2XY flash column 
chromatography M, hexane/EtOAc 92:8-3:1-65:35) gave 23-2 (53.7 mg) in 71% yield. 
To a solution of 23-2 (51.0 mg, 0.108 mmol) in 1,2-dimethoxyethane (1.00 mL) and EtOH (1.00 mL) at room 
temperature was added 1.0 M sodium hydroxide (1.00 mL, 1.00 mmol).  After stirred at room temperature for 
2 h, the reaction mixture was extracted with tert-BuOMe. The aqueous layer was acidified by 1.0 M 
hydrochloric acid and extracted with EtOAc. The EtOAc layer was washed with brine and dried over MgSO4.  
Concentration gave 21d (40.4 mg) in 93% yield. 
1
H NMR (300 MHz, CDCl3) δ 8.30 (s, 1H), 7.27 (t, J = 7.5 Hz, 2H), 6.93 (t, J = 7.5 Hz, 1H), 6.89 (d, J = 7.5 Hz, 
2H), 5.17 (t, J =4.8 Hz, 1H), 4.16 (m, 1H), 4.00 (t, J = 6.3 Hz, 2H), 3.95 (m, 1H), 2.32-2.15 (m, 2H), 2.07-1.90 
(m, 6H), 1.76-1.43 (m, 4H) (Peaks of OH and CO2H were not observed.).  LCMS (ELSD) RT = 0.89 min 
(>98%). 1.5 min.  MS (FAB, Neg.) m/z 402 (M - H)
-
.  HRMS (FAB, Neg.) C21H24NO5S (M - H)
-
 calc. mass 
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402.1375, found 402.1372. 
 
Scheme 2-1-3C 
Isopropyl 2-[(2R,4aR,5R,6R,7aS)-6-hydroxy-5-({[(2-methyl-2-propanyl)(diphenyl) 
-silyl]oxy}methyl)octahydrocyclopenta[b]pyran-2-yl]-1,3-thiazole-4-carboxylate 
(13-3) 
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To a solution of 13 (44.2 g, 72.8 mmol) in MeOH (900 mL) at room temperature was added 1.0M sodium 
hydroxide (180 mL, 180 mmol).  After stirred at room temperature for 2 h, the reaction mixture was 
evaporated. The residue was dissolved in THF (400 mL), 1 M hydrochloric acid (210 mL) and EtOAc (400 mL).  
The mixture was extracted with EtOAc and the organic layer was washed with brine and dried over Na 2SO4.  
Concentration gave 13-2 (40.5 g, crude), which was directly used in the next reaction. 
To a solution of 13-2 (40.5 g, crude) and isopropyl iodide (24.7 g, 145 mmol) in DMF (190 mL) at room 
temperature was added K2CO3 (20.1 g, 145 mmol).  After the reaction mixture was stirred at 50 °C for 14 h, 
H2O (200 mL) was added and the mixture was extracted with EtOAc. The organic layer was washed with brine 
and dried over Na2SO4.  Concentration and flash column chromatography (Fuji silicia BW-820MH, 
hexane/EtOAc 4:1-3:1-2:1) gave 13-3 (23.1 g) in 54% yield. 
1
H NMR (300 MHz, CDCl3)  8.12 (s, 1H), 7.66-7.61 (m, 4H), 7.43-7.34 (m, 6H), 5.26 (sep, J = 6.3 Hz, 1H), 
5.16 (t, J = 5.4 Hz, 1H), 4.20-4.12 (m, 2H), 3.78 (dd, J = 9.9, 4.5 Hz, 1H), 3.61 (dd, J = 9.9, 6.3 Hz, 1H), 2.63 
(d, J = 7.5 Hz, 1H), 2.24-2.06 (m, 4H), 1.95 (m, 1H), 1.90 (m, 1H), 1.79-1.74 (m, 1H), 1.55-1.48 (m, 1H), 1.37 
(d, J = 6.3 Hz, 6H), 1.04 (s, 9H). 
Isopropyl 2-[(2R,4aR,5R,6R,7aS)-5-(hydroxymethyl)-6-(tetrahydro-2H-pyran-2- 
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yloxy)octahydrocyclopenta[b]pyran-2-yl]-1,3-thiazole-4-carboxylate (24)  
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To a solution of 13-3 (54.8 g, 94.5 mmol) and pyridinium para-toluenesulfonate (2.30 g, 9.45 mmol) in CH2Cl2 
(220 mL) at room temperature was added 3,4-dihydro-2H-pyran (15.9 g, 189 mmol).  After stirred at room 
temperature for 14 h, the reaction mixture was quenched with saturated aqueous NaHCO3 and extracted with 
EtOAc.  The organic layer was washed with H2O and brine and dried over Na2SO4.  Concentration gave 13-4 
(64.0 g, crude), which was directly used in the next reaction. 
To a solution of 13-4 (64.0 g, crude) in THF (160 mL) at room temperature was added tetra-n-butylammonium 
fluoride (1.00 M in THF, 240 mL, 240 mmol).  After stirred at room temperature for 2.5 h, the reaction 
mixture was evaporated.  The residue was dissolved in H2O (200 mL) and extracted with EtOAc.  The 
organic layer was washed with brine and dried over Na2SO4.  Concentration and flash column chromatography 
(Fuji silicia BW-820MH, hexane/EtOAc 1:1-1:2) gave 24 (38.8 g) in 96% yield. 
1
H NMR (300 MHz, CDCl3)  8.11 (s, 1H), 5.27 (sep, J = 6.3 Hz, 1H), 5.14 (t, J = 6.3 Hz, 1H), 4.76 (m, 0.5H), 
4.62 (m, 0.5H), 4.24-4.02 (m, 2H), 3.96-3.86 (m, 2H), 3.77 (dd, J = 10.8, 4.5 Hz, 0.5H), 3.71 (dd, J = 10.8, 5.7 
Hz, 0.5H), 3.62-3.48 (m, 2H), 2.38-2.23 (m, 3H), 2.19-1.92 (m, 4H), 1.92-1.48 (m, 7H), 1.37 (d, J = 6.3 Hz, 
6H). 
 
Isopropyl 2-[(2R,4aR,5R,6R,7aS)-5-(2-methoxyvinyl)-6-(tetrahydro-2H-pyran-2 
-yloxy)octahydrocyclopenta[b]pyran-2-yl]-1,3-thiazole-4-carboxylate (24-3) 
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To a solution of 24 (200 mg, 0.470 mmol) in CH2Cl2 (3.0 mL) at 0 °C was added Dess-Martin periodinane (259 
mg, 0.611 mmol).  After stirred at room temperature for 1 h, the reaction mixture was quenched with saturated 
aqueous Na2S2O3 and extracted with EtOAc. The organic layer was washed with saturated aqueous NaHCO3 
and brine and dried over Na2SO4.  Concentration gave 24-2, which was directly used in next reaction. 
To a suspension of 85%-potassium tert-butoxide (79.1 mg, 0.705 mol) in THF (4.70 mL) at 0 °C was slowly 
added (methoxymethyl)triphenylphosphonium chloride (242 mg, 0.705 mol).  After the mixture was stirred at 
0 °C for 30 min, 24-2 in THF (1.4 mL) was added and the mixture was stirred at room temperature for 2 h.  
The reaction mixture was quenched with saturated aqueous NH4Cl and extracted with EtOAc.  The organic 
layer was washed with brine and dried over Na2SO4.  Concentration and a medium-pressure preparative liquid 
chromatography (Yamazen W-prep 2XY flash column chromatography L, hexane/EtOAc 9:1-7:3) gave 24-3 
(137 mg) in 64% yield. 
1
H NMR (300 MHz, CDCl3)  8.10 (s, 1H), 6.40-6.36 (m, 0.8H), 6.03-5.96 (m, 0.2H), 5.26 (sep, J = 6.3 Hz, 
1H), 5.14 (t, J = 5.4 Hz, 1H), 4.71 (m, 1H), 4.58 (m, 1H), 4.16 (m, 1H), 3.95-3.78 (m, 2H), 3.53 (brs, 3H), 3.48 
(m, 1H), 2.58 (m, 1H), 2.37 (m, 1H), 2.18 (m, 2H), 1.94-1.81 (m, 3H), 1.74-1.45 (m, 7H), 1.37 (d, J = 6.3 Hz, 
6H). 
 
Isopropyl 2-[(2R,4aR,5R,6R,7aS)-6-acetoxy-5-(2-hydroxyethyl)octahydro 
-cyclopenta[b]pyran-2-yl]-1,3-thiazole-4-carboxylate (26) 
THPO
O
N
S
CO
2
iPr
O
CH
3
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O
N
S
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2
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O
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N
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24-3 25 25-2 26  
39 
 
To a solution of 24-3 (120 mg, 0.266 mmol) in acetone (4.95 mL) and H2O (50 μL) at room temperature was 
added p-toluene sulfonic acid monohydrate (15.1 mg, 0.0795 mmol).  After stirred at room temperature for 3 h, 
the reaction mixture was quenched with saturated aqueous NaHCO3 and extracted with EtOAc.  The organic 
layer was washed with brine and dried over Na2SO4.  Concentration and a medium-pressure preparative liquid 
chromatography (Yamazen W-prep 2XY flash column chromatography L, hexane/EtOAc 3:2-1:3-0:100) gave 
25 (73.0 mg) in 78% yield. 
1
H NMR (300 MHz, CDCl3)  9.85 (t, J = 1.2 Hz, 1H), 8.12 (s, 1H), 5.26 (sep, J = 6.3 Hz, 1H), 5.18 (t, J = 5.1 
Hz, 1H), 4.14 (m, 1H), 3.89 (m, 1H), 3.08 (d, J = 5.1 Hz, 1H), 2.75 (m, 1H), 2.54 (m, 1H), 2.45 (m, 1H), 
2.29-2.16 (m, 3H), 2.04 (m, 1H), 1.93 (m, 1H), 1.57 (m, 1H), 1.37 (d, J = 6.3 Hz, 6H) (Peak of OH was not 
observed.). 
To a solution of 25 (70.0 mg, 0.198 mmol) in pyridine (1.50 mL) at 0 °C was added acetic anhydride (37.4 μL, 
0.396 mmol).  After stirred at room temperature for 2 h, the reaction mixture was quenched with saturated 
aqueous NH4Cl and extracted with EtOAc.  The organic layer was washed with brine and dried over Na2SO4.  
Concentration and a medium-pressure preparative liquid chromatography (Yamazen W-prep 2XY flash column 
chromatography L, hexane/EtOAc 3:1-1:1) gave 25-2 (64.0 mg) in 82% yield. 
1
H NMR (300 MHz, CDCl3)  9.79 (t, J = 1.2 Hz, 1H), 8.12 (s, 1H), 5.27 (sep, J = 6.0 Hz, 1H), 5.17 (t, J = 5.1 
Hz, 1H), 4.84 (m, 1H), 4.19 (m, 1H), 2.68-2.56 (m, 2H), 2.45 (m, 1H), 2.26 (m, 1H), 2.18-1.97 (m, 3H), 2.07 (s, 
3H), 1.86 (m, 1H), 1.70-1.53 (m, 2H), 1.37 (d, J = 6.0 Hz, 6H). 
To a solution of 25-2 (62.0 mg, 0.157 mmol) in THF (1.50 mL) at 0 °C was added NaBH4 (7.1 mg, 0.188 
mmol).  After stirred at room temperature for 1 h, the reaction mixture was quenched with saturated aqueous 
NH4Cl and extracted with EtOAc.  The organic layer was washed with brine and dried over Na2SO4.  
Concentration and a medium-pressure preparative liquid chromatography (Yamazen W-prep 2XY flash column 
chromatography L, hexane/EtOAc 3:2-3:7) gave 26 (38.1 mg) in 61% yield. 
1
H NMR (300 MHz, CDCl3)  8.11 (s, 1H), 5.26 (sep, J = 6.3 Hz, 1H), 5.14 (t, J = 5.7 Hz, 1H), 4.86 (m, 1H), 
4.24 (m, 1H), 3.73 (m, 2H), 2.42 (m, 1H), 2.23 (m, 2H), 2.14-2.01 (m, 2H), 2.09 (s, 3H), 1.97 (m, 1H), 1.86 (m, 
1H), 1.75 (m, 1H), 1.63-1.55 (m, 2H), 1.37 (d, J = 6.3 Hz, 6H) (Peak of OH was not observed.). 
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Isopropyl 2-[(2R,4aR,5R,6R,7aS)-6-acetoxy-5-(2-phenoxyethyl)octahydro 
-cyclopenta[b]pyran-2-yl]-1,3-thiazole-4-carboxylate (26-2) 
AcO
O
N
S
CO
2
iPr
OH
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O
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S
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2
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O
26 26-2  
To a solution of 26 (35.1 mg, 0.0883 mmol), phenol (11.3 mg, 0.120 mmol) and 
1,1'-azobis(N,N-dimethylformamide) (31.7 mg, 0.184 mmol) in THF (0.90 mL) at room temperature was added 
tributylphosphine (45.4 μL, 0.184 mmol).  After stirred at room temperature for 16 h, the mixture was 
concentrated. A medium-pressure preparative liquid chromatography (Yamazen W-prep 2XY flash column 
chromatography M, hexane/EtOAc 9:1-2:3) gave 26-2 (26.4 mg) in 63% yield. 
1
H NMR (300 MHz, CDCl3) δ 8.12 (s, 1H), 7.30-7.24 (m, 2H), 6.93 (t, J = 7.5 Hz, 1H), 6.87 (d, J = 7.5 Hz, 
2H), 5.27 (sep, J = 6.6 Hz, 1H), 5.16 (t, J = 5.4 Hz, 1H), 4.93 (m, 1H), 4.20 (m, 1H), 4.06-3.97 (m, 2H), 
2.50-2.36 (m, 2H), 2.26 (m, 1H), 2.17 (m, 1H), 2.05 (s, 3H), 2.05-1.92 (m, 2H), 1.83 (m, 1H), 1.75 (m, 1H), 
1.72-1.64 (m, 2H, 1.37 (d, J = 6.6 Hz, 6H). 
 
2-[(2R,4aR,5R,6R,7aS)-6-hydroxy-5-(2-phenoxyethyl)octahydrocyclopenta[b]pyran-2-yl]-1,3-thiazole-4-ca
rboxylic acid (21e) 
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21e26-2  
To a solution of 26-2 (25.0 mg, 0.0528 mmol) in MeOH (1.0 mL) at room temperature was added 2.0 M 
sodium hydroxide (0.14 mL, 0.28 mmol).  After stirred at room temperature for 1.5 h, the reaction mixture 
was extracted with tert-BuOMe. The aqueous layer was acidified by 1.0 M hydrochloric acid and extracted with 
EtOAc. The EtOAc layer was washed with brine and dried over MgSO4.  Concentration gave 21e (17.5 mg) in 
85% yield. 
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1
H NMR (300 MHz, DMSO-d6) δ 8.42 (s, 1H), 7.27 (dd, J = 8.7, 7.2 Hz, 2H), 6.90 (m, 3H), 5.06 (t, J = 6.6 Hz, 
1H), 4.81 (d, J = 5.4 Hz, 1H), 4.07 (m, 3H), 3.66 (m, 1H), 2.14 (m, 2H), 1.81 (m, 5H), 1.64 (m, 1H), 1.56 (m, 
2H) (Peak of CO2H was not observed.).  LCMS (ELSD) RT = 0.85 min (>98%).  MS (FAB, Neg.) m/z 388 
(M - H)
-
.  HRMS (FAB, Neg.) C20H22NO5S (M - H)
-
 calc. mass 388.1219, found 388.1215. 
 
Scheme 2-1-3D 
2-[(2R,4aR,5R,6R,7aS)-6-hydroxy-5-(phenoxymethyl)octahydrocyclopenta[b]pyran-2-yl]-1,3-thiazole-4-ca
rboxylic acid (27a) 
AcO
OH
O
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S
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2
Et
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14 14-3 27a  
To a solution of 14 (50.0 mg, 0.135 mmol), phenol (38.2 mg, 0.406 mmol) and 
1,1'-azobis(N,N-dimethylformamide) (70.0 mg, 0.406 mmol) in THF (1.0 mL) at room temperature was added 
tributylphosphine (82.5 mg, 0.406 mmol).  After the mixture was stirred at 50 °C for 2 h, concentration and a 
medium-pressure preparative liquid chromatography (Yamazen W-prep 2XY flash column chromatography M, 
hexane/EtOAc 9:1-2:3) gave 14-3 (55.6 mg) in 92% yield. 
1
H NMR (300 MHz, CDCl3) δ 8.17 (s, 1H), 7.29 (d, J = 7.2 Hz, 2H), 6.94 (t, J = 7.2 Hz, 1H), 6.87 (d, J = 7.2 
Hz, 2H), 5.18 (t, J = 5.4 Hz, 1H), 5.10 (m, 1H), 4.41 (q, J = 7.2 Hz, 2H), 4.40 (m, 1H), 4.13-4.01 (m, 2H), 
2.57-2.48 (m, 1H), 2.43 (m, 1H), 2.32-2.23 (m, 1H), 2.18-2.11 (m, 1H), 2.09 (s, 3H), 2.08-1.97 (m, 2H), 1.93 
(m, 1H), 1.75 (m, 1H), 1.40 (t, J = 7.2 Hz, 3H).  
To a solution of 14-3 (44.6 mg, 0.100 mmol) in MeOH (1.0 mL) at room temperature was added 2.0 M sodium 
hydroxide (0.50 mL, 1.0 mmol).  After stirred at room temperature for 16 h, the reaction mixture was 
quenched with 1.0 M hydrochloric acid and extracted with EtOAc. The organic layer was washed with H2O and 
brine and dried over Na2SO4.  Concentration gave 27a (36.2 mg) in 96 % yield 
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1
H NMR (300 MHz, CDCl3) δ 8.32 (s, 1H), 7.30 (t, J = 7.2 Hz, 2H), 6.96 (t, J = 7.2 Hz, 2H) 6.89 (d, J = 7.2 Hz, 
2H), 5.22 (t, J = 4.8 Hz, 1H), 4.23 (m, 2H), 4.08 (m, 1H), 3.96 (dd, J = 9.0, 6.0 Hz, 1H), 2.46 (m, 1H), 2.29 (m, 
2H), 2.16 (m, 1H), 2.11-1.95 (m, 2H), 1.90 (m, 1H), 1.74 (m, 1H) (Peaks of OH and CO2H were not observed.).  
13
C NMR (75 MHz, CDCl3) δ 20.52, 23.65, 40.01, 40.91, 50.81, 68.91, 72.83, 74.92, 75.91, 114.45(2C), 121.00, 
129.50(2C), 129.55, 146.08, 158.81, 163.24, 173.64.  LCMS (ELSD) RT = 0.82 min (>98%).  MS (FAB, 
Neg.) m/z 374 (M - H)
-
.  HRMS (FAB, Neg.) C19H20NO5S (M - H)
-
 calc. mass 374.1062, found 374.1070. 
 
All compounds in Table 2-1-3 were synthesized in the same procedure. 
2-{(2R,4aR,5R,6R,7aS)-5-[(2-chlorophenoxy)methyl]-6-hydroxyoctahydrocyclopenta[b]pyran-2-yl}-1,3-th
iazole-4-carboxylic acid (27b) 
1
H NMR (300 MHz, DMSO-d6) δ 7.99 (s, 1H), 7.40 (dd, J = 8.1, 1.8 Hz, 1H), 7.29 (ddd, J = 8.1, 7.5, 1.8 Hz, 
1H), 7.40 (dd, J = 8.1, 1.8 Hz, 1H), 6.92 (ddd, J = 8.1, 7.5, 1.8 Hz, 1H), 5.04 (t, J = 6.0 Hz, 1H), 4.18 (m, 2H), 
4.02 (m, 1H), 3.92 (m, 1H), 2.23-2.08 (m, 3H), 1.95-1.65 (m, 5H) (Peaks of OH and CO2H were not observed.).  
LCMS (ELSD) RT = 0.87 min (>98%).  MS (FAB, Neg.) m/z 408 (M - H)
-
.  HRMS (FAB, Neg.) 
C19H19
35
ClNO5S (M - H)
-
 calc. mass 408.0672, found 408.0682. 
 
2-[(2R,4aR,5R,6R,7aS)-6-hydroxy-5-{[2-(trifluoromethyl)phenoxy]methyl}octahydrocyclopenta[b]pyran-
2-yl]-1,3-thiazole-4-carboxylic acid (27c)  
1
H NMR (300 MHz, DMSO-d6) δ 8.22 (s, 1H), 7.61 (t, J = 7.5 Hz, 1H), 7.59 (d, J = 7.5 Hz, 1H), 7.26 (d, J = 
7.5 Hz, 1H), 7.07 (t, J = 7.5 Hz, 1H), 5.08 (t, J = 5.4 Hz, 1H), 4.21 (dd, J = 9.9, 3.0 Hz, 1H), 4.11 (m, 2H), 3.88 
(m, 1H), 2.15 (m, 3H), 1.86 (m, 3H), 1.70 (m, 2H) (Peaks of OH and CO2H were not observed.).  LCMS 
(ELSD) RT = 0.90 min (>98%).  MS (FAB, Neg.) m/z 442 (M - H)
-
.  HRMS (FAB, Neg.) C20H19F3NO5S (M 
- H)
-
 calc. mass 442.0936, found 442.0932 
. 
2-{(2R,4aR,5R,6R,7aS)-5-[(2-fluorophenoxy)methyl]-6-hydroxyoctahydrocyclopenta[b]pyran-2-yl}-1,3-thi
azole-4-carboxylic acid (27d) 
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1
H NMR (300 MHz, DMSO-d6) δ 8.34 (s, 1H), 7.17 (m, 3H), 6.94 (m, 1H), 5.07 (t, J = 5.4 Hz, 1H), 4.21-4.10 
(m, 2H), 4.04 (m, 1H), 3.90 (m, 1H), 2.27-2.04 (m, 3H), 1.96-1.65 (m, 5H) (Peaks of OH and CO2H were not 
observed.).  LCMS (ELSD) RT = 0.83 min (>98%).  MS (FAB, Neg.) m/z 392 (M - H)
-
.  HRMS (FAB, 
Neg.) C19H19FNO5S (M - H)
-
 calc. mass 392.0968, found 392.0964 
 
2-{(2R,4aR,5R,6R,7aS)-6-hydroxy-5-[(3-methylphenoxy)methyl]octahydrocyclopenta[b]pyran-2-yl}-1,3-th
iazole-4-carboxylic acid (27e) 
1
H NMR (300 MHz, DMSO-d6) δ 8.42 (s, 1H), 7.13 (t, J = 7.8 Hz, 1H), 6.74-6.70 (m, 3H), 5.08 (t, J = 6.3 Hz, 
1H), 4.88 (d, J = 5.1 Hz, 1H), 4.15-4.03 (m, 2H), 3.95-3.82 (m, 2H), 2.26 (s, 3H), 2.23-2.08 (m, 3H), 1.90-1.65 
(m, 5H) (Peak of CO2H was not observed.).  LCMS (ELSD) RT = 0.88 min (>98%).  MS (FAB, Neg.) m/z 
388 (M - H)
-
.  HRMS (FAB, Neg.) C20H22NO5S (M - H)
-
 calc. mass 388.1219, found 388.1212 
 
2-{(2R,4aR,5R,6R,7aS)-5-[(3-chlorophenoxy)methyl]-6-hydroxyoctahydrocyclopenta[b]pyran-2-yl}-1,3-th
iazole-4-carboxylic acid (27f) 
1
H NMR (300 MHz, DMSO-d6) δ 8.42 (s, 1H), 7.28 (dd, J = 8.1, 7.8 Hz, 1H), 7.01 (m, 1H), 6.97 (d, J = 7.8 Hz, 
1H), 6.91 (d, J = 8.1 Hz, 1H), 5.08 (t, J = 6.0 Hz, 1H), 4.89 (d, J = 5.4 Hz, 1H), 4.10 (m, 2H), 4.01 (m, 1H), 
3.86 (m, 1H), 2.25-2.04 (m, 3H), 1.93-1.60 (m, 5H) (Peak of CO2H was not observed.).  LCMS (ELSD) RT = 
0.90 min (>98%).  MS (FAB, Neg.) m/z 408 (M - H)
-
.  HRMS (FAB, Neg.) C19H19
35
ClNO5S (M - H)
-
 calc. 
mass 408.0672, found 408.0663 
 
2-[(2R,4aR,5R,6R,7aS)-6-hydroxy-5-{[3-(trifluoromethoxy)phenoxy]methyl}octahydrocyclopenta[b]pyran
-2-yl]-1,3-thiazole-4-carboxylic acid (27g)  
1
H NMR (300 MHz, CDCl3) δ 8.30 (s, 1H), 7.27 (m, 1H), 6.81 (m, 2H), 6.74 (m, 1H), 5.22 (t, J = 4.8 Hz, 1H), 
4.21 (m, 2H), 4.07 (m, 1H), 3.96 (m, 1H), 2.47 (m, 1H), 2.27 (m, 2H), 2.22-2.12 (m, 1H), 2.11-2.00 (m, 2H), 
1.87 (m, 1H), 1.77 (m, 1H) (Peaks of OH and CO2H were not observed.).  LCMS (ELSD) RT = 0.95 min 
(>98%).  MS (FAB, Neg.) m/z 458 (M - H)
-
.  HRMS (FAB, Neg.) C20H19F3NO6S (M - H)
-
 calc. mass 
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458.0885, found 458.0883 
. 
2-[(2R,4aR,5R,6R,7aS)-6-hydroxy-5-{[3-(trifluoromethyl)phenoxy]methyl}octahydrocyclopenta[b]pyran-
2-yl]-1,3-thiazole-4-carboxylic acid (27h) 
1
H NMR (300 MHz, CDCl3) δ 8.31 (s, 1H), 7.38 (dd, J = 8.1, 7.8 Hz, 1H), 7.22 (m, 1H), 7.07 (m, 2H), 5.22 (t, J 
= 5.1 Hz, 1H), 4.23 (m, 2H), 4.10 (m, 1H), 3.99 (m, 1H), 2.49 (m, 1H), 2.32 (m, 2H), 2.19 (m, 1H), 2.05 (m, 
2H), 1.91 (m, 1H), 1.79 (m, 1H) (Peaks of OH and CO2H were not observed.).  LCMS (ELSD) RT = 0.92 min 
(>98%).  MS (FAB, Neg.) m/z 442 (M - H)
-
.  HRMS (FAB, Neg.) C20H19F3NO5S (M - H)
-
 calc. mass 
442.0936, found 442.0930 
 
2-{(2R,4aR,5R,6R,7aS)-5-[(3-fluorophenoxy)methyl]-6-hydroxyoctahydrocyclopenta[b]pyran-2-yl}-1,3-thi
azole-4-carboxylic acid (27i) 
1
H NMR (300 MHz, CDCl3) δ 8.30 (s, 1H), 7.19 (m, 1H), 6.68-6.57 (m, 3H), 5.22 (t, J = 4.8 Hz, 1H), 4.22 (m, 
2H), 4.04 (m, 1H), 3.94 (m, 1H), 2.45 (m, 1H), 2.27 (m, 2H), 2.20-1.98 (m, 3H), 1.87 (m, 1H), 1.75 (m, 1H) 
(Peaks of OH and CO2H were not observed.).  LCMS (ELSD) RT = 0.85 min (>98%).  MS (FAB, Neg.) m/z 
392 (M - H)
-
.  HRMS (FAB, Neg.) C19H19FNO5S (M - H)
-
 calc. mass 392.0968, found 392.0959 
 
2-{(2R,4aR,5R,6R,7aS)-6-hydroxy-5-[(4-methylphenoxy)methyl]octahydrocyclopenta[b]pyran-2-yl}-1,3-th
iazole-4-carboxylic acid (27j) 
1
H NMR (300 MHz, DMSO-d6) δ 8.42 (s, 1H), 7.06 (d, J = 8.1 Hz, 2H), 6.81 (d, J = 8.1 Hz, 2H), 5.08 (t, J = 
5.7 Hz, 1H), 4.87 (d, J = 5.4 Hz, 1H), 4.11 (m, 1H), 4.03 (m, 1H), 3.88 (m, 2H), 2.21 (s, 3H), 2.15 (m, 1H), 
2.07 (m, 2H), 1.91-1.64 (m, 5H) (Peak of CO2H was not observed.).  LCMS (ELSD) RT = 0.88 min (>98%).  
MS (FAB, Neg.) m/z 388 (M - H)
-
.  HRMS (FAB, Neg.) C20H22NO5S (M - H)
-
 calc. mass 388.1219, found 
388.1215 
 
2-{(2R,4aR,5R,6R,7aS)-5-[(4-chlorophenoxy)methyl]-6-hydroxyoctahydrocyclopenta[b]pyran-2-yl}-1,3-th
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iazole-4-carboxylic acid (27k)  
1
H NMR (300 MHz, DMSO-d6) δ 8.40 (s, 1H), 7.29 (d, J = 9.0 Hz, 2H), 6.95 (d, J = 9.0 Hz, 2H), 5.08 (t, J = 
6.0 Hz, 1H), 4.91 (m, 1H), 4.09 (m, 2H), 3.96 (m, 1H), 3.85 (m, 1H), 2.27-2.07 (m, 3H), 1.90-1.63 (m, 5H) 
(Peak of CO2H was not observed.).  LCMS (ELSD) RT = 0.90 min (>98%).  MS (FAB, Neg.) m/z 408 (M - 
H)
-
.  HRMS (FAB, Neg.) C19H19
35
ClNO5S (M - H)- calc. mass 408.0672, found 408.0677 
 
2-[(2R,4aR,5R,6R,7aS)-6-hydroxy-5-{[4-(trifluoromethoxy)phenoxy]methyl}octahydrocyclopenta[b]pyran
-2-yl]-1,3-thiazole-4-carboxylic acid (27l) 
1
H NMR (300 MHz, DMSO-d6) δ 8.40 (s, 1H), 7.27 (d, J = 8.4 Hz, 2H), 7.03 (d, J = 8.4 Hz, 2H), 5.08 (t, J = 
6.3 Hz, 1H), 4.90 (m, 1H), 4.10 (m, 2H), 3.99 (m, 1H), 3.87 (m, 1H), 2.19 (m, 1H), 2.10 (m, 2H), 1.90-1.64 (m, 
5H) (Peak of CO2H was not observed.).  LCMS (ELSD) RT = 0.94 min (>98%).  MS (FAB, Neg.) m/z 458 
(M - H)
-
.  HRMS (FAB, Neg.) C20H19F3NO6S (M - H)
-
 calc. mass 458.0885, found 458.0883 
 
2-[(2R,4aR,5R,6R,7aS)-6-hydroxy-5-{[4-(trifluoromethyl)phenoxy]methyl}octahydrocyclopenta[b]pyran-
2-yl]-1,3-thiazole-4-carboxylic acid (27m)  
1
H NMR (300 MHz, DMSO-d6) δ 8.39 (s, 1H), 7.63 (d, J = 9.0 Hz, 2H), 7.12 (d, J = 9.0 Hz, 2H), 5.09 (t, J = 
6.3 Hz, 1H), 4.92 (m, 1H), 4.14 (m, 2H), 4.09 (m, 1H), 3.87 (m, 1H), 2.21 (m, 1H), 2.12 (m, 2H), 1.92-1.61 (m, 
5H) (Peak of CO2H was not observed.).  LCMS (ELSD) RT = 0.93 min (>98%).  MS (FAB, Neg.) m/z 442 
(M - H)
-
.  HRMS (FAB, Neg.) C20H19F3NO5S (M - H)
-
 calc. mass 442.0936, found 442.0932 
 
2-{(2R,4aR,5R,6R,7aS)-5-[(4-fluorophenoxy)methyl]-6-hydroxyoctahydrocyclopenta[b]pyran-2-yl}-1,3-thi
azole-4-carboxylic acid (27n) 
1
H NMR (300 MHz, CDCl3) δ 8.31 (s, 1H), 6.96 (m, 2H), 6.83 (m, 2H), 5.21 (t, J = 4.8 Hz, 1H), 4.22 (m, 2H), 
4.04 (m, 1H), 3.91 (m, 1H), 2.43 (m, 1H), 2.29 (m, 2H), 2.18 (m, 1H), 2.04 (m, 2H), 1.90 (m, 1H), 1.76 (m, 1H) 
(Peaks of OH and CO2H were not observed.).  LCMS (ELSD) RT = 0.83 min (>98%).  MS (FAB, Neg.) m/z 
392 (M - H)
-
.  HRMS (FAB, Neg.) C19H19FNO5S (M - H)
-
 calc. mass 392.0968, found 392.0962 
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Synthesis of 7 
Isopropyl 2-[(2R,4aR,5R,6R,7aS)-5-[(1E)-3-oxo-4-phenoxy-1-buten-1-yl]-6- 
(tetrahydro-2H-pyran-2-yloxy)octahydrocyclopenta[b]pyran-2-yl]-1,3-thiazole-4-carboxylate (24-4) 
THPO
O
O
N
S
CO
2
iPr
H THPO
O
N
S
CO
2
iPr
O
O
24-424-2  
To a solution of 24-2 (450 mg, 1.06mmol), dimethyl (2-oxo-3-phenoxypropyl)-phosphonate (549 mg, 2.13 
mmol) and triethylamine (0.296 mL, 2.13 mmol) in THF (5.0 mL) at room temperature was added LiCl (91 mg, 
2.13 mmol).  After stirred at room temperature for 16 h, the reaction mixture was quenched with 1.0 M 
hydrochloric acid and extracted with EtOAc.  The organic layer was washed with brine and dried over Na2SO4.  
Concentration and a medium-pressure preparative liquid chromatography (Yamazen W-prep 2XY flash column 
chromatography L SI50, hexane/EtOAc 3:1-1:1) gave 24-4 (309 mg) in 52% yield. 
1
H NMR (300 MHz, CDCl3)  8.12 (brs, 1H), 7.33-7.25 (m, 2H), 7.05-6.98 (m, 2H), 6.90 (d, J = 9.0 Hz, 2H), 
6.57 (dd, J = 15.0, 7.5 Hz, 1H), 5.27 (sep, J = 6.3 Hz, 1H), 5.16 (m, 1H), 4.72 (s, 1H), 4.70 (s, 1H), 4.62 (m, 
0.5H), 4.51 (m, 0.5H), 4.21-3.96 (m, 2H), 3.84 (m, 0.5H), 3.71 (m, 0.5H), 3.42 (m, 1H), 2.94 (m, 1H), 2.41 (m, 
1H), 2.22-2.17 (m, 2H), 1.92 (m, 1H), 1.84-1.69(m, 3H), 1.63-1.45 (m, 6H), 1.37 (d, J = 6.3 Hz, 6H). 
 
Isopropyl 2-[(2R,4aR,5R,6R,7aS)-5-[(1E,3R)-3-hydroxy-4-phenoxy-1-buten-1-yl] 
-6-(tetrahydro-2H-pyran-2-yloxy)octahydrocyclopenta[b]pyran-2-yl]-1,3-thiazole-4-carboxylate (24-5) 
THPO
O
N
S
CO
2
iPr
OH
O
THPO
O
N
S
CO
2
iPr
O
O
24-4 24-5  
To a solution of 24-4 (289 mg, 0.520 mmol) and 
(3aR)-1-methyl-3,3-diphenyl-tetrahydro-3H-pyrrolo[1,2-c][1,3,2]oxazaborole (1.0 M THF solution, 0.182 mL, 
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0.182 mmol) in THF (4.0 mL) at 0 °C was added borane-dimethyl sulfide complex (35.6 mg, 0.468 mmol).  
After stirred at 0 °C for 1 h, the reaction mixture was quenched with MeOH and H2O and extracted with EtOAc.  
The organic layer was washed with brine and dried over Na2SO4.  Concentration and a medium-pressure 
preparative liquid chromatography (Yamazen W-prep 2XY flash column chromatography L SI50, 
hexane/EtOAc 3:1-1:1) gave 24-5 (267 mg) in 92% yield. 
1
H NMR (300 MHz, CDCl3)  8.12 (brs, 1H), 7.31 (t, J = 7.5 Hz, 2H), 7.00 (t, J = 7.5 Hz, 1H), 6.92 (d, J = 7.5 
Hz, 2H), 5.85-5.65 (m, 2H), 5.27 (sep, J = 6.0 Hz, 1H), 5.16 (t, J = 5.4 Hz, 1H), 4.70 (m, 1H), 4.54 (m, 1H), 
4.17 (m, 1H), 4.02 (m, 2H), 3.87 (m, 2H), 3.46 (m, 1H), 2.78 (m, 1H), 2.40 (m, 2H), 2.29-2.10 (m, 2H), 
1.97-1.76 (m, 3H), 1.72-1.43 (m, 6H), 1.33 (d, J = 6.0 Hz, 6H) (Peak of OH was not observed.). 
 
The stereochemistry of C15 position was determined by modified Mosher’s method.  
OH
O
N
S
OMTPA
O
O
O
CH
3
CH
3
=S-R
-0.018
-0.016
-0.046
-0.017
-0.021
+0.140
+0.173
+0.062
+0.011
+0.017
+0.039
+0.056
+0.094
+0.033
+0.015
+0.011
+0.011+0.008
+0.008
+0.006
-0.003
 
  
Isopropyl 2-{(2R,4aR,5R,6R,7aS)-6-hydroxy-5-[(1E,3R)-3-hydroxy-4-phenoxy-1-buten-1-yl]octahydro 
cyclopenta[b]pyran-2-yl}-1,3-thiazole-4-carboxylate (24-6) 
THPO
O
N
S
CO
2
iPr
OH
O
OH
O
N
S
CO
2
iPr
OH
O
24-5 24-6  
To a solution of 24-5 (130 mg, 0.233 mmol) in MeOH (4.0 mL) at room temperature was added p-toluene 
sulfonic acid monohydrate (4.4 mg, 0.023 mmol).  After stirred at room temperature for 5 h, the reaction 
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mixture was quenched with Et3N.  Concentration and a medium-pressure preparative liquid chromatography 
(Yamazen W-prep 2XY flash column chromatography L SI50, hexane/EtOAc 3:1-1:1) gave 24-6 (89.0 mg) in 
81% yield. 
1
H NMR (300 MHz, CDCl3)  8.14 (s, 1H), 7.31 (t, J = 7.5 Hz, 2H), 6.98 (t, J = 7.5 Hz, 1H), 6.92 (d, J = 7.5 
Hz, 2H), 5.73 (m, 2H), 5.27 (sep, J = 6.0 Hz, 1H), 5.19 (t, J = 5.1 Hz, 1H), 4.55 (m, 1H), 4.16 (m, 1H), 4.01 (dd, 
J = 15.3, 3.3 Hz, 1H), 3.97 (m, 1H), 3.89 (dd, J = 15.3, 7.8 Hz, 1H), 2.66 (m, 1H), 2.46 (m , 1H), 2.33-2.24 (m, 
3H), 1.98 (m, 1H), 1.85 (m, 1H), 1.64 (m, 1H), 1.38 (d, J = 6.0 Hz, 6H) (Peaks of OH were not observed.). 
 
2-{(2R,4aR,5R,6R,7aS)-6-hydroxy-5-[(1E,3R)-3-hydroxy-4-phenoxy-1-buten-1-yl]octahydrocyclopenta[b]
pyran-2-yl}-1,3-thiazole-4-carboxylic acid (7) 
OH
O
N
S
CO
2
iPr
OH
O
OH
O
N
S
OH
O
CO
2
H
24-6
7  
To a solution of 24-6 (64.0 mg, 0.135 mmol) in MeOH (2.0 mL) at room temperature was added 2.0 M sodium 
hydroxide (1.0 mL, 2.0 mmol).  After stirred at room temperature for 2 h, the reaction mixture was quenched 
with 1.0 M hydrochloric acid and extracted with EtOAc. The organic layer was washed with H2O and brine and 
dried over Na2SO4.  Concentration gave 7 (56.2 m) in 96 % yield: colorless viscous oil. 
1
H NMR (300 MHz, CDCl3) δ 8.30 (s, 1H), 7.28 (m, 2H), 6.99 (t, J = 6.6 Hz, 1H), 6.92 (d, J = 6.6 Hz, 2H), 
5.74 (m, 2H), 5.19 (t, J = 5.1 Hz, 1H), 4.56 (m, 1H), 4.14 (m, 1H), 4.01 (m, 2H), 3.91 (m, 1H), 2.68 (m, 1H), 
2.33 (m, 1H), 2.25 (m, 2H), 1.96 (m, 1H), 1.85 (m, 1H), 1.69-1.56 (m, 2H) (Peaks of OH and CO2H were not 
observed.).  LCMS (ELSD) RT = 0.75 min (>98%).  MS (FAB, Neg.) m/z 430 (M - H)
-
.  HRMS (FAB, 
Neg.) C22H24NO6S (M - H)
-
 calc. mass 430.1324, found 430.1321. 
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Biology In vitro assay 
EP2, EP4 and IP cAMP assay 
Chinese hamster ovary (CHO) cells (1.25×10
5
 cells/well) expressing human EP2 or human EP4 or human IP 
receptor were harvested and suspended in a 96-well 1/2 area plate. cAMP concentrations were measured using a 
cAMP HTRF HiRange kit (Cisbio Bioassays)* after treatment of compounds. The reaction rate (%) of the 
compounds relative to the cAMP concentration obtained with PGE2 treatment at 1μM was calculated. 
Furthermore, a non-linear regression analysis was performed using the Sigmoid Emax Model to estimate EC50 
values. 
*http://www.cisbio.com/usa/drug-discovery/membrane-based-assays-camp-hirange-assay-kit (accessed Nov 24, 
2015) 
 
EP2 β arrestin recruitment assay 
PathHunter β-arrestin HEK-293 PTGER2 cell lines (DiscoveRx) were seeded at a density of 5000 cells/well 
into a 384-well plate and cultured at 37 °C in the presence of 5 % CO2 for 24 hours. β-arrestin recruitment were 
measured using a PathHunter Detection Kit (DiscoveRx)* after treatment of compounds. The reaction rate (%) 
of the compounds relative to the β-arrestin recruitment obtained with PGE2 treatment at 10μM was calculated. 
Furthermore, a non-linear regression analysis was performed using the Sigmoid Emax Model to estimate EC50 
values. 
* https://www.discoverx.com/product-data-sheets-3-tab/93-0214c1 (accessed Nov 24, 2015) 
 
EP1, EP3 and FP Ca assay 
Chem-1 cells expressing human FP receptor or Chinese hamster ovary (CHO) cells expressing human EP1 or 
human EP3 were seeded at a density of 1×10
4
 cells per well into 96-well plates and cultured at 37℃ in the 
presence of 5% CO2 for 2 days. Load buffer (HBSS containing Calcium 5, 10 mM HEPES, 20μM indomethacin, 
and 2.5 mM probenecid) was added in each well and incubated in the dark at room temperature for 1 hour. After 
addition of the compounds, intracellular Ca
2+
 concentration was measured using a fluorescence drug screening 
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system (FDSS-7000 : Hamamatsu Photonics, Tokyo, Japan)*. The reaction rate (%) of the compounds relative 
to intracellular Ca
2+ 
concentration obtained with maximum increases of PGE2 treatment was calculated. 
Futhermore, a non-linear analysis was performed using the Sigmoid Emax Model to estimate EC50 values.  
* http://www.hamamatsu.com/jp/ja/FDSS7000EX.html (accessed Nov 24, 2015)  
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Chapter 2-2 
Structural optimization and structure-functional selectivity 
relationship studies of   
G protein-biased EP2 receptor agonists 
 
Abstract:  
Further modification of novel G protein-biased EP2 agonist 1 was undertaken to improve G protein activity and 
investigate structure-functional selectivity relationship.  Optimization of substituents on phenyl group, followed 
by modification of 11-OH led the author find 9 with 100-fold increase in G protein activity relative to 1 without 
increase of β arrestin recruitment.  Furthermore, SFSR studies revealed that the combination of meta and para 
substituents on phenyl moiety was crucial to regulate the functional selectivity.  
 
 
Figure 2-2-1. Outline of Chapter 2-2 
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Introduction 
 
G protein-coupled receptors (GPCRs) are the one of the most successful targets of drug discovery. A lot of 
drugs targeting GPCRs have already been launched as therapeutic agents for a variety of diseases.  In addition to 
G protein activation, GPCRs can also activate other distinct signaling pathways like β arrestin signaling. β 
arrestins were regarded as negative regulators of G protein-mediated signaling. It is suggested that the  arrestin 
also have a variety of functions by regulating GPCR internalization and promoting intracellular signaling 
independently.  Recently, GPCR biased ligands are identified to engage signals selectively and also inhibit other 
signals mediated by the same receptor.  Biased ligand received a fair amount of attention in drug discovery, 
because they might have potentials to enhance efficacy or remove on-target adverse effect. A number of GPCR 
biased ligands have been revealed
1-6 
and some of them have already tested in clinical development.  
 
O
N
H
S
O
CH
3
N
Sar-Arg-Val-Tyr-Ile-His-Pro-D-Ala-OH
TRV130 ( opioid receptor G protein-biased ligand)TRV027 (AT1R  arrestin-biased ligand)
2 3
 
.  
Figure 2-2-2; Reported GPCR biased ligands 
 
TRV027 (2)
6
 is a β arrestin-biased agonist of angiotensin II type I receptor.  TRV027 exhibited unique 
pharmacology, distinct from classical angiotensin II receptor blockers (ARBs, i.e. losartan and varsartan).  
Classical ARBs is known to decrease both blood pressure and cardiac performance in rat.  On the other hand, 
TRV027, which particularly activates β arrestin signaling, exerted potent hypotensive action without decrease of 
cardiac performance and preserved stroke volume in rat.  These findings suggested that TRV027 would be a 
beneficial therapeutic agent for acute heart failure (AHF).
7
  TRV130 (3)
5
is reported as G protein-biased agonist 
of μ opioid receptor to exert desired analgesic effects in mice and rat with reducing morphine’s side effects, such 
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as constipation and respiratory depression.  TRV130 is under evaluation in Phase IIb for the treatment of acute 
severe pain. 
In previous study, the author has reported the identification of novel G protein-biased EP2 agonist 1
8
.  
Recently a number of studies of EP2 receptor signaling and their functions were reported.  EP2 receptor exerted 
beneficial neuroprotective effects in the brain via G protein-mediated cAMP-PKA signaling
9-12
, on the other hand, 
the activation of β arrestin signaling of EP2 receptor led to deleterious effects, like tumorigenesis and 
angiogenesis.
13-15
  Therefore, EP2 receptor G protein-biased ligand is expected to be new generation of EP2 
agonists that particularly increase the efficacy and avoid deleterious effect of EP2 receptor.  
In this chapter, the author describes further optimization of novel G protein-biased agonist 1 to increase G protein 
activity and functional selectivity.  Structure-functional selectivity relationship (SFSR)
4
 studies are also reported. 
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Results and discussion 
 
Optimization of substituents on pheny group  
In chapter 2-1
8
, the author reported the identification of highly selective EP2 agonists 1 and investigated SFSR 
study.  The SFSR indicated that introduction of meta substituent into phenyl group of 1 remarkably improved G 
protein activity while it also increased β arrestin activity (4a).  On the other hand, introduction of para 
substituent (4b) showed decreased β arrestin recruitment (Emax 28% → 12%) without loss of G protein 
activity.  The author supposed that combination of meta substituent and para substituent improved both G 
protein activity and functional selectivity.  Therefore, the author synthesized and evaluated di-substituted 
analogues 4c-j. The results are shown in Table2-2-1. 
O
OH
O
N
S
CO
2
H
R1
R2
R3
R4
R5
 
Cpmd R1 R2 R3 R4 R5 
hEP2 
G protein (cAMP) β arrestin 
EC50(nM) Emax
b
 EC50(nM) Emax 
1 H H H H H 13 118 >10,000 28  
4a H CF3 H H H 0.90 112 9.0 62  
4b H H Cl H H 3.9 96 >10000 12  
4c H CF3 Cl H H 0.11 78 >10,000 41  
4d H Cl Cl H H 0.57 100 >10,000 23  
4e H Me Cl H H 0.69 88 >10,000 23  
4f H Et Cl H H 0.68 95 >10,000 29  
4g H iPr Cl H H 2.0 122 >10,000 29  
4h H OMe Cl H H 1.8 83 >10,000 19  
4i H Me Me H H 2.9 90 >10,000 36  
4j H Me CF3 H H 3.9 85 >10,000 46  
4k H Me Cl Me H 0.17 102 2.3 98  
4l H Cl Cl H Cl 0.20 99 3.7 94  
4m Cl Cl Cl H H 0.21 102 2.3 98  
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a
Assay protocols are provided in the Supporting Information. EC50 values represent the mean of two experiments. 
 b
All Emax were normalized to PGE2 
results. 
Table 2-2-1. Optimization of substituents on the pheny group 
 
As the author expected, compound 4c, which hybridizes the substituents of 4a and 4b, showed a 35-fold 
increased G protein activity compared to 4b with decreasing  arrestin activity relative to 4a.  However, 4c still 
modulated β arrestin recruitment (Emax 41%) while its G protein activity is partial (78%).  Therefore, the author 
continued further optimization of meta substituents of 4c. Both of 3,4-diCl analogue 4d and 3-Me-4-Cl analogue 
4e decreased β arrestin efficacy relative to 4c (Emax 41% to 23%), retaining potent G protein activity.  
Introductions of more steric hindered substituent 3-Et and 3-iPr group gave 4f and 4g, both of which also 
decreased β arrestin activity (Emax 41% to 29%) without significant loss of G protein activity. Electron donating 
group 3-MeO analogue 4h showed less potent G protein activity than 4c though it decreased β arrestin activity 
(Emax 41% to 19%).  Conversion of para-substituents of 4e to Me and CF3 group gave 4i and 4j, both of which 
exerted lower G protein activity and increased β arrestin activity compared to 4e (Emax 23% to 36% and 46%, 
respectively).  Introduction of 5-Me substituent into another meta position of 4e gave 4k, which showed 
significant increase of β arrestin recruitment compared to 4e (EC50 >10,000nM to 2.3 nM).  The other 
tri-substituents analogues 4l and 4m also showed highly potent β arrestin activity similar to 4k.  These results 
suggested that the combination of meta and para substituent should be essential to satisfy both G protein biased 
agonist activity and selectivity. 
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Optimization of  chain of 4e 
In next attempts, transformation of heterocyclic group of α chain was carried out to investigate the effect of 
thiazole group as outlined in Table 2-2-2.  Introduction of oxazole group instead of thiazole of 4e gave 5, which 
showed a 21-fold decrease of G protein activity.  2,5-Furan analogue 6 showed slightly decreased G protein 
activity without loss of functional and receptor-subtype selectivity.  On the other hand, 2,4-thiophene analogue 7 
and 2,4-furan analogue 8 significantly decreased G protein activity (167-fold and 80-fold).  These results 
indicate that thiazole group should be an optimal moiety of the heterocyclic part for potent EP2 activity.  
 
 
 
 
cmpd R 
hEP2 
hEP1 
EC50(nM)
a
 
hEP3 
EC50(nM)
a
 
hEP4 
EC50(nM)
a
 
hIP 
EC50(nM)
a
 
hFP 
EC50(nM)
a
 
G protein(cAMP) β arrestin 
EC50(nM)
a
 Emax(%) EC50(nM)
a
 Emax(%) 
4e NS
CO
2
H
 
0.69 88 >10,000 23 >10,000 >10,000 >10,000 4900 >10,000 
5 NO
CO
2
H
 
15 127 >10,000 18 >10,000 >10,000 >10,000 7900 >10,000 
6 O
CO
2
H
 
2.2 96 >10,000 17 >10,000 >10,000 >10,000 5300 >10,000 
7 
S
CO
2
H
 
114 102 >10,000 28 >10,000 >10,000 >10,000 >10,000 >10,000 
8 
O
CO
2
H
 
55 109 >10,000 21 >10,000 >10,000 >10,000 >10,000 >10,000 
 
aAssay protocols are provided in the Supporting Information. EC50 values represent the mean of two experiments. 
Table 2-2-2. Optimization of chain 
 
  
R
OH
O
O
Cl
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Optimization of 11-hydroxyl group 
Chemical modification of 11-OH was performed to improve G protein activity and investigate SFSR as shown 
in Table 2-2-3.  Compound 9 with 11β-hydroxyl moiety exerted 4.9-fold more potent G protein activity than 4e 
without any change in β arrestin recruitment.  On the other hand, 11β-methoxy analogue 10 and 11β-fluoride 
analogue 11 decreased G protein activity relative to compound 9.  These results indicate that hydrogen donating 
profile of 11-hydroxyl group would be crucial to show potent G protein activity.  To the author’s best 
knowledge, there are no reports of potent EP2 agonist which has unnatural 11-hydroxyl group, therefore the 
author supposed that hydroxyl moiety of 9 interacts with EP2 receptor in a different manner from 11-hydroxyl 
group of PGE2 or previously reported EP2 agonist (PGE2 analogues). Furthermore, the interaction of 
11-hydroxyl group with EP2 receptor might cause conformational change of intracellular region to interact with 
G protein preferentially. 
 
 
 
      
 
cmpd R 
hEP2 
hEP1 
EC50(nM)
a
 
hEP3 
EC50(nM)
a
 
hEP4 
EC50(nM)
a
 
hIP 
EC50(nM)
a
 
hFP 
EC50(nM)
a
 
G protein(cAMP) β arrestin 
EC50(nM)
a
 Emax(%) EC50(nM)
a
 Emax(%) 
4e 
OH
 
0.69 88 >10,000 23  >10,000 >10,000 >10,000 4900 >10,000 
9 
OH
 
0.14 97 >10,000 21 >10,000 >10,000 >10,000 >10,000 >10,000 
10 
MeO
 
23 73 >10,000 - >10,000 >10,000 >10,000 >10,000 >10,000 
11 
F
 
11 110 >10,000 31 >10,000 >10,000 >10,000 1700 >10,000 
 
aAssay protocols are provided in the Supporting Information. EC50 values represent the mean of two experiments. 
Table 2-2-3; Optimization of 11-hydroxyl group 
R
O
O
Cl
N
S
CO
2
H
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Recently, a fair number of researches on relationship between the structure of GPCRs and biased signaling have 
been reported.  X-ray crystallography and NMR spectroscopy studies give useful information to consider the 
differences between biased agonist and full agonist, particularly, binding site of biased ligands
16,17 
, interactions of 
receptor with G protein and  arrestin
18
,
 
and conformational change of intracellular loop of receptors when biased 
ligand or unbiased ligands bind to the receptor.
19
  Taking into account these reports, the interaction of ligand 
with transmembrane 5 (TM5) and TM6 of receptor is considered to play a key role to activate G protein-mediated 
signaling, and the interaction of ligands with TM7 would result in activating β arrestin recruitment.  The author 
supposes that meta and para substituents of phenyl group obtained a specific hydrophobic or Van der Waals 
interaction with TM5 and/or TM6 of EP2 receptor, and ortho substituents may interact with TM7. The technical 
innovation in analyzing the structure of GPCRs (i.e. X-ray crystallography and NMR spectroscopy) makes 
enormous strides forward in these days.  These technologies might reveal three- dimensional structure of EP2 
receptor and its structure would enable the author to validate the author hypothesis.  
 
Figure 2-2-3; Proposed interaction between EP2 agonists and receptor. 
 
Syntheses of bicyclic derivatives 
All tested compounds in Tables 2-2-1, 2 and 3 were synthesized as outlined in Schemes 2-2-1A-F. 
Compounds 4c-l were synthesized by a sequential procedure: step 1; introduction of 3-chloro-4-methylphenol by 
Mitsunobu reaction, step 2; removal of protecting groups of 11-hydroxyl or carboxylic acid moiety as outlined in 
Scheme 2-2-1A. 
Syntheses of 6, 7 and 8 were described in Scheme 2-2-1B.  Transformations of the thiazole part were performed 
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by coupling reaction of 18 with Reformatsky type reagents.  Deprotection of the TBS group gave alcohols, 
followed by a sequential procedure afforded compounds 6-8.   
Compound 5 couldn’t be synthesized in similar manner as described in Scheme 2-2-1B due to instability of 
Reformatsky reagent, therefore oxazole ring was constructed stepwise procedure as described in Scheme 2-2-1C. 
Firstly, the acetyl protecting group of 13 was converted to THP group, which is tolerable to reducing agent.  
Nitrile 14 was reduced to an aldehyde, Pinnick oxidation of which afforded the carboxylic acid derivative.  The 
resulting product was transformed to serine ester 15 through an acid anhydride intermediate.  The oxazoline ring 
was constructed under dehydration condition, and aromatization under oxidation condition gave oxazole 16. 
Deprotection of the TBS group, followed by a sequential procedure gave 5. 
As described in Scheme 2-2-1D, the 11β-hydroxyl group of 9 was introduced by Mitsunobu reaction with 20. 
Deprotection of the TBDPS group afforded 21, which was transformed to 9 by a sequential procedure. 
Synthesis of 10 was outlined in Scheme 2-2-1E.  11β-OH group was introduced in the similar manner of 
Scheme 1D. Methylation was performed with methyl iodide in the presence of silver oxide.         
Synthesis of 11 was shown in Scheme 2-2-1F.  A sequential procedure from 25 gave 26.  11β-fluoride was 
introduced by using Deoxo-Fluor, and hydrolysis of ester gave 11. 
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Reagents & conditions: (a) TMAD, Bu3P, THF, rt, 32-100%, (b) NaOHaq., DME, MeOH, rt, 86-100%, (c) 
K2CO3, MeOH, rt, 85-93%, (d) DHP, PPTS, CH2Cl2, rt, 92%, (e) DIBAL, CH2Cl2, –78 °C, (f) NaOCl, NaH2PO4, 
t-BuOH, H2O, THF, rt, (g) isobutyl chloroformate, NMM, THF, –30 °C, (h) L-serine, rt, 42% (4 steps), (i) 
[bis(2-methoxyethyl)amino]sulfur trifluoride, CH2Cl2, –20 °C, 35%, (j) BrCCl3, DBU, CH2Cl2, 0 °C, 89%, (k) 
TBAF, THF, rt, 48-84%, (l) TsOH, MeOH, rt, 81-93%, (m) BrZnRCO2Et, AlCl3, CH3CN, 0 °C-rt, 31-87%, (n) 
TBAF, AcOH, THF, 31-86%, (o) AcOH, DEAD, Ph3P, THF, rt, (p) HCO2H, DEAD, Ph3P, rt, 93%, (q) MeI, 
Ag2O, MeCN, rt, 22%, (r) diethyl-aminosulfur trifluoride, CH2Cl2, –78 °C, 57%, 
Scheme 2-2-1. Syntheses of G protein-biased EP2 agonists 
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Overall, precise optimization of substituents on the phenyl group of 1 and introduction of 11 hydroxyl 
group led the author find 100-fold more potent G protein-biased EP2 agonist 9.  SFSR studies revealed 
that structure of ω chain dramatically changes the functional selectivity of EP2 receptor.  Particularly, the 
combination of meta and para substituents on the phenyl group enhanced G protein-biased signaling of 
EP2 receptor.  A series of G protein-biased EP2 agonists showed potent intraocular lowering effect in 
rabbit and monkey.
20
  Further studies of EP2 biased agonists will be reported in due course. 
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General Experimental. 
Analytical samples were homogeneous as confirmed by TLC, and spectroscopic results were consistent with the 
assigned structures.  NMR spectra were recorded as designated on either a Varian Mercury 300 spectrometer or 
INOVA-500 spectrometer using deuterated chloroform (CDCl3) or deuterated dimethyl sulfoxide (DMSO-d6) as 
the solvent.  Mass spectral analyses with fast atom bombardment (FABMS, HRMS) and electron ionization (EI) 
were performed on a JEOL JMS-DX303HF spectrometer.  Purity analysis was carried out by the following 
LC/MS system. LC/MS: Waters ACQUITY UPLC system fitted by with Waters Micromass ZQ-2000 
spectrometer. Column; YMC Triart C18 (2.0 mm × 30 mm). Eluting over 1.5 min with 5−95% 
acetonitrile( 0.1% TFA) in water (0.1%TFA), flow rate of 1.0 mL/min, column temperature of 30 °C, detection 
with UV (PDA) and ELSD.  Column chromatography was performed with silica gel [Merck Silica Gel 60 
(0.063−0.200 μm), Wako gel C- 200, Fuji Silysia PSQ-100B or Fuji Silysia FL60D].  Thin layer 
chromatography was performed with silica gel (Merck TLC or HPTLC plates, Silica Gel 60 F254). 
Medium-pressure preparative liquid chromatography was performed with a medium-pressure preparative liquid 
chromatograph W-prep 2XY (manufactured by Yamazen Corporation; column: main column size S-5L, inject 
column size SS-2L).  
The following abbreviations for solvents and reagents are used: DMF, N,N-dimethylformamide; DMSO, 
dimethyl sulfoxide; EtOH, ethanol; EtOAc, ethyl acetate; MeOH methanol; THF, tetrahydrofuran; CH2Cl2, 
dichloromethane; tert-BuOMe, tert-butyl methyl ether; iPr2O, diisopropyl ether; CH3CN, acetonitrile; Et3N, 
triethylamine; TFA, trifluoroacetic acid; IPA, isopropyl alcohol; 
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Experimental Procedure 
Scheme 2-2-1A  
2-{(2R,4aR,5S,6R,7aS)-5-[(4-chloro-3-methylphenoxy)methyl]-6-hydroxyoctahydrocyclopenta[b]pyran-2-yl}
-1,3-thiazole-4-carboxylic acid (4e) 
AcO
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S
CO
2
Et
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Cl
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H
12 12-2
4e
 
To a solution of 12 (30.0 mg, 0.081 mmol), 3-methyl-4-chlorophenol (15.0 mg, 0.105 mmol) and 
1,1'-azobis(N,N-dimethylformamide) (27.9 mg, 0.162 mmol) in THF (0.8 mL) at room temperature was added 
tributylphosphine (40 L, 0.162 mmol)).  After the mixture was stirred at room temperature for 16 h, 
concentration and a medium-pressure preparative liquid chromatography (Yamazen W-prep 2XY flash column 
chromatography S, hexane/EtOAc 4:1-3:2) gave 12-2 (26.3 mg) in 66% yield. 
1
H NMR (300 MHz, CDCl3) δ 8.16 (s, 1H), 7.20 (d, J = 8.7 Hz, 1H), 6.75 (d, J = 3.0 Hz, 1H), 6.64 (dd, J = 8.7, 
3.0 Hz, 1H), 5.17 (t, J = 5.4 Hz, 1H), 5.07 (m, 1H), 4.40 (q, J = 6.9 Hz, 2H), 4.32 (m, 1H), 4.02 (m, 2H), 
2.50-2.43 (m, 1H), 2.41 (m, 1H), 2.33 (s, 3H), 2.32-2.22 (m, 1H), 2.16 (m, 1H), 2.09 (s, 3H), 2.06-1.97 (m, 2H), 
1.92 (m, 1H), 1.74 (m, 1H), 1.40 (t, J = 6.9 Hz, 3H). 
To a solution of 12-2 (26.3 mg, 0.053 mmol) in MeOH (1.0 mL) at room temperature was added 2.0 M sodium 
hydroxide (0.14 mL 0.28 mmol).  After stirred at room temperature for 16 h, the reaction mixture was quenched 
with 1.0 M hydrochloric acid and extracted with EtOAc. The organic layer was washed with H2O and brine and 
dried over Na2SO4.  Concentration gave 4e (25.0 mg) in 100 % yield. 
1
H NMR (300 MHz, DMSO-d6) δ 8.35 (s, 1H), 7.27 (d, J = 8.7 Hz, 1H), 6.95 (d, J = 3.0 Hz, 1H), 6.79 (dd, J = 8.7, 
3.0 Hz, 1H), 5.07 (t, J = 6.6 Hz, 1H), 4.89 (m, 1H), 4.14-4.04 (m, 2H), 3.92 (m, 1H), 3.84 (m, 1H), 2.26 (s, 3H), 
2.21-2.04 (m, 3H), 1.90-1.63 (m, 5H). (Peak of CO2H was not observed.)  
13
C NMR (75 MHz, CDCl3) δ 20.32, 
20.68, 24.19, 38.80, 41.92, 45.65, 67.20, 72.46, 72.79, 73.59, 113.11, 117.08, 126.30, 129.04, 129.70, 137.18, 
145.96, 157.12, 162.24, 174.54.  LCMS (ELSD) RT = 0.95 min (>983%).  MS (FAB, Neg.) m/z 422 (M - H)
-
.  
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HRMS (FAB, Neg.) C20H21
35
ClNO5S (M - H)
-
 calc. mass 422.0829, found 422.0829. 
 
All compounds in Table 2-2-3 were synthesized in the same procedure. 
2-[(2R,4aR,5S,6R,7aS)-5-{[4-chloro-3-(trifluoromethyl)phenoxy]methyl}-6-hydroxyoctahydrocyclopenta[b]
pyran-2-yl]-1,3-thiazole-4-carboxylic acid (4c) 
1
H NMR (300 MHz, DMSO-d6) δ 8.36 (s, 1H), 7.61 (d, J = 8.4 Hz, 1H), 7.34 (d, J = 3.0 Hz, 1H), 7.27 (dd, J = 8.4, 
3.0 Hz, 1H), 5.08 (t, J = 6.0 Hz, 1H), 4.90 (m, 1H), 4.18-4.04 (m, 3H), 3.87 (m, 1H), 2.20 (m, 1H), 2.11 (m, 2H), 
1.90-1.64 (m, 5H). (Peak of CO2H was not observed.)  LCMS (ELSD) RT = 0.95 min (>98%).  MS (FAB, 
Neg.) m/z 476 (M - H)
-
.  HRMS (FAB, Neg.) C20H18
35
ClF3NO5S (M - H)
-
 calc. mass 476.0546, found 476.0549. 
 
2-{(2R,4aR,5S,6R,7aS)-5-[(3,4-dichlorophenoxy)methyl]-6-hydroxyoctahydrocyclopenta[b]pyran-2-yl}-1,3-t
hiazole-4-carboxylic acid (4d) 
1
H NMR (300 MHz, DMSO-d6) δ 8.37 (s, 1H), 6.83 (d, J = 9.0 Hz, 1H), 6.54 (d, J = 2.7 Hz, 1H), 6.42 (dd, J = 9.0, 
2.7 Hz, 1H), 5.08 (t, J = 6.6 Hz, 1H), 4.87 (m, 1H), 4.12 (m, 1H), 4.00 (m, 1H), 3.89 (m, 2H), 3.72 (s, 3H), 3.67 (s, 
3H), 2.18 (m, 1H), 2.08 (m, 2H), 1.90-1.69 (m, 5H). (Peak of CO2H was not observed.)  LCMS (ELSD) RT = 
0.96 min (>98%).  MS (FAB, Neg.) m/z 442 (M - H)
-
.  HRMS (FAB, Neg.) C19H18
35
Cl2NO5S (M - H)
-
 calc. 
mass 442.0283, found 442.0278. 
 
2-{(2R,4aR,5S,6R,7aS)-5-[(4-chloro-3-ethylphenoxy)methyl]-6-hydroxyoctahydrocyclopenta[b]pyran-2-yl}-1
,3-thiazole-4-carboxylic acid (4f) 
1
H NMR (300 MHz, DMSO-d6) δ 8.39 (s, 1H), 7.25 (d, J = 8.7 Hz, 1H), 6.91 (d, J = 3.0 Hz, 1H), 6.79 (dd, J = 8.7, 
3.0 Hz, 1H), 5.08 (t, J = 6.3 Hz, 1H), 4.90 (m, 1H), 4.11 (m, 1H), 4.07 (m, 1H), 3.95 (m, 1H), 3.85 (m, 1H), 2.64 
(q, J = 7.2 Hz, 2H), 2.28-2.04 (m, 4H), 1.95-1.59 (m, 4H), 1.15 (t, J = 7.2 Hz, 3H). (Peak of CO2H was not 
observed.)  LCMS (ELSD) RT = 0.98 min (>98%).  MS (FAB, Neg.) m/z 436 (M - H)
-
.  HRMS (FAB, Neg.) 
C21H23
35
ClNO5S (M - H)
-
 calc. mass 436.0985, found 436.0988.  
 
67 
 
2-{(2R,4aR,5S,6R,7aS)-5-[(4-chloro-3-isopropylphenoxy)methyl]-6-hydroxyoctahydrocyclopenta[b]pyran-2-
yl}-1,3-thiazole-4-carboxylic acid (4g) 
1
H NMR (300 MHz, CDCl3) δ 8.31 (s, 1H), 7.22 (d, J = 8.4 Hz, 1H), 6.80 (d, J = 3.0 Hz, 1H), 6.64 (dd, J = 8.4, 
3.0 Hz, 1H), 5.21 (t, J = 5.1 Hz, 1H), 4.21 (m, 2H), 4.04 (m, 1H), 3.93 (m, 1H), 3.35 (sep, J = 6.9 Hz, 1H), 2.43 
(m, 1H), 2.28 (m, 2H), 2.20-2.05 (m, 2H), 1.95 (m, 1H), 1.87 (m, 1H), 1.76 (m, 1H), 1.22 (d, J = 6.9 Hz, 6H). 
(Peaks of OH and CO2H were not observed.)  LCMS (ELSD) RT = 1.02 min (>98%).  MS (FAB, Neg.) m/z 450 
(M - H)
-
.  HRMS (FAB, Neg.) C22H25
35
ClNO5S (M - H)
-
 calc. mass 450.1142, found 450.1140.  
 
2-{(2R,4aR,5S,6R,7aS)-5-[(4-chloro-3-methoxyphenoxy)methyl]-6-hydroxyoctahydrocyclopenta[b]pyran-2-
yl}-1,3-thiazole-4-carboxylic acid (4h) 
1
H NMR (300 MHz, CDCl3) δ 8.31 (s, 1H), 7.24 (d, J = 9.0 Hz, 1H), 6.47 (d, J = 2.4 Hz, 1H), 6.41 (dd, J = 9.0, 
2.4 Hz, 1H), 5.22 (t, J = 4.8 Hz, 1H), 4.21 (m, 2H), 4.04 (m, 1H), 3.94 (m, 1H), 3.87 (s, 3H), 2.47 (m, 1H), 2.28 
(m, 2H), 2.20-2.07 (m, 2H), 1.90 (m, 1H), 1.87 (m, 1H), 1.76 (m, 1H). (Peaks of OH and CO2H were not 
observed.)  LCMS (ELSD) RT = 0.87 min (>98%).  MS (FAB, Neg.) m/z 438 (M - H)
-
.  HRMS (FAB, Neg.) 
C20H18
35
ClF3NO6S (M - H)
-
 calc. mass 438,0778, found 438.0779.  
 
2-{(2R,4aR,5S,6R,7aS)-5-[(3,4-dimethylphenoxy)methyl]-6-hydroxyoctahydrocyclopenta[b]pyran-2-yl}-1,3-t
hiazole-4-carboxylic acid (4i) 
1
H NMR (300 MHz, DMSO-d6) δ 8.33 (s, 1H), 6.99 (d, J = 8.4 Hz, 1H), 6.73 (d, J = 2.4 Hz, 1H), 6.64 (dd, J = 8.4, 
2.4 Hz, 1H), 5.07 (t, J = 6.3 Hz, 1H), 4.88 (m, 1H), 4.11 (m, 1H), 4.02 (m, 1H), 3.86 (m, 2H), 2.21-2.03 (m, 3H), 
2.16 (s, 3H), 2.12 (s, 3H), 1.87-1.61 (m, 5H). (Peak of CO2H was not observed.)  LCMS (ELSD) RT = 0.94 min 
(97.3%).  MS (FAB, Neg.) m/z 402 (M - H)
-
  HRMS (FAB, Neg.) C21H24NO5S (M - H)
-
 calc. mass 402.1375, 
found 402.1381.  
 
2-[(2R,4aR,5S,6R,7aS)-6-hydroxy-5-{[3-methyl-4-(trifluoromethyl)phenoxy]methyl}octahydrocyclopenta[b]
pyran-2-yl]-1,3-thiazole-4-carboxylic acid (4j) 
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1
H NMR (300 MHz, CDCl3) δ 8.31 (s, 1H), 7.51 (d, J = 9.0 Hz, 1H), 6.77 (m, 1H), 6.72 (m, 1H), 5.22 (t, J = 4.8 
Hz, 1H), 4.24-4.18 (m, 2H), 4.09 (dd, J = 9.0 , 5.4 Hz, 1H), 3.98 (dd, J = 9.0 , 6.3 Hz, 1H), 2.48 (m, 1H), 2.44 (m, 
3H), 2.29 (m, 2H), 2.20-1.98 (m, 3H), 1.88 (m, 1H), 1.72 (m, 1H). (Peaks of OH and CO2H were not observed.)  
LCMS (ELSD) RT = 0.96 min (>98%).  MS (FAB, Neg.) m/z 456 (M - H)
-
.  HRMS (FAB, Neg.) 
C21H21F3NO5S (M - H)
-
 calc. mass 456.1093, found 456.1100.  
 
2-{(2R,4aR,5S,6R,7aS)-5-[(4-chloro-3,5-dimethylphenoxy)methyl]-6-hydroxyoctahydrocyclopenta[b]pyran-
2-yl}-1,3-thiazole-4-carboxylic acid (4k) 
1
H NMR (300 MHz, DMSO-d6) δ 8.14 (s, 1H), 6.79 (s, 2H), 5.05 (t, J = 6.6 Hz, 1H), 4.85 (m, 1H), 4.12 (m, 1H), 
4.04 (dd, J = 9.6, 4.2 Hz, 1H), 3.91 (dd, J = 9.6, 6.3 Hz, 1H), 3.84 (m, 1H), 2.29 (s, 6H), 2.22-2.05 (m, 3H), 
1.91-1.60 (m, 5H). (Peak of CO2H was not observed.)  LCMS (ELSD) RT = 0.98 min (>98%).  MS (FAB, 
Neg.) m/z 436 (M - H)
-
.  HRMS (FAB, Neg.) C21H23
35
ClNO5S (M - H)
-
 calc. mass 436.0985, found 436.0978.  
 
2-[(2R,4aR,5S,6R,7aS)-6-hydroxy-5-[(2,4,5-trichlorophenoxy)methyl]octahydrocyclopenta[b]pyran-2-yl}-1,3
-thiazole-4-carboxylic acid (4l) 
1
H NMR (300 MHz, DMSO-d6) δ 8.36 (s, 1H), 7.79 (s, 1H), 7.46 (s, 1H), 5.09 (t, J = 5.7 Hz, 1H), 4.91 (m, 1H), 
4.25 (dd, J = 9.6, 3.3 Hz, 1H), 4.11 (m, 2H), 3.87 (dt, J = 7.8, 6.6 Hz, 1H), 2.25-2.05 (m, 3H), 1.94-1.65 (m, 5H). 
(Peak of CO2H was not observed.)  LCMS (ELSD) RT = 1.01 min (>98%).  MS (FAB, Neg.) m/z 476 (M - H)
-
.  
HRMS (FAB, Neg.) C19H17
35
Cl3NO5S (M - H)
-
 calc. mass 475.9893, found 475.9897.  
 
2-[(2R,4aR,5S,6R,7aS)-6-hydroxy-5-[(2,3,4-trichlorophenoxy)methyl]octahydrocyclopenta[b]pyran-2-yl}-1,3
-thiazole-4-carboxylic acid (4m) 
1
H NMR (300 MHz, DMSO-d6) δ 8.27 (s, 1H), 7.60 (d, J = 9.0 Hz, 1H), 7.20 (d, J = 9.0 Hz, 1H), 5.08 (t, J = 6.0 
Hz, 1H), 4.25 (dd, J = 9.9, 3.6 Hz, 1H), 4.10 (m, 2H), 3.89 (m, 1H), 2.29-2.04 (m, 3H), 1.86 (m, 3H), 1.71 (m, 
2H). (Peaks of OH and CO2H were not observed.)  LCMS (ELSD) RT = 0.99 min (97.3%).  MS (FAB, Neg.) 
m/z 476 (M - H)
-
.  HRMS (FAB, Neg.) C19H17
35
Cl3NO5S (M - H)
-
 calc. mass 475.9893, found 475.9897.  
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Scheme 2-2-1B 
Isopropyl4-[(2R,4aR,5S,6R,7aS)-6-acetoxy-5-(hydroxymethyl)octahydrocyclopenta[b]pyran-2-yl]-2- 
thiophenecarboxylate (19) 
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To a solution of 18 (490 mg, 0.960 mmol) in acetonitrile (9.0 mL) at 0 °C was added 
bromo-(5-isopropoxycarbonyl-3-thienyl)zinc (1.00 M in acetonitrile, 1.91 mL, 1.91 mmol).  After stirred at 0 °C 
for 5 min, aluminum chloride (256 mg, 1.91 mmol) was added and stirred at 0 °C for 5 min. The reaction was 
quenched with saturated aqueous potassium sodium tartrate and extracted with EtOAc. The organic layer was 
washed with brine and dried over Na2SO4.  Concentration and a medium-pressure preparative liquid 
chromatography (Yamazen W-prep 2XY flash column chromatography L, hexane/EtOAc 98:2-85:15) gave 18-2 
(519 mg) in 87% yield. 
18-2
 1
H NMR (300 MHz, CDCl3) δ 7.73 (s, 1H), 7.64-7.60 (m, 4H), 7.42-7.34 (m, 7H), 5.20 (sep, J = 6.3 Hz, 1H), 
5.13 (m, 1H), 4.93 (m, 1H), 4.05 (m, 1H), 3.78 (dd, J = 10.5, 4.5 Hz, 1H), 3.64 (dd, J = 10.5, 4.2 Hz, 1H), 2.36 (m, 
2H), 2.10 (m, 2H), 2.05 (s, 3H), 1.88-1.77 (m, 4H), 1.35 (d, J = 6.3 Hz, 6H), 1.03 (s, 9H).  
To a solution of 18-2 (519 mg, 0.836 mmol) in THF (5.0 mL) at 0 °C was added acetic acid (151 mg, 2.51 mmol) 
and tetra-n-butylammonium fluoride (1.0 M in THF, 2.51 mL, 2.51 mmol).  After stirred at room temperature for 
16 h and stirred at 50 °C for 3h, the reaction mixture was quenched with 1.0M HCl and extracted with EtOAc.  
The organic layer was washed with saturated aqueous NaHCO3 and brine and dried over Na2SO4. Concentration 
and flash a medium-pressure preparative liquid chromatography (Yamazen W-prep 2XY flash column 
chromatography M, hexane/EtOAc 3:2-1:3) gave 19 (317 mg) in 99% yield.  
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4-{(2R,4aR,5S,6R,7aS)-5-[(4-chloro-3-methylphenoxy)methyl]-6-hydroxyoctahydrocyclopenta[b]pyran-2-yl}
-2-thiophenecarboxylic acid (7) 
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To a solution of 19 (60.0 mg, 0.157 mmol), 3-methyl-4-chlorophenol (67.1 mg, 0.471 mmol) and 
1,1'-azobis(N,N-dimethylformamide) (81.0 mg, 0.471 mmol) in THF (1.0 mL) at room temperature was added 
tributylphosphine (95.2 mg, 0.471 mmol).  After the mixture was stirred at 50 °C for 3 h, concentration and a 
medium-pressure preparative liquid chromatography (Yamazen W-prep 2XY flash column chromatography S, 
hexane/EtOAc 9:1-2:3) gave 19-2 (75.2 mg) in 95% yield. 
1
H NMR (300 MHz, CDCl3) δ 7.74 (d, J = 1.5 Hz, 1H), 7.36 (d, J = 1.5 Hz, 1H), 7.19 (d, J = 8.7 Hz, 1H), 6.74 (d, 
J = 2.7 Hz, 1H), 6.65 (dd, J = 8.7, 2.7 Hz, 1H), 5.20 (sep, J = 6.3 Hz, 1H), 5.08 (m, 1H), 4.96 (t, J = 4.5 Hz, 1H), 
4.11 (m, 1H), 4.06-3.98 (m, 2H), 2.53 (m, 1H), 2.39-2.29 (m, 1H), 2.32 (s, 3H), 2.14 (m, 1H), 2.07 (s, 3H), 
1.93-1.85 (m, 4H), 1.74 (m, 1H), 1.35 (d, J = 6.3 Hz, 6H).  
To a solution of 19-2 (24.0 mg, 0.0473 mmol) in MeOH (1.0 mL) at room temperature was added 2.0 M sodium 
hydroxide (0.20 mL, 0.40 mmol).  After stirred at room temperature for 16 h, the reaction mixture was quenched 
with 1.0 M hydrochloric acid and extracted with EtOAc. The organic layer was washed with H2O and brine and 
dried over Na2SO4.  Concentration gave 7 (17.3 mg) in 86 % yield 
1
H NMR (300 MHz, CDCl3) δ 7.82 (br s, 1H), 7.46 (br s, 1H), 7.18 (m, 1H), 6.75 (s, 1H), 6.64 (dd, J = 8.7, 3.0 Hz, 
1H), 5.03 (m, 1H), 4.14 (m, 1H), 4.06 (m, 1H), 3.98 (m, 1H), 3.90 (m, 1H), 2.45 (m, 1H), 2.33 (s, 3H), 2.24 (m, 
1H), 1.98 (m, 3H), 1.77 (m, 3H). (Peaks of OH and CO2H were not observed.)  LCMS (ELSD) RT = 1.01 min 
(>98%).  MS (FAB, Neg.) m/z 421 (M - H)
-
.  HRMS (FAB, Neg.) C21H22
35
ClO5S (M - H)
-
 calc. mass 421.0876, 
found 421.0870.  
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Compound 6 and 8 were synthesized in the same procedure. 
5-{(2R,4aR,5S,6R,7aS)-5-[(4-chloro-3-methylphenoxy)methyl]-6-hydroxyoctahydrocyclopenta[b]pyran-2-yl}
-2-furoic acid (6) 
1
H NMR (300 MHz, DMSO-d6) δ 7.27 (d, J = 8.7 Hz, 1H), 7.14 (d, J = 3.6 Hz, 1H), 6.94 (d, J = 2.7 Hz, 1H), 6.78 
(dd, J = 8.7, 2.7 Hz, 1H), 6.57 (d, J = 3.6 Hz, 1H), 4.84 (m, 2H), 4.06 (m, 1H), 3.96 (m, 1H), 3.86 (m, 2H), 2.27 (s, 
3H), 2.17 (m, 2H), 1.92 (m, 2H), 1.74 (m, 2H), 1.60 (m, 2H). (Peak of CO2H was not observed.)  LCMS (ELSD) 
RT = 0.96 min (>98%).  MS (FAB, Neg.) m/z 405 (M - H)
-
.  HRMS (FAB, Neg.) C21H22
35
ClO6 (M - H)
-
 calc. 
mass 405.1105, found 405.1100.  
 
4-{(2R,4aR,5S,6R,7aS)-5-[(4-chloro-3-methylphenoxy)methyl]-6-hydroxyoctahydrocyclopenta[b]pyran-2-yl}
-2-furoic acid (8) 
1
H NMR (300 MHz, CDCl3) δ 7.54 (br s, 1H), 7.30 (br s, 1H), 7.20 (d, J = 9.0 Hz, 1H), 6.75 (d, J = 2.7 Hz, 1H), 
6.64 (dd, J = 9.0, 2.7 Hz, 1H), 5.01 (m, 1H), 4.14 (m, 1H), 4.06 (m, 1H), 3.99 (m, 1H), 3.91 (m, 1H), 2.46 (m, 1H), 
2.33 (s, 3H), 2.22 (m, 1H), 2.09-1.92 (m, 3H), 1.85-1.60 (m, 3H). (Peaks of OH and CO2H were not observed.)  
LCMS (ELSD) RT = 0.82 min (>98%).  MS (FAB, Neg.) m/z 405 (M - H)
-
.  HRMS (FAB, Neg.) C21H22
35
ClO6 
(M - H)
-
 calc. mass 405.1105, found 405.1114.  
 
Scheme 2-2-1C 
(4aR,5S,6R,7aS)-5-({[(2-methyl-2-propanyl)(diphenyl)silyl]oxy}methyl)-6-(tetrahydro-2H-pyran-2-yloxy)oct
ahydrocyclopenta[b]pyran-2-carbonitrile (14) 
O
AcO
OTBDPS
NC
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OTBDPS
NC
O
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OTBDPS
NC
13 13-2 14
 
To a solution of 13 (200 mg, 0.42 mmol) in MeOH (2.0 mL) at room temperature was added K2CO3 (69 mg, 0.50 
mmol).  After the reaction mixture was stirred at room temperature for 5 h, H2O (200 mL) was added and the 
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mixture was extracted with tert-BuOMe. The organic layer was washed with brine and dried over Na2SO4.  
Concentration gave 13-2 (196 mg), which was directly used in the next reaction.  
To a solution of 13-2 (196 mg, crude) and pyridinium para-toluenesulfonate (10.0 mg, 0.040 mmol) in CH2Cl2 
(2.0 mL) at room temperature was added 3,4-dihydro-2H-pyran (77g, 0.84 mmol).  After stirred at room 
temperature for 14 h, the reaction mixture was quenched with saturated aqueous NaHCO3 and extracted with 
EtOAc.  The organic layer was washed with H2O and brine and dried over Na2SO4.  Concentration and a 
medium-pressure preparative liquid chromatography (Yamazen W-prep 2XY flash column chromatography S, 
hexane/EtOAc 97:3-4:1) gave 14 (227 mg) in 100% in 2 steps.   
14
 1
H NMR (300 MHz, CDCl3) δ 7.66-7.60 (m, 4H), 7.43-7.35 (m, 6H), 4.80 (m, 1H), 4.57-4.51 (m, 1H), 
4.33-4.21 (m, 2H), 4.12 (m, 1H), 3.91-3.87 (m, 1H), 3.79-3.76 (m, 2H), 2.33-2.18 (m, 3H), 2.05-2.00 (m, 2H), 
1.91-1.65 (m, 6H), 1.52-1.43 (m, 3H), 1.04 (s, 9H).  
Methyl (2R)-3-hydroxy-2-({[(2R,4aR,5S,6R,7aS)-5-({[(2-methyl-2-propanyl)(diphenyl)silyl]oxy}methyl)-6- 
(tetrahydro-2H-pyran-2-yloxy)octahydrocyclopenta[b]pyran-2-yl]carbonyl}amino)propanoate (15) 
 
O
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N
H
O
OH
CO
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1514 14-2 14-3  
To a solution of 14 (227 mg, 0.470 mmol) in CH2Cl2 (2.0 mL) at -78 °C was added diisobutylaluminiumhydride 
(1.00 M in toluene, 0.42 mL, 0.42 mmol).  After stirred at -78 °C for 1h, the reaction was quenched with 
saturated aqueous potassium sodium tartrate and extracted with EtOAc. The organic layer was washed with 
brine and dried over Na2SO4.  Concentration gave 14-2, which was directly used in the next reaction. 
To a solution of 14-2 (166 mg, 0.320 mmol) in tert-butanol (1.2 mL), THF (1.0 mL) and H2O (0.3 mL) at room 
temperature was added 2-methyl-2-butene (152 L, 1.4 mmol) and sodium chlorite (72 mg, 0.80 mmol).  After 
stirred for 1h, the reaction was quenched with 1M HCl and extracted with EtOAc. The organic layer was washed 
with brine and dried over Na2SO4.  Concentration and a medium-pressure preparative liquid chromatography 
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(Yamazen W-prep 2XY flash column chromatography S, hexane/EtOAc 9:1-0:100) gave 14-3 (113 mg), including 
inseparable compound, which was used in the next reaction.  
To a solution of 14-3 (109 mg, 0.200 mmol) in THF (2.0 mL) at -30 °C was added N-methyl morpholine (0.46 L, 
0.42 mmol) and isobutyl chloroformate (29 L, 0.22 mmol).  After stirred at -30 °C for 1h, L-serine methyl 
ester-HCl (34 mg, 0.22 mmol) was added to the reaction mixture.  After stirred at room temperature for 14 h, the 
reaction was quenched with brine and extracted with EtOAc. The organic layer was dried over MgSO4.  
Concentration and a medium-pressure preparative liquid chromatography (Yamazen W-prep 2XY flash column 
chromatography S, hexane/EtOAc 4:1-0:100) gave 15 (78 mg) in 61%. 
15
 1
H NMR (300 MHz, CDCl3) δ 7.67-7.59 (m, 4H), 7.45-7.34 (m, 6H), 4.70 (m, 1H), 4.59-4.49 (m, 1H), 4.25 (m, 
2H), 4.18 (m, 1H), 4.05-3.97 (m, 2H), 3.93 (m, 1H), 3.87 (m, 1H), 3.81-3.80 (m, 3H), 3.74 (m, 2H), 2.36 (m, 1H), 
2.24-2.18 (m, 2H), 2.03-1.92 (m, 2H), 1.88-1.67 (m, 5H), 1.54-1.40 (m, 4H), 1.05 (s, 9H). (Peaks of OH and NH 
were not observed.)  
 
Methyl 2-[(2R,4aR,5S,6R,7aS)-5-({[(2-methyl-2-propanyl)(diphenyl)silyl]oxy}methyl)-6-(tetrahydro-2H- 
pyran-2-yloxy)octahydrocyclopenta[b]pyran-2-yl]-1,3-oxazole-4-carboxylate (16) 
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To a solution of 15 (209 mg, 0.327 mmol) in THF (3.0 mL) at room temperature was added Burgess reagent (117 
mg, 0.49 mmol). After stirred under reflux for 2.5 h, the reaction mixture was concentrated and a 
medium-pressure preparative liquid chromatography (Yamazen W-prep 2XY flash column chromatography S, 
hexane/EtOAc 3:1- MeOH/EtOAc 3:7) gave 15-2 (46 mg) in 22% 
To a solution of 15-2 (46 mg, 0.074 mmol) in CH2Cl2 (1.0 mL) at 0 °C was added DBU (17 L, 0.11 mmol) and 
BrCl3 (11 L, 0.11 mmol).  After stirred at 0 °C for 8h, the reaction was quenched with saturated aqueous NH4Cl 
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and extracted with EtOAc. The organic layer was washed with brine and dried over MgSO4.  Concentration and a 
medium-pressure preparative liquid chromatography (Yamazen W-prep 2XY flash column chromatography S, 
hexane/EtOAc 85:15-65:35) gave 16 (33 mg) in 72% 
16
 1
H NMR (300 MHz, CDCl3) δ 8.25 (s, 1H), 7.68-7.60 (m, 4H), 7.44-7.35 (m, 6H), 4.64-4.53 (m, 1H), 
4.30-4.05 (m, 2H), 3.92 (s, 3H), 3.88 (m, 1H), 3.78-3.65 (m, 2H), 3.48 (m, 2H), 2.34 (m, 1H), 2.24-2.18 (m, 2H), 
2.03-1.91 (m, 2H), 1.83-1.67 (m, 5H), 1.54-1.40 (m, 4H), 1.04 (s, 9H).  
 
Methyl 2-[(2R,4aR,5S,6R,7aS)-5-[(4-chloro-3-methylphenoxy)methyl]-6-(tetrahydro-2H-pyran-2-yloxy 
octa hydrocyclopenta[b]pyran-2-yl]-1,3-oxazole-4-carboxylate (17) 
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To a solution of 16 (58 mg, 0.090 mmol) in THF (1.0 mL) at room temperature was added tetra-n-butylammonium 
fluoride (1.00 M in THF, 140 L, 0.140 mmol).  After stirred at room temperature for 16 h, the reaction mixture 
was quenched with H2O and extracted with EtOAc. The organic layer was washed with brine and dried over 
Na2SO4.  Concentration and flash column chromatography (Fuji silicia BW-820MH, hexane / EtOAc 
15:85-0:100) gave alcohol 16-2 (23 g) in 67% yield. 
16-2
 1
H NMR (300 MHz, CDCl3) δ 8.24 (s, 1H), 5.04 (m, 1H), 4.76-4.58 (m, 1H), 4.06 (m, 1H), 3.91 (s, 3H), 
3.89-3.74 (m, 2H), 3.60 (m, 1H), 3.50 (m, 1H), 3.13 (m, 1H), 2.44-2.23 (m, 3H), 2.20-2.03 (m, 4H), 1.96-1.45 (m, 
7H). (Peak of OH was not observed.) 
To a solution of 16-2 (36.5 mg, 0.0962 mmol), 3-methyl-4-chlorophenol (41.0 mg, 0.288 mmol) and 
1,1'-azobis(N,N-dimethylformamide) (49.0 mg, 0.284 mmol) in THF (1.0 mL) at room temperature was added 
tributylphosphine (0.071 mL, 0.287 mmol).  After the mixture was stirred at 50 °C for 3 h, concentration and a 
medium-pressure preparative liquid chromatography (Yamazen W-prep 2XY flash column chromatography S, 
hexane/EtOAc 9:1-2:3) gave 17 (75.2 mg) in 95% yield. 
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17
 1
H NMR (300 MHz, CDCl3) δ 8.24 (s, 1H), 7.20 (m, 1H), 6.77 (m, 1H), 6.60 (m, 1H), 5.05 (m, 1H), 4.65 (m, 
1H), 4.25 (m, 1H), 4.06 (m, 2H), 3.96 (m, 1H), 3.91 (s, 3H), 3.44 (m, 2H), 2.58-2.40 (m, 2H), 2.33 (s, 3H), 
2.19-2.09 (m, 3H), 1.89-1.68 (m, 4H), 1.68-1.49 (m, 5H).  
 
2-{(2R,4aR,5S,6R,7aS)-5-[(4-chloro-3-methylphenoxy)methyl]-6-hydroxyoctahydrocyclopenta[b]pyran-2-yl}
-1,3-oxazole-4-carboxylic acid (5) 
O
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To a solution of 17 (46.5 mg, 0.0923 mmol) in MeOH (1.5 mL) at room temperature was added p-toluene sulfonic 
acid monohydrate (3.0 mg, 0.0157 mmol).  After stirred at room temperature for 4 h, the reaction mixture was 
quenched with H2O and extracted with EtOAc.  The organic layer was washed with brine and dried over Na2SO4.  
Concentration and a medium-pressure preparative liquid chromatography (Yamazen W-prep 2XY flash column 
chromatography S, hexane/EtOAc 4:1-0:100) gave 17-2 (38.9 mg) in 93% yield. 
17-2 
1
H NMR (300 MHz, CDCl3) δ 8.26 (s, 1H), 7.19 (d, J = 8.7 Hz, 1H), 6.75 (d, J = 2.7 Hz, 1H), 6.65 (dd, J = 
8.7, 2.7 Hz, 1H), 5.10 (m, 1H), 4.19-4.12 (m, 2H), 4.09 (m, 1H), 4.02 (m, 1H), 3.92 (s, 3H), 2.63 (m, 1H), 2.45 (m, 
1H), 2.33 (s, 3H), 2.19 (m, 3H), 2.09 (m, 1H), 1.94 (m, 1H), 1.84 (m, 1H), 1.74 (m, 1H).  
To a solution of 17-2 (10.0 mg, 0.0237 mmol) in MeOH (1.0 mL) at room temperature was added 2.0 M sodium 
hydroxide (0.20 mL, 0.4 mmol).  After stirred at room temperature for 18 h, the reaction mixture was quenched 
with 1.0 M hydrochloric acid and extracted with EtOAc. The organic layer was washed with H2O and brine and 
dried over Na2SO4.  Concentration gave 5 (8.4 mg) in 87 % yield. 
1
H NMR (300 MHz, CDCl3) δ 8.34 (s, 1H), 7.20 (d, J = 8.7 Hz, 1H), 6.75 (d, J = 3.0 Hz, 1H), 6.65 (dd, J = 8.7, 
3.0 Hz, 1H), 5.12 (m, 1H), 4.15 (m, 1H), 4.10 (m, 1H), 4.03 (m, 1H), 3.93 (m, 1H), 2.46 (m, 1H), 2.33 (s, 3H), 
2.20 (m, 2H), 2.17-2.06 (m, 2H), 1.95 (m, 1H), 1.87 (m, 1H), 1.77 (m, 1H). (Peaks of OH and CO2H were not 
observed.)  LCMS (ELSD) RT = 0.89 min (>98%).  MS (FAB, Neg.) m/z 406 (M - H)
-
.  HRMS (FAB, Neg.) 
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C20H21
35
ClNO6 (M - H)
-
 calc. mass 406.1057, found 406.1051.  
 
Scheme 2-2-1D 
Isopropyl 2-[(2R,4aR,5S,6R,7aS)-6-acetoxy-5-(hydroxymethyl)octahydrocyclopenta[b]pyran-2-yl]-1,3- 
thiazole-4-carboxylate (21) 
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To a solution of 20 (250 mg, 0.431 mmol) and acetic acid (51.8 mg, 0.862 mmol) in THF (2.0 mL) at room 
temperature was added triphenylphosphine (226 mg, 0.862 mmol) and diethyl azodicarboxylate (2.2 M in toluene, 
0.391 mL, 0.862 mmol).  After stirred at room temperature for 2 h, the reaction mixture was concentrated. A 
medium-pressure preparative liquid chromatography (Yamazen W-prep 2XY flash column chromatography M, 
hexane/EtOAc 9:1-7:3-1:1) gave 20-2 (312 mg), including inseparable compound, which was used in the next 
reaction.  
To a solution of 20-2 (268 mg, crude) in THF (2.0 mL) and acetic acid (77.7 mg, 1.29 mmol) at room temperature 
was added tetra-n-butylammonium fluoride (1.00 M in THF,1.29 mL, 1.29 mmol).  After stirred at 50 °C for 2 h, 
the reaction mixture was quenched with saturated aqueous NaHCO3 and extracted with EtOAc. The organic layer 
was washed with brine and dried over Na2SO4.  Concentration and a medium-pressure preparative liquid 
chromatography (Yamazen W-prep 2XY flash column chromatography M, hexane/EtOAc 3:7-0:1) gave 21 (78.9 
mg) in 48% yield. 
 
2-{(2R,4aR,5S,6R,7aS)-5-[(4-chloro-3-methylphenoxy)methyl]-6-hydroxyoctahydrocyclopenta[b]pyran-2-yl}
-1,3-thiazole-4-carboxylic acid (9) 
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To a solution of 21 (70.0 mg, 0.182 mmol) and 3-methyl-4-chlorophenol (78.1 mg, 0.548 mmol) and 
1,1'-azobis(N,N-dimethylformamide) (94.2 mg, 0.547 mmol) in THF (2.0 mL) at room temperature was added 
tributylphosphine (0.140 mL, 0.547 mmol).  After the mixture was stirred at room temperature for 3 h, 
concentration and a medium-pressure preparative liquid chromatography (Yamazen W-prep 2XY flash column 
chromatography S, hexane/EtOAc 95:5-3:2-1:4) gave 21-2 (75.2 mg) in 100% yield. 
1
H NMR (300 MHz, CDCl3) δ 8.11 (s, 1H), 7.20 (d, J = 8.7 Hz, 1H), 6.74 (d, J = 3.0 Hz, 1H), 6.64 (dd, J = 8.7, 
3.0 Hz, 1H), 5.51 (m, 1H), 5.26 (sep, J = 6.3 Hz, 1H), 5.10 (t, J = 6.0 Hz, 1H), 4.30 (m, 1H), 4.03 (m, 1H), 
4.04-3.90 (m, 2H), 2.62 (m, 1H), 2.33 (s, 3H), 2.25 (m, 1H), 2.19 (m, 1H), 2.17-2.01 (m, 3H), 2.04 (s, 3H), 1.67 
(m, 1H), 1.37 (d, J = 6.3 Hz, 6H).  
To a solution of 21-2 (36.0 mg, 0.0708 mmol) in MeOH (1.0 mL) at room temperature was added 2.0 M sodium 
hydroxide (0.071 mL, 0.142 mmol).  After stirred at room temperature for 2 h, the reaction mixture was 
quenched with 1.0 M hydrochloric acid and extracted with EtOAc. The organic layer was washed with H2O and 
brine and dried over Na2SO4.  Concentration gave 9 (30.8 mg) in 100 % yield. 
1
H NMR (300 MHz, CDCl3) δ 8.28 (s, 1H), 7.22 (d, J = 9.0 Hz, 1H), 6.79 (d, J = 2.7 Hz, 1H), 6.69 (dd, J = 9.0, 
2.7 Hz, 1H), 5.10 (t, J = 6.0 Hz, 1H), 4.63 (m, 1H), 4.31 (m, 1H), 4.10 (m, 2H), 2.49 (m, 1H), 2.34 (s, 3H), 2.24 
(m, 1H), 2.20-1.95 (m, 5H), 1.60 (m, 1H). (Peaks of OH and CO2H were not observed.)  
13
C NMR (75 MHz, 
CDCl3) δ 20.32, 20.68, 24.19, 38.80, 41.92, 45.65, 67.20, 72.46, 72.79, 73.59, 113.11, 117.08, 126.30, 129.04, 
129.70, 137.18, 145.96, 157.12, 162.24, 174.54.  LCMS (ELSD) RT = 0.95 min (>98%).  MS (FAB, Neg.) m/z 
422 (M - H)
-
.  HRMS (FAB, Neg.) C20H21
35
ClNO5S (M - H)
-
 calc. mass 422.0829, found 422.0829.  
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Scheme 2-2-1E 
Ethyl 2-[(2R,4aR,5S,6R,7aS)-6-(formyloxy)-5-({[(2-methyl-2-propanyl)(diphenyl)silyl]oxy}methyl)octa 
hydrocyclopenta[b]pyran-2-yl]-1,3-thiazole-4-carboxylate (23) 
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To a solution of 22 (3.3 g, 5.40 mmol) in MeOH (27 mL) at room temperature was added K2CO3 (1.50 g, 11.0 
mmol).  After the reaction mixture was stirred at room temperature for 5 h, saturated aqueous NH4Cl was added 
and extracted with EtOAc. The organic layer was washed with brine and dried over Na2SO4.  Concentration and a 
medium-pressure preparative liquid chromatography (Yamazen W-prep 2XY flash column chromatography L, 
hexane/EtOAc 19:1-7:3-1:1-0:1) gave 22-2 (2.76 g) in 93% yield. 
22-2
 1
H NMR (300 MHz, CDCl3) δ 8.19 (s, 1H), 7.65-7.59 (m, 4H), 7.41-7.34 (m, 6H), 5.16 (t, J = 5.1 Hz, 1H), 
4.20-4.12 (m, 2H), 3.94 (s, 3H), 3.78 (dd, J = 10.2, 4.8 Hz, 1H), 3.61 (dd, J = 10.2, 6.0 Hz, 1H), 2.62 (m, 1H), 
2.12-2.05 (m, 5H), 1.96-1.86 (m, 2H), 1.79 (m, 1H), 1.04 (s, 9H).  
To a solution of 22-2, phenol (2.70 g, 4.89 mmol) and triphenyl phosphine (2.57 g, 9.79 mmol) in THF (20 mL) at 
room temperature was added diethyl azodicarboxylate (2.2 M in toluene, 4.45 mL, 9.79 mmol).  After stirred at 
room temperature for 1 h, the reaction mixture was concentrated. A medium-pressure preparative liquid 
chromatography (Yamazen W-prep 2XY flash column chromatography L, hexane/EtOAc 19:1-7:3-1:1-0:1) gave 
23 (2.99 g), including inseparable compound, which was used in the next reaction. 
 
Ethyl 2-[(2R,4aR,5S,6R,7aS)-6-methoxy-5-({[(2-methyl-2-propanyl)(diphenyl)silyl]oxy}methyl)octahydro 
cyclopenta[b]pyran-2-yl]-1,3-thiazole-4-carboxylate (24) 
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To a solution of 23 (2.84 g, 4.89 mmol) in MeOH (20 mL) at room temperature was added K2CO3 (1.35 g, 9.79 
mmol).  After the reaction mixture was stirred at room temperature for 5 h, saturated aqueous NH4Cl was added 
and extracted with EtOAc. The organic layer was washed with brine and dried over Na2SO4.  Concentration and a 
medium-pressure preparative liquid chromatography (Yamazen W-prep 2XY flash column chromatography L, 
hexane/EtOAc 19:1-7:3-1:1-0:1) gave 23-2 (2.43 g) in 90% yield. 
23-2
 1
H NMR (300 MHz, CDCl3) δ 8.17 (s, 1H), 7.68-7.63 (m, 4H), 7.47-7.36 (m, 6H), 5.03 (t, J = 5.7 Hz, 1H), 
4.60 (m, 1H), 4.30 (m, 1H), 3.95 (m, 1H), 3.94 (s, 3H), 3.80 (dd, J = 10.2, 6.3 Hz, 1H), 3.01 (m, 1H), 2.14-1.94 
(m, 7H), 1.78 (m, 1H), 1.06 (s, 9H). 
To a solution of 23-2 (400 mg, 0.725 mmol) in acetonitrile (2.0 mL) at room temperature was added methyliodide 
(206 mg, 1.45 mmol) and Ag2O (336 mg, 1.45 mmol). After the reaction mixture was stirred at room temperature 
for 4 days, filterated wit celite pad and the filtrate was concentrated and a medium-pressure preparative liquid 
chromatography (Yamazen W-prep 2XY flash column chromatography M, hexane/EtOAc 95:5-6:4-0:1) gave 24 
(89.5 mg) in 22% yield. 
24
 1
H NMR (300 MHz, CDCl3) δ 8.16 (s, 1H), 7.69-7.62 (m, 4H), 7.41-7.35 (m, 6H), 5.05 (t, J = 6.6 Hz, 1H), 
4.25 (m, 1H), 3.95 (m, 1H), 3.93 (s, 3H), 3.89 (m, 1H), 3.64 (m, 1H), 3.25 (s, 3H), 2.25-2.09 (m, 4H), 1.98-1.87 (.  
(m, 4H), 1.05 (s, 9H).  
 
2-{(2R,4aR,5S,6R,7aS)-5-[(4-chloro-3-methylphenoxy)methyl]-6-methoxyoctahydrocyclopenta[b]pyran-2-yl
}-1,3-thiazole-4-carboxylic acid (10) 
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To a solution of 24 (86 mg, 0.152 mmol) in THF (2.0 mL) at room temperature was added tetra-n-butylammonium 
fluoride (1.00 M in THF, 0.304 mL, 0.304 mmol).  After stirred at room temperature for 2 h, the reaction mixture 
was quenched with saturated aqueous NaHCO3 and extracted with EtOAc. The organic layer was washed with 
H2O and brine and dried over Na2SO4.  Concentration and a medium-pressure preparative liquid chromatography 
(Yamazen W-prep 2XY flash column chromatography S, hexane/EtOAc 6:4-0:1) gave alcohol 24-2 (32.5 mg), 
including inseparable compound, which was used in the next reaction. 
To a solution of 24-2 (32.0 mg, 0.0977 mmol) and 3-methyl-4-chlorophenol (41.8 mg, 0.293 mmol) and 
1,1'-azobis(N,N-dimethylformamide) (50.5 mg, 0.293 mmol) in THF (1.0 mL) at room temperature was added 
tributylphosphine (59.3 mg, 0.293 mmol).  After the mixture was stirred at room temperature for 3 h, 
concentration and a medium-pressure preparative liquid chromatography (Yamazen W-prep 2XY flash column 
chromatography S, hexane/EtOAc 95:5-7:3-1:1) gave 24-3 (40.8 mg) in 59% yield in 2 steps. 
1
H NMR (300 MHz, CDCl3) δ 8.18 (s, 1H), 7.21 (d, J = 8.7 Hz, 1H), 6.78 (d, J = 2.7 Hz, 1H), 6.69 (dd, J = 8.7, 
2.7 Hz, 1H), 5.09 (t, J = 6.3 Hz, 1H), 4.31 (m, 1H), 4.01-3.89 (m, 2H), 3.94 (s, 3H), 3.25 (s, 3H), 2.45 (m, 1H), 
2.34 (s, 3H), 2.33-2.25 (m, 2H), 2.19 (m, 1H), 2.05-1.90 (m, 4H), 1.60 (m, 1H).  
To a solution of 24-3 (16.0 mg, 0.0354 mmol) in MeOH (2.0 mL) at room temperature was added 2.0 M sodium 
hydroxide (0.035 mL, 0.071 mmol).  After stirred at room temperature for 2 h, the reaction mixture was 
quenched with 1.0 M hydrochloric acid and extracted with EtOAc. The organic layer was washed with H2O and 
brine and dried over Na2SO4.  Concentration gave 10 (15.8 mg) in 100 % yield. 
1
H NMR (300 MHz, CDCl3) δ 8.27 (s, 1H), 7.20 (d, J = 9.0 Hz, 1H), 6.78 (d, J = 2.7 Hz, 1H), 6.68 (dd, J = 9.0, 
2.7 Hz, 1H), 5.09 (t, J = 6.3 Hz, 1H), 4.26 (m, 1H), 4.16 (dd, J = 9.3, 7.5 Hz, 1H), 3.99 (m, 1H), 3.90 (dd, J = 9.3, 
6.6 Hz, 1H), 3.25 (s, 3H), 2.43 (m, 1H), 2.34 (s, 3H), 2.29 (m, 1H), 2.18 (m, 1H), 2.09-1.92 (m, 4H), 1.60 (m, 1H). 
(Peaks of CO2H was not observed.)  LCMS (ELSD) RT = 1.12 min (>98%).  MS (FAB, Neg.) m/z 436 (M - H)
-
.  
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HRMS (FAB, Neg.) C21H23
35
ClNO5S (M - H)
-
 calc. mass 436.0985, found 436.0988.  
 
Scheme 2-2-1F 
Isopropyl 2-{(2R,4aR,5S,6R,7aS)-5-[(4-chloro-3-methylphenoxy)methyl]-6 hydroxyoctahydrocyclopenta [b] 
pyran-2-yl}-1,3-thiazole-4-carboxylate (26) 
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To a solution of 25 (500 mg, 1.175 mmol) and 3-methyl-4-chlorophenol (503 mg, 3.53 mmol) and 
1,1'-azobis(N,N-dimethylformamide) (405 mg, 2.35 mmol) in THF (4.0 mL) at room temperature was added 
tributylphosphine (0.587 mL, 2.35 mmol).  After the mixture was stirred at room temperature for 4 h, 
concentration and a medium-pressure preparative liquid chromatography (Yamazen W-prep 2XY flash column 
chromatography L, hexane/EtOAc 95:5-75:25) gave 25-2, including inseparable compound, which was used in the 
next reaction. 
To a solution of 25-2 (500 mg, crude) in MeOH (8.4 mL mL) at room temperature was added p-toluene sulfonic 
acid monohydrate (19.3 mg, 0.102 mmol).  After stirred at room temperature for 2 h, the reaction mixture was 
quenched with triethylamine. Concentration and a medium-pressure preparative liquid chromatography (Yamazen 
W-prep 2XY flash column chromatography L, hexane/EtOAc 3:2-2:3) gave 26 (444 mg) in 81% yield in 2 steps 
26
 1
H NMR (300 MHz, CDCl3) δ 8.15 (s, 1H), 7.19 (d, J = 8.7 Hz, 1H), 6.75 (d, J = 2.4 Hz, 1H), 6.65 (dd, J = 8.7, 
2.4 Hz, 1H), 5.26 (sep, J = 6.3 Hz, 1H), 5.20 (t, J = 4.8 Hz, 1H), 4.24 (m, 1H), 4.15 (m, 1H), 4.02 (m, 1H), 3.90 
(m, 1H), 2.61 (m, 1H), 2.41 (m, 1H), 2.33 (s, 3H), 2.31-2.26 (m, 2H), 2.17-1.96 (m, 3H), 1.85 (m, 1H), 1.71 (m, 
1H), 1.38 (d, J = 6.3 Hz, 6H).  
 
2-{(2R,4aR,5S,6R,7aS)-5-[(4-chloro-3-methylphenoxy)methyl]-6-fluorooctahydrocyclopenta[b]pyran-2-yl}-1
82 
 
,3-thiazole-4-carboxylic acid (11) 
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To a solution of diethylaminofsulfur trifluoride (103 mg, 0.643 mmol) in CH2Cl2 (1.5 mL) at -78 °C was added 26 
(100 mg, 0.215 mmol) in CH2Cl2 (0.75 mL).  After stirred at -78 °C for 30 min, the reaction was quenched with 
saturated aqueous NaHCO3 and extracted with EtOAc. The organic layer was washed with brine and dried over 
Na2SO4.  Concentration and a medium-pressure preparative liquid chromatography (Yamazen W-prep 2XY flash 
column chromatography L, hexane/EtOAc 97:3-7:3) gave 26-2 (100 mg) in 57% yield. 
26-2
 1
H NMR (300 MHz, CDCl3) δ 8.12 (s, 1H), 7.20 (d, J = 9.0 Hz, 1H), 6.79 (d, J = 3.0 Hz, 1H), 6.79 (dd, J = 
9.0, 3.0 Hz, 1H), 5.53-5.19 (m, 1H), 5.27 (sep, J = 6.0 Hz, 1H), 5.10 (t, J = 6.0 Hz, 1H), 4.36 (m, 1H), 4.15 (m, 
1H), 3.98 (m, 1H), 2.65-2.42 (m, 1H), 2.43-2.24 (m, 2H), 2.34 (s, 3H), 2.22-1.97 (m, 4H), 1.64 (m, 1H), 1.37 (d, J 
= 6.0 Hz, 6H).  
To a solution of 26-2 (23.0 mg, 0.0491 mmol) in MeOH (0.30 mL) at room temperature was added 2.0 M sodium 
hydroxide (0.15 mL, 0.300 mmol).  After stirred at room temperature for 2 h, the reaction mixture was quenched 
with 1.0 M hydrochloric acid and extracted with EtOAc. The organic layer was washed with H2O and brine and 
dried over Na2SO4.  Concentration gave 11 (18.8 mg) in 89 % yield. 
1
H NMR (300 MHz, CDCl3) δ 8.30 (s, 1H), 7.23 (d, J = 9.0 Hz, 1H), 6.79 (d, J = 3.0 Hz, 1H), 6.70 (dd, J = 9.0, 
3.0 Hz, 1H), 5.48-5.22 (m, 1H), 5.11 (t, J = 6.3 Hz, 1H), 4.34 (m, 1H), 4.18 (m, 1H), 3.99 (m, 1H), 2.69 (m, 1H), 
2.49 (m, 1H), 2.34 (s, 3H), 2.34-2.22 (m, 2H), 2.21-2.03 (m, 3H), 1.66 (m, 1H). (Peak of CO2H was not 
observed.)  LCMS (ELSD) RT = 1.10 min (>98%).  MS (FAB, Neg.) m/z 424 (M - H)
-
.  HRMS (FAB, Neg.) 
C20H20
35
ClFNO4S (M - H)
-
 calc. mass 424.0786, found 424.0792.  
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Biology 
In vitro assay 
EP2, EP4 and IP cAMP assay 
Chinese hamster ovary (CHO) cells (1.25×10
5
 cells/well) expressing human EP2 or human EP4 or human IP 
receptor were harvested and suspended in a 96-well 1/2 area plate. cAMP concentrations were measured using a 
cAMP HTRF HiRange kit (Cisbio Bioassays)* after treatment of compounds. The reaction rate (%) of the 
compounds relative to the cAMP concentration obtained with PGE2 treatment at 1μM was calculated. Furthermore, 
a non-linear regression analysis was performed using the Sigmoid Emax Model to estimate EC50 values. 
*http://www.cisbio.com/usa/drug-discovery/membrane-based-assays-camp-hirange-assay-kit (accessed Nov 24, 
2015) 
 
EP2 β arrestin recruitment assay 
PathHunter β-arrestin HEK-293 PTGER2 cell lines (DiscoveRx) were seeded at a density of 5000 cells/well into a 
384-well plate and cultured at 37 °C in the presence of 5 % CO2 for 24 hours. β-arrestin recruitment were 
measured using a PathHunter Detection Kit (DiscoveRx)* after treatment of compounds. The reaction rate (%) of 
the compounds relative to the β-arrestin recruitment obtained with PGE2 treatment at 10μM was calculated. 
Furthermore, a non-linear regression analysis was performed using the Sigmoid Emax Model to estimate EC50 
values. 
* https://www.discoverx.com/product-data-sheets-3-tab/93-0214c1 (accessed Nov 24, 2015) 
 
EP1, EP3 and FP Ca assay 
Chem-1 cells expressing human FP receptor or Chinese hamster ovary (CHO) cells expressing human EP1 or 
human EP3 were seeded at a density of 1×10
4
 cells per well into 96-well plates and cultured at 37℃ in the 
presence of 5% CO2 for 2 days. Load buffer (HBSS containing Calcium 5, 10 mM HEPES, 20μM indomethacin, 
and 2.5 mM probenecid) was added in each well and incubated in the dark at room temperature for 1 hour. After 
addition of the compounds, intracellular Ca
2+
 concentration was measured using a fluorescence drug screening 
84 
 
system (FDSS-7000 : Hamamatsu Photonics, Tokyo, Japan)*. The reaction rate (%) of the compounds relative to 
intracellular Ca
2+ 
concentration obtained with maximum increases of PGE2 treatment was calculated. Futhermore, 
a non-linear analysis was performed using the Sigmoid Emax Model to estimate EC50 values.  
* http://www.hamamatsu.com/jp/ja/FDSS7000EX.html (accessed Nov 24, 2015) 
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Chapter 3 
Total Synthesis and Bioactivity of Resolvin E2 
 
Abstract:  
Resolvin E2 is a potent anti-inflammatory compound, derived from eicosapentaenoic acid.  The efficient total 
synthesis of resolvin E2 by taking advantage of its intrinsic pseudoenantiomeric substructures is reported.  The 
synthetic resolvin E2 proved to be biologically active in blocking neutrophil infiltration and reducing 
proinflammatory cytokines in the acute peritonitis model. 
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Introduction 
 
Resolvins are a new family of lipid mediators derived from ω-3 polyunsaturated fatty acids, namely, 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are generated during the resolution phase 
of acute inflammation. 
1
  Resolvin E1 is biosynthesized from EPA via cyclooxygenase (COX)-2- and 
5-lipoxygenase-mediated conversion and has been shown to possess significant anti-inflammatory and 
proresolution properties, thereby protecting organs from collateral damage.
2
  Another E series resolvin, namely, 
resolvin E2 (1), is formed via reduction of 5S-hydroperoxy-18R-hydroxy-EPE, an intermediate in the biosynthesis 
of resolvin E1, and exhibits potent anti-inflammatory properties in murine peritonitis.
3
  It has been hypothesized 
that these E series resolvins contribute to the beneficial actions that have been attributed to EPA in certain human 
diseases, particularly those in which inflammation is suspected as a key component in pathogenesis. Motivated by 
their therapeutic potential for new treatment of human disorders associated with aberrant inflammation, the author 
launched the synthetic studies of resolvins as well as other lipid mediators. In this Chapter, the author reports an 
efficient total synthesis of resolvin E2
4
 and its biological activity in reducing neutrophil infiltration and 
proinflammatory cytokine productions in vivo. 
 
 
Figure 3-1. Anti-inflamamatory lipid mediators (resolvins) from ω-3 fatty acids.
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Results and discussion 
 
Synthetic plan of resolvin E2 
The author planned to simplify the synthetic route to resolvin E2 (1) by taking advantage of its two symmetric 
substructures at C5-10 and C13-18 (Scheme 3-1).  Retrosynthetic disconnections at C10-11 and C12-13 provided 
a C11-12 unit together with pseudo-enantiomeric fragments, 2 and 3, both of which have the E,Z-conjugated 
olefin and allylic alcohol groups.  Because of their structural similarity, 2 and 3 would be prepared from 
enantiomers of 6 by applying the same strategy.  Specifically, the stereocenters at C5 of 4 and C18 of 5 would be 
generated by substrate-controlled stereoselective addition of the corresponding carbon nucleophiles, while the 
E,Z-olefins at C6 of 2 and C17 of 3 would be constructed using a torquoselective thermal electrocyclic 
ring-opening reaction
5
 of cyclobutene aldehydes 4 and 5, respectively.
6
  Hence, the stereochemistries of the 
cyclobutane of (-)- or (+)-6 were envisioned to be transferred to the stereochemistries of the hydroxyl group at C5 
or C18 and the diene at C6 or C17.  A pair of optically active six-carbon units 6
7
 would be obtained from the 
known achiral meso anhydride 7
8
 by enantioselective desymmetrization. 
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Scheme 3-1. Retrosynthesis of resolvin E2 
 
Syntheses of chiral lactones (+)-6 and (-)-6 
Both enantiomers of 6 were prepared from methyl ester (+)-10 (Scheme 3-2).
9
  The critical desymmetrization of 
meso-7 into (+)-10 was realized using a catalytic amount of the quinine derivative 9, according to the conditions 
developed by Song.
10,11 
 Namely, 1 mol % of 9 and 10 equiv of methanol were applied to 7 in Et2O to generate 
(+)-10 in highly enantioselective fashion (95% yield, 87% ee).  Interestingly, methanolysis of the same 7 using 
the quinidine derivative 8, the pseudo-enantiomer of 9, indeed gave the enantiomeric (-)-10, albeit in lower 
enantioselectivity (64% ee).  Due to this, the author decided to synthesize (-)- and (+)-6 from the same (+)-10 
using chemoselective reduction of either the carboxylic acid or the ester.  Lactone (-)-6 was prepared from (+)-10 
in three steps: conversion of the carboxylic acid of (+)-10 into an acid chloride, followed by chemoselective 
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NaBH4 reduction,
12
 and subsequent acid-mediated cyclization of methyl ester 11.  The enantiomer (+)-6 was in 
turn synthesized by LiEt3BH reduction
13
 of the methyl ester of (+)-10 and subsequent cyclization of carboxylic 
acid 12 under acidic conditions. 
 
 Reagents and conditions: (a) 8 (1mol%), Et2O, MeOH(10 eq) (100%, 64%ee). (b) 9(1mol%), Et2O, MeOH(10 
eq) (95%, 87%ee). (c) (i) (COCl)2, DMF, CH2Cl2 (ii) NaBH4, DMF. (d) TFA, CH2Cl2 (61%, 3 steps). (e) LiEt3BH, 
THF. (f) TsOH, benzene (66%, 2 steps). 
Scheme 3-2. Synthesis of both enantiomers of 6. 
 
Synthesis of C1-10 fragment 
Synthesis of the C1-10 fragment 2 started with reduction of (-)-6 by DIBAL-H, followed by addition of Grignard 
reagent of 14 in one pot,
14
 resulting in stereoselective introduction of the C5-hydroxy group of 16 (dr = 6:1, 
Scheme 3-3).
15
  The high diastereoselectivity is attributable to chelation between the magnesium alkoxide and 
the aldehyde and subsequent nucleophilic attack from the convex face of the 4/7-fused ring system 15.
6b,d  
Next, 
1,4-diol 16 was transformed to alcohol 18 by a protection/deprotection procedure: stepwise introduction of Piv 
H
O
O
OH
N
O H
N
H
N
S
O O
CF3
CF3
H
N
O
H
N
N
H
H
S
CF3
CF3
O O 98 7
H
H
OMe
O
OH
O
(+)-10
H
H
OH
O
OMe
O
(-)-10
H
H
OMe
O
OH
O
OH
H
11
(-)-6
H
H
OH
OLi
O
O
H
H O
(+)-6 12
a
b
c
d
e
f
92 
 
and TBS groups to the primary and the secondary hydroxy groups, respectively, and subsequent reductive 
removal of the Piv ester from 17.  Swern oxidation of alcohol 18 at -78 °C generated aldehyde 4, which 
underwent the crucial torquoselective electrocyclic ring-opening reaction even at room temperature to deliver 
E,Z-diene 19 as a sole isomer.
5
  Stereoselective formation of the diene of 19 would originate from strong 
preference of the electron-accepting aldehyde of 4 for the inward rotation (Figure 3-2)
6
.  Because of its chemical 
instability, the resulting α, β, γ, δ-unsaturated aldehyde 19 was immediately subjected to NaBH4 reduction without 
purification to give allylic alcohol 20.
16
 Finally, bromination of the chemically-sensitive allylic alcohol was 
realized by the action of CBr4 and (CH2PPh2)2 to give the C1-10 fragment 2.
17
 
 
 
 Reagents and conditions: (a) DIBAL, THF (b) 14. (c) PivCl, pyridine, CH2Cl2 (68%, 2 steps). (d) TBSOTf, 
lutidine, CH2Cl2. (e) DIBAL, CH2Cl2 (98%, 2 Steps). (f) (COCl)2, DMSO, Et3N, CH2Cl2. (g) NaBH4, EtOH (86%, 
2 steps). (h) CBr4, (Ph2PCH2)2, CH2Cl2 (100%). 
 
Scheme 3-3. Synthesis of C1-10 fragment 2 
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Figure 3-2. Torquoselective electrocyclic ring-opening reaction.
 
 
Synthesis of C13-20 fragment 
The C13-20 fragment 3 was synthesized from (+)-6 similarly to the C1-10 fragment 2 (Scheme 3-4).  Reduction 
of (+)-lactone 6 with DIBAL was followed by stereoselective addition of ethyl magnesium bromide in the 
presence of zinc bromide to afford 21 with the desired C18-stereochemistry (dr = 7:1).  The stereochemistries of 
16 and 21 were identified by the modified Mosher’s method (Figure 3-3).  After protecting group manipulations 
from 21 to 22 in two steps, Swern oxidation of the primary alcohol of 22 to aldehyde 5 accelerated the thermal 
ring-opening reaction to produce E,Z-diene 23 as a single isomer.  Reduction of the resulting aldehyde of 23 into 
alcohol 24, followed by bromination, led to the C13-20 fragment 3. 
 
Reagents and conditions: (a) DIBAL, toluene. (b) EtMgBr (68%). (c) PivCl, pyridine, CH2Cl2 (68%, 2 steps). (d) 
TBSOTf, lutidine, CH2Cl2. (e) DIBAL, CH2Cl2 (100%, 2 steps). (f) (COCl)2, DMSO, Et3N, CH2Cl2. (g) NaBH4, 
EtOH (81%, 2 steps). (h) CBr4, (Ph2PCH2)2, CH2Cl2 (100%). 
                           Scheme 3-4. Synthesis of C13-20 fragment 3
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Reagents and conditions: (a) TBSCl, imidazole, DMAP, DMF. (b) (S) or (R) MTPACl, Et3N, DMAP, CH2Cl2 
Figure 3-3. Syntheses of (S)- and (R)-Mosher esters 30a,b and 31a,b and their 
1
H NMR data 
 
Coupling of each fragments 
Final convergent assemblies of the three partial structures utilized two copper-mediated couplings (Scheme 3-5).  
The bromide of 3 was first displaced with the copper acetylide, generated from ethynyl magnesium bromide and 
CuCl,
18
 delivering the C11-20 fragment 25.  Deprotonation of the C11-proton of 25 by n-BuLi in the presence of 
CuBr-SMe2
19
 at -78 °C then afforded the corresponding copper acetylide, which was treated with the C1-10 
fragment 2, giving rise to the entire structure 26.  Intriguingly, only this particular condition produced a 
sufficient amount of the adduct 26.  For instance, use of copper iodide instead of copper bromide for the 
coupling only gave a mixture of byproducts, in which the C6-E,Z-olefins were reacted or isomerized. 
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Reagents and conditions: (a) ethynylmagnesium bromide, CuCl, THF (84%). (b) 2, n-BuLi, CuBr・Me2S, HMPA, 
THF (54%). 
Scheme 3-5. Coupling of each fragments. 
 
Synthesis of resolvin E2 (1). 
Four transformations from 26 led to the targeted resolving E2 (Scheme 3-6).  Lindlar conditions
20
 enabled 
partial reduction of the alkyne of 26 into alkene 27 without reduction and/or isomerization of the reactive C6- and 
C17-E,Z-conjugated olefins.  Acid-mediated removal of the ketal of 27 was troublesome because of the presence 
of the acid-labile allylic TBS ethers.  After many attempts, the author found that Kita’s conditions
21
 were 
effective for selective reaction of the cyclic ketal.  Treatment of 27 with an excess amount of TMSOTf and 
lutidine followed by aqueous work-up provided aldehyde 28 in high yield. Lastly, NaClO2-mediated oxidation of 
the obtained aldehyde 28 into a carboxylic acid and subsequent desilylation with TBAF gave rise to resolvine E2 
(1). 
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Reagents and conditions: (a) H2, 5% Pd/BaSO4, quinoline, EtOAc (54%). (b) TMSOTf, lutidine, CH2Cl2 then H2O. 
(c) NaClO2, NaH2PO4・2H2O, 2-methyl-2-butene, t-BuOH/H2O. (d) TBAF, THF (67%, 3 steps). 
Scheme 3-6. Synthesis of resolvin E2(1). 
 
Biological evaluation of synthetic resolvin E2 (1). 
The author evaluated the bioactivity of synthetic 1 using the in vivo inflammation model (Figures 3-4 and 3-5).
3
  
Zymosan A, a glucan from the yeast cell wall, was used to induce sterile inflammation characterized by local 
neutrophil infiltration and proinflammatory cytokine productions.  In acute peritonitis with zymosan A, 
intravenous administration of synthetic resolvin E2 as low as 0.1 or 1.0 μg significantly blocked neutrophil 
infiltrations at 2 h in the inflamed peritoneal cavity (Figure 3-4).  The potency of resolvin E2’s anti-inflammatory 
action was comparable to that of a higher dose of dexamethasone at 10 μg (data not shown).  Also 1 (1.0 μg 
i.v./mouse) markedly reduced production of proinflammatory cytokines such as tumor necrosis factor (TNF)-α 
(123.2 pg vs 56.7 pg, p 0.005) and interleukin (IL)-6 (3.40 ng vs 2.05 ng, p 0.02) (Figure 3-5). 
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Figure 3-4. Synthetic resolvin E2 reduced neutrophil infiltrations. 
 
 
Figure 3-5. Resolvin E2 reduced productions of TNF-α and IL-6 in zymosan-induced peritonitis. 
 
In summary, the efficient total synthesis of resolvin E2 (1) was achieved by utilizing the intrinsic 
pseudoenantiomeric nature of the key fragments 2 and 3.  Most importantly, the two stereochemistries of 6 
introduced via the desymmetrization step were effectively transferred to those of the hydroxyl group and the diene 
for preparing 2 and 3.  The obtained fragments were assembled into 1 in a convergent fashion. Furthermore, the 
author confirmed synthetic resolving E2 blocked neutrophil infiltrations in the inflamed peritoneal cavity in acute 
peritonitis with zymosan A.  And it also markedly reduced production of proinflammatory cytokines such as 
tumor necrosis factor (TNF)-α and interleukin (IL)-6.  
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Experimental Section 
 
General Methods. 
All reactions sensitive to air or moisture were carried out under argon atmosphere in dry, freshly distilled solvents 
under anhydrous conditions, unless otherwise noted.  THF was distilled from sodium/benzophenone, pyridine, 
triethylamine (Et3N) and 2,6-lutidine from calcium hydride under reduced pressure.  All other reagents were 
used as supplied unless otherwise stated. Analytical thin-layer chromatography (TLC) was performed using E. 
Merck Silica gel 60 F254 pre-coated plates.  Column chromatography was performed using 75-150 μm 
BW-820MH (Fuji Silysia Co., Inc.).  Flash column chromatography was performed using 40-63 μm Silica Gel 
60 (Merck Co., Inc.) or 32-53 μm BW-300 (Fuji Silysia Co., Inc.).  
1
H- and 
13
C-NMR spectra were recorded on a 
JEOL JNM ECA-500 (500 MHz) or JEOL JNM ECX-500 (500 MHz) spectrometer.  Chemical shifts are 
reported in δ (ppm) with reference to solvent signals [
1
H NMR: CHCl3 (7.26), C6D6 (7.16), (CD3)2CO (2.05), 
CD3OD (3.30); 
13
C NMR: CHCl3 (77.0), C6D6 (128.06), (CD3)2CO (29.84), CD3OD (49.00).  Signal patterns are 
indicated as s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad peak.  IR spectra were recorded on 
a JASCO FT/IR-4100 spectrometer. FAB-MS and EI-MS were on JEOL JMS-700.  ESI-MS were on BRUKER 
DALTONICS Bio TOF-Q.  Optical rotations were recorded on a JASCO DIP-1000 polarimeter. Melting points 
were measured on a Yanaco MP-J3 micro melting point apparatus and uncorrected. 
 
Experimantal procedure 
 
Methyl ester (+)-10.  
Methanol (0.16 mL, 4.0 mmol) was added to a solution of meso-7 (50 mg, 0.40 mmol) and quinine derivative 9 
(2.4 mg, 4.0 μmol) in Et2O (4 mL) at room temperature.  The reaction mixture was stirred at room temperature 
for 20 h and 1M HCl solution was added. The mixture was extracted with EtOAc and the organic layer was dried 
H
O
O
OH7
H
H
OMe
O
OH
O(+)-10
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over Na2SO4.  Concentration gave methyl ester (+)-10 (60 mg, 0.38 mmol) in 95% yield.  The enantiomeric 
excess was determined to be 87% from  
1
H NMR analysis of Mosher ester of alcohol 11. 
pale yellow oil [α]D
25
 = 3.3 (c 0.87, CHCl3); IR (neat) ν 3475, 2956, 1728, 1573, 1210 cm
–1
.  
1
H NMR (500 MHz, 
CDCl3) δ 3.65 (3H, s, Me), 3.93 (2H, s, CH-CO2Me, CH-CO2H), 6.22 (1H, d, J = 2.8 Hz, CHA=CHB), 6.24 (1H, 
d, J = 2.8 Hz, CHA=CHB), 11.20 (1H, br s, CO2H).  
13
C NMR (125 MHz, CDCl3) δ 48.66, 48.74, 52.0, 136.2, 
136.9, 171.1, 176.8.  HRMS (FAB), calcd for C7H8O4Cs 288.9477 (M+Cs)
+
, found 288.9470. 
 
 
(–)-Lactone 6.  
To a solution of methyl ester (+)-10 (2.12 g, 13.7 mmol) in CH2Cl2 (60 mL) and DMF (0.3 mL) at 0 °C was added 
(COCl)2 (1.7 mL, 21 mmol).  The reaction mixture was stirred at 0 °C for 1.5 h and was transferred to a 
suspension of NaBH4 (3.11 g, 82.2 mmol) in DMF (120 mL) at 0 °C.  The reaction mixture was stirred for 
further 1.5 h at 0 °C and 1M HCl solution was added.  The mixture was extracted with CH2Cl2 and the organic 
layer was dried over Na2SO4.  Concentration gave methyl ester 11, which was directly used in the next reaction. 
Trifluoroacetic acid (2.9 mL, 39 mmol) was added to a solution of crude methyl ester 11 in CH2Cl2 (70 mL) at 
0 °C and the reaction mixture was stirred at room temperature for 15 h.  Concentration and flash column 
chromatography (CH2Cl2/MeOH 99:1-97:3 then hexane/EtOAc 4:1-2:1) gave (–)-lactone 6 (919 mg, 8.35 mmol) 
in 61% yield over 3 steps. 
Colorless oil; [α]D
24
 = –272.2 (c 0.62, CHCl3); IR (neat) ν 2974, 1759, 1170, 984 cm
–1
.  
1
H NMR (500 MHz, 
CDCl3) δ 3.59 (1H, ddd, J = 6.7, 3.9, 2.2 Hz, OCH2CH), 3.62 (1H, d, J = 3.9 Hz, COCH), 4.24 (1H, dd, J = 9.6, 
2.3 Hz, OCHAHB), 4.27 (1H, dd, J = 9.6, 6.7 Hz, OCHAHB), 6.28 (1H, d, J = 2.8 Hz, CHA=CHB), 6.33 (1H, d, 
J = 2.8 Hz, CHA=CHB).  
13
C NMR (125 MHz, CDCl3) δ 41.8, 46.5, 67.9, 138.9, 141.5, 175.4.  HRMS (EI), 
calcd for C6H6O2 110.0368 (M
+
), found 110.0368. 
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(+)-Lactone 6.  
To a solution of methyl ester (+)-10 (85 mg, 0.55 mmol) in THF (5 mL) at 0 °C was added LiEt3BH (1.0 M in 
THF, 1.8 ml, 1.8 mmol).  The reaction mixture was stirred at 0 °C for 10 min and additional LiEt3BH (1.0 M in 
THF, 2.4 ml, 2.4 mmol) was added.  The reaction mixture was stirred for further 10 min at 0 °C and additional 
LiEt3BH (1.0 M in THF, 0.82 ml, 0.82 mmol) was added again. The reaction mixture was stirred at 0 °C for 10 
min, and then 1M HCl solution was added.  The resulting solution was neutralized by careful addition of 0.5 M 
LiOH solution.  Concentrated gave carboxylic acid 12, which was directly used in the next reaction. 
p-Toluenesulfonic acid monohydrate (400 mg, 2.11 mmol) was added to a solution of crude carboxylic acid 12 in 
benzene (40 mL) at 0 °C.  The reaction mixture was heated at 100 °C for 1 h and cooled to room temperature, 
and then H2O was added.  The mixture was extracted with CH2Cl2 and the organic layer was dried over Na2SO4.  
Concentration and flash column chromatography (hexane/EtOAc 6:1-4:1) gave (+)-lactone 6 (37 mg, 0.33 mmol) 
in 66% yield over 2 steps. 
Colorless oil; [α]D
27
 276.7 (c 0.22, CHCl3); IR (neat) ν 2974, 1758, 1171, 983 cm
–1
; 
1
H NMR (500 MHz, CDCl3) 
δ 3.60 (1H, ddd, J = 6.8, 3.4, 2.3 Hz, OCH2CH), 3.64 (1H, d, J = 3.9 Hz, COCH), 4.26 (1H, dd, J = 9.7, 2.3 Hz, 
OCHAHB), 4.29 (1H, dd, J = 9.7, 6.8 Hz, OCHAHB), 6.31 (1H, d, J = 2.8 Hz, CHA=CHB), 6.35 (1H, d, J = 2.8 
Hz, CHA=CHB).  
13
C NMR (125 MHz, CDCl3) δ 41.8, 46.5, 68.0, 139.0, 141.6, 175.4.  HRMS (EI), calcd for 
C6H6O2 110.0368 (M
+
), found 110.0363. 
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Piv ester 17.  
To a solution of (–)-lactone 6 (239 mg, 2.17 mmol) in THF (31 mL) at –78 °C was added DIBAL (1.0 M in 
hexane, 2.4 ml, 2.4 mmol).  The reaction mixture was stirred at –78 °C for 20 min and a solution of Grignard 
reagent 14 (ca. 0.6 M in THF, 31 mL, 18 mmol) was added at –78 °C.  The reaction mixture was stirred at room 
temperature for further 2 h and saturated aqueous potassium sodium tartrate was added.  The mixture was 
extracted with EtOAc and the organic layer was washed with brine and dried over anhydrous Na2SO4.  
Concentration and flash column chromatography (hexane/EtOAc 1:1-1:2-1:3) gave 1,4-diol 16 (508 mg), and its 
diastereomer (46.2 mg, 0.204 mmol) in 9% yield. 
To a solution of the impure 1,4-diol 16 and pyridine (1.8 mL, 22 mmol) in CH2Cl2 (100 mL) at 0 °C was added 
PivCl (1.1 ml, 8.9 mmol).  The reaction mixture was stirred at room temperature for 4 h and saturated aqueous 
NH4Cl solution was added. The mixture was extracted with CH2Cl2 and the organic layer was dried over Na2SO4. 
Concentration and flash column chromatography (hexane/EtOAc 9:1-3:1-1:1) gave Piv ester 17 (463 mg, 1.48 
mmol) in 68% yield over 3 steps. 
Pale yellow oil; [α]D
25
 = –19.9 (c 0.59, CHCl3); IR (neat) ν 3493, 2958, 2908, 2880, 1726, 1480, 1461, 1288, 1149, 
967, 945 cm
–1
.  
1
H NMR (500 MHz, CDCl3) δ 1.18 (9H, s, t-Bu of Piv), 1.40-1.58 (2H, m, H-4), 1.56-1.72 (4H, 
m, H-2, H-3), 2.93 (1H, dd, J = 10.1, 3.9 Hz, H-6), 3.19 (1H, ddd, J = 9.5, 5.0, 3.9 Hz, H-9), 3.68 (1H, ddd, J = 
10.1, 8.4, 2.8 Hz, H-5), 3.79-3.86 (2H, m, OCH2CH2O), 3.91-3.98 (2H, m, OCH2CH2O), 4.11 (1H, dd, J = 11.8, 
9.5 Hz, H10), 4.45 (1H, dd, J = 11.8, 5.0 Hz, H10), 4.84 (1H, t, J = 4.5 Hz, H1), 6.02 (1H, d, J = 2.8 Hz, H7), 6.06 
(1H, d, J = 2.8 Hz, H8).  
13
C NMR (125 MHz, CDCl3) δ 19.9, 27.1, 33.7, 34.9, 38.7, 44.7, 52.6, 64.1, 64.8, 70.9, 
104.5, 137.1, 138.1, 178.0.  HRMS (FAB), calcd for C17H29O5 313.2015 (M+H)
+
, found 313.2000. 
 
 
Alcohol 18.  
To a solution of Piv ester 17 (406 mg, 1.30 mmol) and 2,6-lutidine (1.2 mL, 10 mmol) in CH2Cl2 (100 mL) at 
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0 °C was added TBSOTf (890 μL, 3.90 mmol).  The reaction mixture was stirred at room temperature for 2 h and 
H2O was added.  The mixture was extracted with Et2O and the organic layer was washed with H2O, saturated 
aqueous NaHCO3 and brine, and dried over Na2SO4.  Concentration and flash column chromatography 
(hexane/EtOAc 100:0-9:1) gave TBS ether (694 mg), including inseparable compound, which was used in the 
next reaction.  
To a solution of the impure TBS ether (694 mg) in CH2Cl2 (20 mL) at –78 °C was added DIBAL solution (1.0 M 
in hexane, 2.60 mL, 2.60 mmol).  The reaction mixture was stirred at –78 °C for 10 min and saturated aqueous 
Na2SO4 and saturated aqueous NaHCO3 were added.  The resulting suspension was stirred at room temperature 
for 1 h and was filtrated through a pad of Celite with CH2Cl2.  Concentration and flash column chromatography 
(hexane/EtOAc 2:1-1:1) gave alcohol 18 (435 mg, 1.27 mmol) in 98% yield over 2 steps. 
Pale yellow oil; [α]D
27
 = 6.9 (c 0.41, CHCl3); IR (neat) ν 3421, 2952, 2931, 2886, 2859, 1468, 1254, 1140, 1098, 
1031, 939, 836 cm
–1
.  
1
H NMR (500 MHz, CDCl3) δ 0.09 (3H, s, Me of TBS), 0.10 (3H, s, Me of TBS), 0.88 
(9H, s, t-Bu of TBS), 1.46-1.52 (2H, m, H-3), 1.59-1.67 (4H, m, H-2, H-4), 3.11 (1H, dd, J = 5.0 Hz, H-6), 
3.17-3.20 (1H, m, H-9), 3.75-3.81 (2H, m, H-10), 3.83-3.87 (2H, m, OCH2CH2O), 3.91-3.96 (2H, m, OCH2CH2O), 
3.96-4.00 (1H, m, H-5), 4.83 (1H, t, J = 5.0 Hz, H-1), 5.96 (1H, d, J = 2.8 Hz, H-7) , 6.07 (1H, d, J = 2.8 Hz, H-8).  
13
C NMR (125 MHz, CDCl3) δ –4.1, –3.7, 18.2, 19.9, 25.9, 33.8, 35.5, 49.6, 51.3, 61.8, 64.82, 64.84, 72.7, 104.2, 
137.0, 137.6.  HRMS (FAB), calcd for C18H35O4Si 343.2305 (M+H)
+
, found 343.2307. 
 
 
Allylic alcohol 20.  
Dimethyl sulfoxide (0.95 M in CH2Cl2, 7.4 ml, 6.2 mmol) was added to a solution of (COCl)2 (0.21 mL, 2.5 
mmol) in CH2Cl2 (15 mL) at –78 °C.  The resulting mixture was stirred for 10 min then a solution of alcohol 18 
(423 mg, 1.24 mmol) in CH2Cl2 (7.0 mL) was added at -78 °C.  The reaction mixture was stirred at –78 °C for 2 
h and was treated with Et3N (1.1 mL, 7.9 mmol).  The resulting solution was stirred at –78 °C for further 1 h, 
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warmed to room temperature over 1.5 h, and stirred for further 1 h, and then H2O (8.0 mL) was added.  The 
mixture was extracted with CH2Cl2 (8.0 mL) and the organic layer was poured into a suspension of NaBH4 (233 
mg, 6.18 mmol) in EtOH (30 mL) at 0 °C.  The reaction mixture was stirred at 0 °C for 1 h and saturated 
aqueous NH4Cl was added.  The mixture was extracted with CH2Cl2 and the combined organic layers were dried 
over Na2SO4.  Concentration and flash column chromatography (hexane/EtOAc 4:1-2:1) gave allylic alcohol 20 
(363 mg, 1.06 mmol) in 86% yield. 
Colorless oil; [α]D
27
 = 4.9 (c 0.39, CHCl3); IR (neat) ν 3420, 2952, 2929, 2884, 2857, 1685, 1643, 1254, 1141, 
1034, 957, 837 cm
–1
.  
1
H NMR (500 MHz, CDCl3) δ 0.01 (3H, s, Me of TBS), 0.04 (3H, s, Me of TBS), 0.89 
(9H, s, t-Bu of TBS), 1.37-1.60 (6H, m, H-2, H-3, H-4), 3.82-3.85 (2H, m, OCH2CH2O), 3.91-3.98 (2H, m, 
OCH2CH2O), 4.17 (1H, dt, J = 5.7, 5.7 Hz, H-5), 4.30 (2H, d, J = 6.8 Hz, H-10), 4.83 (1H, t, J = 5.0 Hz, H-1), 
5.57 (1H, dt, J = 11.3, 6.8 Hz, H-9), 5.71 (1H, dd, J = 15.3, 5.7 Hz, H-6), 6.06 (1H, t, J = 11.3 Hz, H-8), 6.41 (1H, 
dd, J = 15.3, 11.3 Hz, H7).  
13
C NMR (125 MHz, CDCl3) δ –4.8 –4.4, 18.2, 19.7, 25.8, 33.8, 38.0, 58.8 (2C), 
64.8, 72.7, 104.5, 123.6, 128.9, 130.3, 139.1.  HRMS (FAB), calcd for C18H34O4SiCs 475.1281 (M+Cs)
+
, found 
475.1274. 
 
 
C1-10 Fragment (2).  
Tetrabromomethane (406 mg, 1.27 mmol) and DPPE (504 mg, 1.27 mmol) were successively added to a solution 
of allylic alcohol 20 (144 mg, 0.422 mmol) in CH2Cl2 (4.0 mL) at 0 °C.  The reaction mixture was stirred for 10 
min at 0 °C and was directly subjected to flash column chromatography (hexane/EtOAc 9:1) to give C1-10 
fragment (2) (170 mg, 0.422 mmol) in 100% yield. 
[α]D
24
 = 37.8 (c 0.24, CHCl3); IR (neat) ν 2952, 2928, 2856, 1652, 1472, 1458, 1252, 1124, 949, 836, 775 cm
–1
.   
1
H NMR (500 MHz, C6D6) δ 0.06 (3H, s, Me of TBS), 0.08 (3H, s, Me of TBS), 1.00 (9H, s, t-Bu of TBS), 
1.43-1.70 (4H, m, H-3, H-4), 1.74-1.79 (2H, m, H-2), 3.34-3.37 (2H, m, OCH2CH2O), 3.52-3.55 (2H, m, 
OCH2CH2O), 3.81 (1H, dd, J = 11.8, 8.4 Hz, H-10), 3.90 (1H, dd, J = 11.8, 7.8 Hz, H-10), 4.06 (1H, dt, J = 6.1, 
OTBS
O
O
HO
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O
O
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5.5 Hz, H-5), 4.81 (1H, t, J = 5.0 Hz, H1), 5.36 (1H, br dt, J = 10.7, 7.8 Hz, H9), 5.61 (1H, dd, J = 15.1, 6.1 Hz, 
H6), 5.90 (1H, br dd, J = 11.2, 10.7 Hz, H8), 6.46 (1H, dd, J = 15.1, 11.2 Hz, H7).  
13
C NMR (125 MHz, C6D6) δ 
–4.6 –4.2, 18.5, 20.2, 26.1, 34.4, 38.4, 39.3, 64.9(2C), 73.0, 104.8, 123.1, 125.5, 132.6, 140.9. 
 
 
1,4-Diol 21.  
To a solution of (+)-lactone 6 (242 mg, 2.19 mmol) in THF (20 mL) at –78 °C was added DIBAL (1.0 M in 
hexane, 2.2 ml, 2.2 mmol).  The reaction mixture was stirred for 20 min at –78 °C, then ZnBr2 (493 mg, 2.19 
mmol) and EtMgBr (0.50 M in THF, 13.1 ml, 6.57 mmol) were added successively.  The reaction mixture was 
warmed to room temperature and stirred for 16 h, and then 1M HCl solution was added.  The mixture was 
extracted with Et2O and the organic layer was dried over Na2SO4.  Concentration and flash column 
chromatography (hexane/EtOAc 3:1-2:1-1:1-1:2) gave 1,4-diol 21 (213 mg, 15.0 mmol) in 68% yield and a 
mixture of 1,4-diol 21 and its diastereomeric isomer in 1:3 ratio in 13% yield. 
White solid; m.p. 53-55 °C; [α]D
24
 = 28.7 (c 0.31, CHCl3); IR (neat) ν 3317, 3044, 2964, 2922, 1461, 1290, 1029, 
967 cm
–1
.  
1
H NMR (500 MHz, CDCl3) δ 1.00 (3H, t, J = 7.4 Hz, H-20), 1.37-1.46 (1H, m, H-19), 1.61-1.70 (1H, 
m, H-19), 2.94 (1H, dd, J = 10.8, 4.0 Hz, H17), 3.20 (1H, dt, J =11.3, 4.0 Hz, H14), 3.63-3.68 (1H, m, H18), 3.69 
(1H, dd, J = 11.3, 11.3 Hz, H13), 3.75-3.94 (2H, m, OH x2), 3.82 (1H, dd, J = 11.3, 4.0 Hz, H13), 6.01 (1H, d, J = 
2.8 Hz, H15 or 16), 6.02 (1H, d, J = 2.8 Hz, H15 or 16). 
 13
C NMR (125 MHz, CDCl3) δ 9.7, 27.9, 48.2, 52.4, 
62.3, 72.6, 137.2, 137.8; HRMS (FAB), calcd for C8H14O2Cs 275.0048 (M+Cs)
+
, found 275.0039. 
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TBS ether 22.  
To a solution of 1,4-diol 21 (291 mg, 2.04 mmol) and 2,6-lutidine (2.2 mL, 20 mmol) in CH2Cl2 (10 mL) at 0 °C 
was added PivCl (0.6 ml, 6.1 mmol).  The reaction mixture was stirred at room temperature for 2 h and 
additional PivCl (0.2 mL, 2.0 mmol) was added.  The reaction mixture was stirred at room temperature for 
further 1 h and cooled to 0 °C, and then TBSOTf (0.9 mL, 4.1 mmol) was added.  The reaction mixture stirred 
for 1 h, and additional TBSOTf (0.9 mL, 4.1 mmol) was added.  The reaction mixture was stirred for further 10 
min and H2O was added.  The mixture was extracted with Et2O and the organic layer was washed with H2O, 
saturated aqueous NaHCO3 and brine, and dried over Na2SO4.  Concentration and flash column chromatography 
(hexane/EtOAc 100:0-9:1) gave product (811 mg), including inseparable compound, which was used in the next 
reaction.  
To a solution of crude product (811 mg) in CH2Cl2 (100 mL) at –78 °C was added DIBAL (1.0 M in hexane, 4.0 
ml, 4.0 mmol).  The reaction mixture was stirred at –78 °C for 10 min and additional DIBALn (1.0 M in hexane, 
0.60 ml, 0.60 mmol) was added.  The reaction mixture was stirred for further 10 min and a mixture of saturated 
aqueous Na2SO4 and saturated aqueous NaHCO3 was added.  The suspension was stirred at room temperature for 
1 h and was filtrated through a pad of Celite with CH2Cl2.  Concentration and flash column chromatography 
(hexane/EtOAc 9:1-2:1) gave TBS ether 22 (529 mg, 2.05 mmol) in 100% yield over 2 steps. 
Pale yellow oil; [α]D
26
 = –8.8 (c 0.42, CHCl3); IR (neat) ν 3343, 3045, 2957, 2931, 2887, 2858, 1467, 1384, 1254, 
1102, 1007, 836 cm
–1
.  
1
H NMR (500 MHz, CDCl3) δ 0.108 (3H, s, Me of TBS), 0.112 (3H, s, Me of TBS), 0.90 
(9H, s, t-Bu of TBS), 0.93 (3H, t, J = 7.4 Hz, H-20), 1.59-1.70 (2H, m, H-19), 3.13 (1H, m, H-17), 3.19 (1H, m, 
H-14), 3.77 (1H, dd, J = 11.3, 6.2 Hz, H-13), 3.84 (1H, dd, J = 11.3, 3.4 Hz, H-13), 3.93 (1H, dt, J = 6.2, 5.6 Hz, 
H-18), 5.97 (1H, d, J = 2.8 Hz, H-16), 6.09 (1H, d, J = 2.8 Hz, H-15). 
 13
C NMR (125 MHz, CDCl3) δ –4.1, –3.7, 
9.9, 18.3, 25.9, 28.4, 49.6, 51.0, 61.9, 74.1, 137.1, 137.5.  HRMS (FAB), calcd for C14H29O2Si 257.1937 (M+H
+
), 
found 257.1933. 
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Allylic alcohol 24. 
Dimethyl sulfoxide (0.95 M in CH2Cl2, 18.2 ml, 17.4 mmol) was added to a solution of (COCl)2 (0.59 mL, 7.0 
mmol) in CH2Cl2 (100 mL) at –78 °C.  The mixture was stirred at –78 °C for 10 min, then a solution of TBS 
ether 22 (891 mg, 3.48 mmol) in CH2Cl2 (17 mL) was added.  The reaction mixture was stirred at –78 °C for 2 h 
and treated with Et3N (3.1 mL, 22 mmol).  The resulting solution was stirred at –78 °C for additional 1 h, 
warmed to room temperature over 1.5 h, and stirred for further1 h, and then H2O (17 mL) was added.  The 
mixture was extracted with CH2Cl2 (17 mL) and the organic layer was poured into a suspension of NaBH4 (659 
mg, 17.4 mmol) in EtOH (85 mL) at 0 °C.  The reaction mixture was stirred for 30 min and saturated aqueous 
NH4Cl was added.  The resulting solution was extracted with CH2Cl2 and the organic layer was dried over 
Na2SO4.  Concentration and flash column chromatography (hexane/EtOAc 9:1-4:1) gave allylic alcohol 24 (751 
mg, 2.93 mmol) in 84% yield. 
Colorless oil; [α]D
25 
= 2.7 (c 0.37, CHCl3); IR (neat) ν 3357, 2956, 2932, 2858, 1679, 1642, 1467, 1362, 1255, 
1065, 1042, 1009, 837 cm
–1
.  
1
H NMR (500 MHz, CDCl3) δ 0.03 (3H, s, Me of TBS), 0.05 (3H, s, Me of TBS), 
0.87 (3H, t, J = 7.4 Hz, H-20), 0.90 (9H, s, t-Bu of TBS), 1.51 (2H, qd, J = 7.4, 6.2 Hz H-19), 4.11 (1H, td, J = 6.2, 
5.7 Hz, H-18), 4.31 (1H, dd, J = 13.6, 6.8 Hz, H-13), 4.33 (1H, dd, J = 13.6, 6.8 Hz, H-13), 5.57 (1H, dt, J = 11.3, 
6.8 Hz, H-14), 5.72 (1H, dd, J = 14.8, 5.7 Hz, H-17), 6.09 (1H, dd, J = 11.3, 11.3 Hz, H15), 6.43 (1H, dd, J = 14.8, 
11.3 Hz, H16).  
13
C NMR (125 MHz, CDCl3) δ –4.8, –4.4, 9.6, 18.3, 25.9, 31.0, 58.8, 73.9, 123.4, 128.8, 130.4, 
139.2.  HRMS (ESI), calcd for C14H28O2SiNa 279.1756 (M+Na)
+
, found 279.1765. 
 
 
C13-20 Fragment (3).  
Tetrabromomethane (129 mg, 0.391 mmol) and DPPE (156 mg, 0.391 mmol) were successively added to a 
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solution of allylic alcohol 24 (100 mg, 0.391 mmol) in CH2Cl2 (3 mL) at 0 °C.  The reaction mixture was stirred 
at room temperature for 20 min and was directly subjected to flash column chromatography (hexane/EtOAc 9:1) 
to give C13-20 fragment (3) (122 mg, 0.384 mmol) in 98% yield. 
Yellow oil ; [α]D
24
 = –72.2 (c 0.47, CHCl3); IR (neat) ν 2957, 2929, 2884, 2857, 1651, 1472, 1362, 1255, 1200, 
1044, 837, 775 cm
–1
.  
1
H NMR (500 MHz, C6D6) δ 0.06 (3H, s, Me of TBS), 0.07 (3H, s, Me of TBS), 0.86 (3H, 
t, J = 7.3 Hz, H-20), 1.01 (9H, s, t-Bu of TBS), 1.38-1.50 (2H, m, H-19), 3.69 (1H, dd, J = 9.5, 8.3 Hz, H-13), 
3.80 (1H, dd, J = 9.5, 9.5 Hz, H-13), 3.96 (1H, td, J = 6.2, 5.6 Hz, H-18), 5.40 (1H, br ddd, J = 10.6, 9.5, 8.3 Hz, 
H14), 5.60 (1H, dd, J = 15.1, 5.6 Hz, H17), 5.87 (1H, dd, J = 11.2, 10.6 Hz, H15), 6.51 (1H, dd, J = 15.1, 11.2 Hz, 
H16).  
13
C NMR (125 MHz, C6D6) δ –4.6, –4.2,9.7, 18.5, 26.1, 26.9, 31.2, 74.1, 123.1, 125.5, 132.9, 140.7. 
 
 
C11-20 Fragment (25). 
Ethynyl magnesium bromide (0.50 M in THF, 4.70 ml, 2.35 mmol) was added to a solution of CuCl (23 mg, 0.23 
mmol) in THF (4.0 mL) at room temperature, and the mixture was stirred for 15 min. A solution of C13-20 
fragment (3) (61 mg, 0.19 mmol) in THF (3.0 mL) was added to the mixture. The reaction mixture was stirred at 
60 °C for 14 h and cooled to room temperature, and then saturated aqueous NH4Cl solution was added.  The 
mixture was extracted with Et2O and the organic layer was washed with brine and dried over anhydrous Na2SO4. 
Concentration and flash column chromatography (hexane/EtOAc 100:0-98:2) gave C11-20 fragment (25) (43 mg, 
0.16 mmol) in 84% yield. 
Pale brown oil; [α]D
28
 = –21.8 (c 0.33, CHCl3); IR (neat) ν 3311, 2957, 2931, 2857, 2122, 1466, 1254, 1065, 837 
cm
–1
.  
1
H NMR (500 MHz, CDCl3) δ 0.03 (3H, s, Me of TBS), 0.05 (3H, s, Me of TBS), 0.87 (3H, t, J = 7.4 Hz, 
H-20), 0.91 (9H, s, t-Bu of TBS), 1.51 (2H, qd, J = 7.4, 5.6 Hz, H-19), 2.00 (1H, t, J = 2.8 Hz, H-11), 3.07 (2H, 
ddd, J = 6.8, 2.8, 2.8 Hz, H-13), 4.11 (1H, dt, J = 6.2, 5.6 Hz, H-18), 5.42 (1H, dt, J = 10.2, 6.8 Hz, H-14), 5.71 
(1H, dd, J = 15.3, 6.2 Hz, H-17), 6.06 (1H, ddd, J = 11.3, 10.2, 2.8 Hz, H-15), 6.38 (1H, dd, J = 15.3, 11.3 Hz, 
H-16).  
13
C NMR (125 MHz, CDCl3) δ –4.8 –4.4, 9.6, 17.2, 18.3, 25.9, 31.0, 68.3, 74.0, 82.4, 123.2, 124.1, 129.9, 
OTBS
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138.7. 
 
 
Coupling product 26.  
n-Buthyl lithium (1.6 M in hexane, 0.21 mL, 0.34 mmol) was added to a solution of CuBr·SMe2 (70 mg, 0.34 
mmol) and C11-20 fragment (25) (100 mg, 0.379 mmol) in THF (2.0 mL) at –78 °C.  The solution was stirred at 
–78 °C for 5 min and then HMPA (2.0 mL) was added.  The resulting mixture was dropped into a solution of 
C1-10 fragment (2) (76.2 mg, 0.189 mmol) in THF (3.0 mL) at 0 °C via cannular.  The reaction mixture was 
stirred at room temperature for 17 h and saturated aqueous NH4Cl was added.  The mixture was extracted with 
CH2Cl2 and the organic layers were washed with brine and dried over Na2SO4.  Concentration and flash column 
chromatography (hexane/EtOAc 99:1-98:2-97:3) gave 26 (59 mg, 0.10 mmol) in 53% yield. 
Colorless oil; [α]D
24
 = –2.2 (c 0.35, CHCl3); IR (neat) ν 2954, 2929, 2857, 1472, 1463, 1254, 1063, 950, 836 cm
–1
.   
1
H NMR (500 MHz, C6D6) δ 0.07 (9H, s, Me of TBS x 3), 0.09 (3H, s, Me of TBS), 0.88 (3H, t, J = 7.3 Hz, H-20), 
1.00 (18H, s, t-Bu of TBS x 2), 1.40-1.57 (3H, m, H-3. H-19), 1.55-1.60 (2H, m, H4), 1.60-1.70 (1H, m, H-3), 
1.74-1.77 (2H, m, H2), 2.95-3.08 (4H, m, H10, H13), 3.35-3.37 (2H, m, CH2 of acetal), 3.52-3.55 (2H, m, 
OCH2CH2O), 4.00 (1H, dt, J = 6.2, 6.2 Hz, H18), 4.08 (1H, dt, J = 6.2, 5.0 Hz, H5), 4.81 (1H, t, J = 4.5 Hz, H1), 
5.43-5.49 (2H, m, H9, H14), 5.60 (2H, dd, J = 15.1, 6.2 Hz, H6, H17), 5.96 (1H, dd, J = 11.2, 11.2 Hz, H8 or 15), 
5.98 (1H, dd, J = 10.6, 10.6 Hz, H8 or 15), 6.49 (1H, dd, J = 15.1, 11.2 Hz, H7 or 16), 6.50 (1H, dd, J = 15.1, 11.2 
Hz, H7 or 16).  
13
C NMR (125 MHz, C6D6) δ –4.60, –4.57, –4.1, –4.0, 9.8, 18.0 (2C), 18.5 (2C), 20.4, 26.13, 
26.15, 31.5, 34.4, 38.6, 64.8 (2C), 73.3, 74.5, 78.5, 78.6, 104.8, 124.1, 124.2, 126.3 (2C), 129.5 (2C), 138.4, 138.6.  
HRMS (EI), calcd for C34H60O4Si2 588.4030 (M
+
), found 588.4044. 
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Alkene 27.  
A suspension of compound 26 (22 mg, 38 μmol), quinoline (38 μL, 0.31 mmol) and 5% Pd-BaSO4 (22 mg) in 
EtOAc (6.0 mL) was exposed to H2 atmosphere (1 atm) and stirred for 10 h at room temperature.  Additional 5% 
Pd-BaSO4 (22 mg) was added and the reaction mixture was stirred for further 4 h at room temperature.  
Additional 5% Pd-BaSO4 (11 mg) was added again and the reaction mixture was stirred for further 2 h at room 
temperature.  The suspension was filtrated through a pad of Celite with EtOAc.  Concentrated and purification 
by HPLC (Inertsil, SIL 100A, 250 x 10 mm, UV 254 nm, hexane/EtOAc 96/4, 3.0 mL/min, TR = 23 min) gave 
alkene 27 (13 mg, 22 μmol) in 54% yield. 
Pale yellow oil; [α]D
23
 = 1.4 (c 0.37, CHCl3); IR (neat) ν 2955, 2928, 2856, 1471, 1463, 1255, 1142, 1063, 952, 
836 cm
–1
.  
1
H NMR (500 MHz, C6D6) δ 0.10 (3H, s, Me of TBS), 0.11 (6H, s, Me of TBS x 2), 0.12 (3H, s, Me 
of TBS), 0.92 (3H, t, J = 7.3 Hz, H20), 1.04 (18H, s, t-Bu of TBS x 2), 1.50-1.58 (2H, m, H19), 1.60-1.73 (4H, m, 
H3, H4), 1.75-1.82 (2H, m, H2), 2.94-3.04 (4H, m, H10, H13), 3.35-3.40 (2H, m, CH2 of acetal), 3.53-3.56 (2H, 
m, CH2 of acetal), 4.08 (1H, dt, J = 6.2, 5.6 Hz, H18), 4.17 (1H, dt, J = 6.2, 5.6 Hz, H5), 4.82 (1H, t, J = 4.5 Hz, 
H1), 5.36-5.43 (2H, m, H9, H14), 5.45 (2H, t, J = 5.0 Hz, H11, H12), 5.67 (2H, dd, J = 15.1, 6.2 Hz, H6, H17), 
6.06 (1H, dd, J = 11.2, 10.1 Hz, H8 or 15), 6.08 (1H, dd, J = 11.2, 10.1 Hz, H8 or 15), 6.65 (1H, dd, J = 15.1, 11.2 
Hz, H7 or 16), 6.67 (1H, dd, J = 15.1, 11.2 Hz, H7 or 16).  
13
C NMR (125 MHz, (CD3)2CO) δ –4.55, –4.51, –4.1, 
–4.0, 9.9, 18.8 (2C), 20.6, 26.29, 26.31, 26.7 (2C), 31.8, 34.7, 39.0, 65.3 (2C), 73.7, 74.9, 105.0, 125.21, 125.24, 
128.8 (2C), 129.2 (2C), 129.74, 129.83, 138.1, 138.2.  HRMS (EI), calcd for C34H62O4Si2 590.4187 (M
+
), found 
590.4165. 
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Resolvin E2 (1).  
To a solution of alkene 27 (7.0 mg, 12 μmol) and 2,6-lutidine (33 μL, 270 μmol) in CH2Cl2 (1.5 mL) at –20 °C 
was TMSOTf (33 μL, 180 μmol).  The reaction mixture was stirred at –20 °C for 1 h and H2O was added.  The 
mixture was stirred at room temperature for 1 h and extracted with CH2Cl2.  The organic layer was washed with 
brine and dried over anhydrous Na2SO4.  Concentration and flash column chromatography (hexane/EtOAc 9:1) 
gave the aldehyde 28 (7.0 mg, 13 μmol).   
A solution of NaClO2 (8.7 mg, 96 μmol) and NaH2PO4·4H2O (16 mg, 0.10 mmol) in H2O (0.5 mL) was added to 
a solution of the crude aldehyde 28 in 2-methyl-2-butene (0.50 mL) and t-BuOH (0.50 mL) at 0 °C was added.  
The reaction mixture was stirred at room temperature for 1 h and brine was added.  The mixture was extracted 
with EtOAc and the organic layer was dried over Na2SO4.  Filtration, concentration gave the carboxylic acid 29 
(8.2 mg), which was directly used in the next reaction.  To a solution of the crude carboxylic acid 29 in THF (3.0 
mL) at 0 °C was added TBAF (1.0 M in THF, 240 μL, 0.24 mmol).  The reaction mixture was stirred at room 
temperature for 11 h and additional TBAF (60 μL, 0.06 μmol) was added.  The reaction mixture was stirred at 
room temperature for further 2 h and brine and saturated aqueous NH4Cl were added.  The mixture was extracted 
with Et2O and the organic layer was dried over Na2SO4.  Concentration, chromatography (silica gel; BW-820, 
CH2Cl2/MeOH 99:1-97:3-10:1), and further purification by HPLC (Inertsil, ODS-3, 150 x 4.6 mm, UV 254 nm, 
MeOH/H2O/AcOH 60/40/0.01-90/10/0.01, 1.0 mL/min, TR = 17 min) gave resolvin E2 (1) (2.60 mg, 7.8 μmol) in 
67% yield over 3 steps. 
Colorless oil; [α]D
24
 = –2.1 (c 0.25, MeOH); IR (neat) ν 3384, 3012, 2963, 2933, 1715, 1244, 1034, 985, 954 cm
–1
.   
1
H NMR (500 MHz, CD3OD) δ 0.91 (3H, t, J = 7.3 Hz, H2), 1.48-1.73 (6H, m, H-3. H-4. H-19), 2.03 (2H, t, J = 
8.4 Hz, H2), 2.98 (4H, m, H10, H13), 4.02 (1H, dt, J = 6.8, 6.7 Hz, H5 or 18), 4.11 (1H, dt, J = 6.8, 6.2 Hz, H5 or 
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18), 5.34-5.42 (4H, m, H9, H11, H12, H14), 5.65 (1H, dd, J = 15.2, 6.8 Hz, H6 or 17), 5.66 (1H, dd, J = 15.2, 6.8 
Hz, H6 or 17), 6.00 (2H, dd, J = 11.2, 10.6 Hz, H8, H15), 6.55 (1H, dd, J = 15.2, 11.2 Hz, H7 or 16), 6.56 (1H, dd, 
J = 15.2, 11.2 Hz, H7 or 16).  
13
C NMR (125 MHz, CD3OD) δ 10.2, 22.3, 27.0 (2C), 31.2, 35.0, 37.8, 72.9, 74.7, 
126.4 (2C), 129.09, 129.11, 129.4, 129.5, 130.5, 130.6, 137.7 (2C), 177.7.  HRMS (FAB), calcd for C20H29O4 
333.2066 (M-H)
-
, found 333.2072. 
 
Bioassay 
Murine peritonitis was carried out using 7- to 8-week old C57BL/6 male mice (CLEA Japan). Resolvin E2 or 
vehicle alone was injected into the tail vein followed by 1 mL of zymosan A (1 mg/mL; Sigma) injected into the 
peritoneum.  At 2 h, peritoneal lavages were collected and cells were enumerated via light microscopy. 
Differential leukocyte counts were performed using Wright Giemsa stain.  Cytokine levels were determined from 
peritoneal cell-free exudates using BD OptEIA Kit for mouse TNFα and IL-6 (BD Biosciences)  
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Chapter 4 
Enantioselective Synthesis of Haterumalide NA Methyl Ester 
and Revised Structure of Haterumalide NA 
 
Abstract:  
The enantioselective synthesis of the enantiomer of the haterumalide NA methyl ester, a cytotoxic macrolide 
from an Okinawan sponge, was achieved from the threitol derivative in 26 steps.  The key steps are the 
stereoselective construction of a chloroolefin unit and the intramolecular Reformatsky-type reaction.  This 
synthesis revised the absolute stereochemistry of haterumalide NA. 
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Introduction 
 
Haterumalide NA is a macrolide isolated from the Okinawan sponge Ircinia sp.  This compound exhibited a 
cytotoxicity against P388 cells with an IC50 of 0.32 g/mL.
1
  The gross structure and stereochemistry were 
elucidated by the spectroscopic analysis and the modified Mosher’s method as structural formula 1.  The 
structural features of this compound are a 14-membered macrolide (long chain fatty acid derivative) involving a 
trans disubstituted tetrahydrofuran ring, a Z-chloroolefin, and a β,γ-unsaturated acid moiety.  The structurally 
related haterumalide B
2
 and oocydin A
3
 were isolated from an Okinawan ascidian and a South American epiphyte, 
respectively, and their stereostructures have not been fully established.  It is noteworthy that haterumalide NA 
was recently isolated from a soil bacterium.
4
  The author describes in this chapter the enantioselective synthesis 
of the ent-haterumalide NA methyl ester, which revises the initially assigned stereostructure. 
 
 
 
Figure 4-1. Structure of haterumalide NA and oocydin A 
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Results and discussion 
 
Retrosynthesis of haterumalide NA 
Retrosynthetic analysis of haterumalide NA is outlined in Scheme 4-1.  The haterumalide NA methyl ester (1: 
R = Me) can be logically divided into the macrolide unit 2 and the side chain unit 3.  The side chain unit 3 can be 
easily prepared from 3-butyn-1-ol 18 (see Scheme 4-8).
5
  The macrocyclic structure of 2 can be established by 
lactonization of the seco acid 4 or by the intramolecular Reformatsky-type reaction of the bromo ester derivative 5.  
These precursors, 4 and 5, can be synthesized from a common intermediate 6, which can be prepared from the 
tetrahydrofuran unit 7 by a coupling reaction with 8. 
 
Scheme 4-1. Retrosynthesis of haterumalide NA methyl ester  
 
Synthesis of C9-C15 fragment 
Scheme 4-2 summarizes the synthesis of the tetrahydrofuran unit 7.  The mono-MPM ether 10 was synthesized 
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from commercially available (+)-2,3-O-isopropylidene-L-threitol 9.
6
  After transformation into the 
corresponding iodide, C1 homologation was effected by using the FAMSO
7
 carbanion to afford sulfoxide 11 
(69%).  Sequential acidic methanolysis
8
 and hydrolysis afforded the hemiacetal 13 in 41% yield.  Wittig 
reaction of 13 and cyclization provided the 5.3:1 diastereomeric mixture of tetrahydrofurans, which could be 
separated after silylation to afford the desired trans-tetrahydrofuran 16 (41%) and the cis-isomer 17.  The latter 
could be isomerized into the former as a 1:1 mixture (isolation yield of 14 42%).  The stereochemistry of 16 and 
17 were determined by the coupling constants from their 
1
H NMR data and the NOE experiments (Figure 4-2).  
The desired trans-tetrahydrofuran 16 was quantitatively converted into the bromide 7 in 3 steps.   
 
 
 
 Reagents and conditions: (a) MPMCl, NaH, DMF (63%). (b) p-TsCl, pyridine. (c) NaI, CaCO3, acetone (89%, 2 
steps). (d) FAMSO, n-BuLi, THF-hexanes (69%). (e) conc. HCl, MeOH (8:92) (41%). (f) 1 M HCl aq, THF 
(99%). (g) Ph3PCHCO2Me, MeCN. (h) NaOMe, MeOH. (i) TBSCl, imidazole (41%, 3 steps). (j) LiAlH4, THF 
(100%). (k) p-TsCl, pyridine. (l) LiBr, DMF (100%, 2 steps). 
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Scheme 4-2. Synthesis of C9-C15 fragment 7 
 
 
Figure 4-2. 
1
H NMR data and the observed NOEs of 16 and 17 
 
Synthesis of C5-C8 fragment 
Synthesis of C5-C8 fragment was started with 3-butyn-1-ol 18 (Scheme 4-3).  3-Butyn-1-ol (18) was 
transformed into the E-alkenylsilane 21 (52%) following a reported procedure
9
.  The E-alkenylsilane 21 was 
photochemically isomerized to the Z-isomer 8 in 99% yield.  The stereochemistry of 8 was determined by the 
NOE experiments (Figure 4-3).  
 
 
 
Reagents and conditions: (a) DHP, p-TsOH (86%). (b) TMSCl, n-BuLi, ether-hexanes (67%). (c) (i) DIBAL, 
ether-hexanes; (ii) pyridine, ether; (iii) Br2, CH2Cl2 (91%). (d) hν, Br2 , pyridine, CH2Cl2 (100%). 
Scheme 4-3. Synthesis of C5-C8 fragment 
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Figure 4-3. NOE experiment of 8 
Synthesis of Z-chloroolefin 22 
The coupling reaction between the tetrahydrofuran unit 7 and the carbanion generated from the Z-alkenylsilane 8 
and sec-butyllithium was accomplished to give compound 6 in 68% yield.  There are only a few published 
procedures for the stereoselective preparation of chloroolefins.  The author modified the procedure
10
 for 
conversion of an alkenylsilane to a bromoolefin for preparation of the chloroolefin 22 (Scheme 4-4).  After 
several attempts, the author found that the addition of a catalytic amount of water was important for the reaction to 
be reproducible.  
 
 
 Reagents and conditions: (e) (i) 8, s-BuLi, THF-hexanes; (ii) 7, HMPA, THF (68%). (f) NCS, H2O, DMF (45%). 
Scheme 4-4. Synthesis of 22  
 
Synthesis of seco acid 4 and macrolactonization 
Scheme 4-5 summarizes the synthesis of the seco acid 4.  Acidic hydrolysis of 22 gave 24 and subsequent Dess 
Martin oxidation afforded a labile aldehyde, which was converted into the Z-conjugated ester 25 by using the 
Still’s modified Horner-Emmons reaction
11
 (62%, three steps).  The regiochemistry at C4 double bond of 25 was 
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determined by the NOE experiment (Figure 4-4).  The DIBAL reduction of 25 gave the allylic alcohol 26 
(100%), which was oxidized to a conjugated aldehyde. The asymmetric aldol reaction
12
 with Corey’s sulfoxide 31 
provided a hydroxysulfoxide, amalgam reduction of which gave the desired hydroxyl ester 28 (49%, three steps).  
The absolute stereochemistry of the C-3 hydroxyl group in 28 was established by the modified Mosher’s 
method.
14
 After acetylation, the protecting groups were removed to give the dihydroxyl acid 29 (84%, two steps), 
the primary hydroxyl group of which was protected as the TBDPS ether to afford the seco acid 4 (47%, two 
steps). 
Thus, the precursors for the macrolide unit 2 were in hand. However, all attempts at macrolactonization of the 
dihydroxyl acid 29 or the seco acid 4 to 2 failed under the Yamaguchi, Keck, and Mukaiyama-Corey conditions 
(Scheme 4-6).  
 
Reagents and conditions: (a) AcOH, THF, H2O (80%). (b) Dess-Martin periodinane, CH2Cl2. (c) 30, KHMDS, 
18-crown-6, TH, toluene (77%, 2 steps). (d) DIBAL, toluene (100%). (e) Dess-Martin periodinane, CH2Cl2. (f) 31, 
t-BuMgCl, THF (57%, 3S:3R ) 19:1, 2 steps). (g) Al-Hg, THF-H2O (86%). (h) Ac2O, pyridine (86%). (i) HF-py, 
pyridine, THF (93%). (j) TMSOTf, 2,6-lutidine, CH2Cl2 (90%). (k) TBDPSCl, DMAP, Et3N, CH2Cl2.(l) AcOH, 
THF, H2O (47%, 2 steps).  
Scheme 4-5. Synthesis of seco acid 4  
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Figure 4-5. NOE experiment of 25 
 
 
Reagents and conditions: (a) 2,4,6-trichlorobenzoylchloride, DMAP, Et3N, CH2Cl2 (b) DCC, DMAP, CSA, 
CH2Cl2 (c) dipyridyl disulfide, PPh3, benzene 
Scheme 4-6. Macrolactonization with seco acid 4 and 29 
 
Synthesis of macrolactone 35 
The author next tried to cyclize the 14-membered ring using the intramolecular Reformatsky-type reaction 
(Scheme 4-7). The hydroxy group of the allylic alcohol 26 was protected as an MMTr ether to quantitatively 
afford compound 32.  The silyl group in 32 was removed, and the resulting alcohol 33 (99%) was converted into 
the bromo ester 34.  The MMTr group was removed to give allylic alcohol intermediate (82%, two steps), which 
was oxidized to afford the conjugated aldehyde 5, a precursor of the intramolecular Reformatsky-type reaction, in 
93% yield.  Attempts toward the intramolecular Reformatsky-type reaction are summarized in Table 4-5.  The 
cyclization with SmI2
15
 provided the cyclic compounds in good yields (86%, 3S:3R = 1:1); however, the 
stereochemistry of the C-4 double bond was totally isomerized into trans (entry 1).  The reaction at lower 
temperature also gave the same trans-products in a lower yield (entry 2).  The molecular mechanics calculation 
indicated that the desired cis compound 34 was less stable (7.5 kJ/mol) than the trans compound. (The 
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calculations were executed by MacroModel (Version 6.0) with the MM2* force field.)  This isomerization might 
be due to the allylic radical nature of the transition state and/or the reactive intermediates.  Therefore, the author 
investigated the cyclization with zinc reagents apt to effect the two-electron reduction.  The reactions under the 
standard conditions
16,17
 afforded no cyclized compounds (entries 3 and 4).  The reaction under Honda’s 
conditions
18
 with Et2Zn-RhCl(PPh3)3 resulted in the decomposition of the starting material; however, the author 
found by TLC monitoring the generation of an intermediate, the -hydroxy lactone 36, which decomposed upon 
workup (entry 5). The addition of Ac2O to trap the reactive products allowed the author to isolate the desired 
cyclized product (3S,4Z)-35 in 9% yield along with the (3R,4Z)- and (4E)-isomers (entry 6). 
 
 
Reagents and conditions: (a) MMTrCl, pyridine (100%). (b) TBAF, THF (99%). (c) BrCH2COBr, pyridine, 
CH2Cl2. (d) AcOH, THF-H2O (82% in 2 steps). (e) Dess-Martin periodinane, CH2Cl2 (93%). (f) (i) Et2Zn, 
RhCl(PPh3)3, THF-hexane; (ii) Ac2O (9%). 
Scheme 4-7. Synthesis of macrolactone 35.
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a After 4 h, Ac2O was added to trap the reactive product 36. b Complex mixture. c Noncyclized reduced products were obtained: debromo-5 (65%) 
and the corresponding debromo-allyl alcohol (23%). 
Table 4-5. Intramolecular Reformatsky type reaction of bromoesrter 5 
 
The stereochemistry at the C-4 double bond was easily determined by the NOE experiments (Figure 4-6).  On 
the other hand, the stereochemistry at C-3 was determined by the modified Mosher’s method.  The minor isomer, 
(3S,4Z)-35, could not be transformed into the corresponding MTPA esters because of the instability during the 
methanolysis of the acetyl group.  However, the modified Mosher’s method could be applied to (3R,4Z)-37-2 
that was obtained by methanolysis of the major isomer, (3R,4Z)-37, establishing that the major isomer possessed 
the undesired stereochemistry 3R, i.e., the minor isomer was the desired (3S)-compound (Figure 4-7). 
 
 
Figure 4-6. NOE studies of 35 and 37 
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Figure 4-7. Determination of the stereochemistry of 37 by modified Mosher’s method 
 
Synthesis of haterumalide NA methyl ester 
Scheme 4-8 summarizes the synthesis of the haterumalide NA methyl ester 41.  The MPM group in (3S,4Z)-35 
was removed to give the alcohol 39 in 88% yield, which was oxidized with the Dess-Martin periodinane to afford 
an unstable aldehyde 40. The Nozaki-Hiyama-Kishi coupling reaction
19
 of the aldehyde and iodide 3, prepared 
from 18,
5
 afforded the coupling product 41 (57%, S:R = 11:1), and the diastereomers were separated with HPLC. 
The major isomer, (15S)-41, was found to be identical with the naturally occurring sample upon comparison of 
their spectral data (Figure 4-8) and chromatographic behavior except for the sign of the CD spectrum (Figure 4-9). 
 
Reagents and conditions: (a) DDQ, CH2Cl2-phosphate buffer (pH 5.9) (88%). (b) Dess-Martin periodinane, 
CH2Cl2. (c) 3, CrCl2, NiCl2, DMSO (57%, 15S:15R = 11: 1, 2 steps). (d) Cp2ZrCl2, Me3Al, then I2, CH2Cl2 (89%). 
(e) CrO3, H2SO4, acetone (68%). (f) TMSCHN2, MeOH, benzene (74%). 
Scheme 4-8. Synthesis of haterumalide NA methyl ester 
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Figure 4-8. Comparison of 
1
H NMR spectrum of synthetic haterumalide NA methyl ester (41) and natural 
haterumalide NA methyl ester 1 (800 MHz, CD3OD) 
 
126 
 
 
Figure 4-9 Comparison of CD spectrum of synthetic haterumalide NA methyl ester (41) and natural haterumalide 
NA methyl ester 1 
 
Revised the absolute stereochemistry of Haterumalide NA 
The author revised the absolute stereochemistry of haterumalide NA 1 (Figure 4-10).  The stereochemistry of 
the C-3, C-11, C-13, and C-14 in synthetic 41 was undoubtedly constructed by the organic synthetic method, and 
the final product was the enantiomer of haterumalide NA methyl ester. As a result, the author unambiguously 
determined the absolute stereochemistry of C-3, C-11, C-13, and C-14 in natural 1 to be R, R, R, and R.  On the 
other hand, since the absolute stereochemistry of C-15 in natural 1 was already determined to be R by the 
modified Mosher’s method, the total absolute stereochemistry of haterumalide NA was revealed, which revised 
the previously reported structure.
1
  To confirm these results, 41 was converted into the (R)-MTPA ester, which 
was found to be the enantiomer of the (S)-MTPA ester of the natural haterumalide NA methyl ester on comparison 
of their 
1
H NMR spectra.  In a previous paper,
1
 in light of the abnormal Δδ values in the experiments of the 
modified Mosher’s method for 1 (R = Me), Uemura et al. postulated the folded conformation of the side chain in 
127 
 
the Mosher esters of 1, which led the author to the wrong conclusion that the stereochemistry at C14-C15 was 
threo (Figure 4-11).  The generally accepted zigzag conformation of the side chain in the Mosher esters of 1 is 
consistent with the revised stereostructure, in which the stereochemistry at C14-C15 is erythro, from the 
viewpoint of the coupling constants and the NOESY correlations of 1. 
In summary, the enantioselective synthesis of haterumalide NA methyl ester (41) has been achieved from the 
threitol derivative 10 in 26 steps. This synthesis revises the absolute stereochemistry of haterumalide NA. 
 
 
 
Figure 4-10. Determination of complete structure of haterumalide NA 
 
 
 
Figure 4-11. Relative stereochemistry of the C14-C15 part of haterumalide NA 
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Experimental Section 
 
General Methods. 
All reactions sensitive to air or moisture were carried out under argon atmosphere in dry, freshly distilled 
solvents under anhydrous conditions, unless otherwise noted.  THF was distilled from sodium/benzophenone, 
pyridine, triethylamine (Et3N) and 2,6-lutidine from calcium hydride under reduced pressure.  All other reagents 
were used as supplied unless otherwise stated.  Analytical thin-layer chromatography (TLC) was performed 
using E. Merck Silica gel 60 F254 pre-coated plates.  Column chromatography was performed using 
BW-820MH or FL60D (Fuji Silysia Co., Inc.).  
1
H- and 
13
C-NMR spectra were recorded on a JEOL JNM 
ECP800 (800 MHz), JNM A600 (600 MHz), JNM A400 (400 MHz) or JNM EX270 (270 MHz) spectrometer.  
Chemical shifts are reported in  (ppm) with reference to solvent signals [
1
H NMR: CHCl3 (7.26), C6D6 (7.16), 
(CD3)2CO (2.05), CD3OD (3.30); 
13
C NMR: CHCl3 (77.0), C6D6 (128.06), (CD3)2CO (29.84), CD3OD (49.00).  
Signal patterns are indicated as s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad peak.  IR spectra 
were recorded on a JASCO FT/IR-230 spectrometer.  FAB-MS and EI-MS were on JEOL JMS-LG2000 or 
JMS-700.  Optical rotations were recorded on a JASCO DIP-1000 polarimeter.  CD spectra were recorded on a 
JEOL J-720WN.  FT/IR-230 spectrometer.   
 
Experimental procedure 
Synthesis of C9-C15 fragment 
 
Mono MPM ether 10 
To a suspension of 60% sodium hydride (1.54 g, 38.5 mmol) in dry DMF (51 mL) at 0 °C was added 9 (3.0 g, 
18.5 mmol) in dry DMF (33 mL) slowly.  MPMCl (2.77 mL, 20.4 mmol) was added and stirred at 0 °C for 2 h 
and stirred at room temperature for 2h.  The reaction mixture was cooled to 0 °C and quenched with H2O (140 
O O
OHHO
O O
OMPMHO
O O
OMPMMPMO
9 10 10-2
+
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mL) and saturated aqueous NH4Cl.  The mixture was extracted with Et2O and the organic layer was washed with 
brine and dried over MgSO4. Concentration and flash column chromatography (hexane/Et2O 3:1-2:1-3:4-1:2) 
gave 10 (3.28 g) in 69% yield. 
Rf = 0.38 (1:1 hexane/EtOAc). []D
29
 +13.2°(c 0.28, CHCl3).  IR (CHCl3) ; 3590, 3460, 1615, 1515, 1460, 1375, 
1245, 1080, 1040, 845 cm
-1
.  
1
H NMR (270 MHz, CDCl3)  7.25 (br d, J = 8.2 Hz, 2H), 6.88 (br.d, J = 8.2 Hz, 
2H), 4.51 (s, 2H), 4.03 (m, 1H), 3.91 (m, 1H), 3.81 (s, 3H), 3.78-3.62 (m, 2H), 3.66 (dd, J = 9.6, 4.6 Hz, 1H), 3.52 
(dd, J = 9.6, 5.9 Hz, 1H), 2.27 (dd, J = 8.3, 4.6 Hz, 1H), 1.41 (s, 6H).  
13
C NMR (67.8 MHz, CDCl3) 159.4, 
129.6, 129.4 (2C), 113.9 (2C), 109.3, 79.8, 77.2, 73.4, 70.0, 62.5, 55.3, 26.9 (2C).  MS (FAB) m/z 305 (M + 
Na)
+ . HRMS (FAB) C15H22NaO5 (M + Na)
+
 calc.305.1365, observed 305.1353 ( -1.2 mmu).
 
 
 
Iodide 10-3 
To a solution of 10 (3.28 g, 11.6 mmol) in pyridine (6.3 mL) at 0 °C was added p-toluenesulfonyl chloride (4.01 g, 
21.0 mmol).  After stirred at 0 °C for 7.5 h, the reaction mixture was quenched with H2O and extracted with Et2O.  
The organic layer was washed with brine and dried over MgSO4.  Concentration gave 10-2 (4.95 g) which was 
directly used in the next reaction. 
To a solution of 10-2 in acetone (24.4 mL) at room temperature was added K2CO3 (2.15 g, 21.5 mmol) and NaI 
(4.75 g, 31.7 mmol).  After stirred for 16.5 h under reflux, the reaction mixture was diluted with H2O and 
extracted with Et2O.  The organic layer was washed with brine and dried over MgSO4.  Concentration and 
column chromatography (silicagel, hexane/Et2O, 11:1-5:1) gave 10-3 (4.04 g) in 89% yield. 
Rf = 0.63 (1:1 hexane/Et2O).  [] D
30
 -9.3°(c 0.35, CHCl3).  IR (CHCl3) ; 1615, 1515, 1460, 1375, 1245, 1190, 
1135, 820 cm
-1
.  
1
H NMR (270 MHz, CDCl3) 7.25 (br d, J = 8.9 Hz, 2H), 6.88 (br d, J = 8.9 Hz, 2H), 4.52 (s, 
2H), 3.95 (ddd, J = 7.6, 5.0, 5.0 Hz, 1H), 3.84 (ddd, J = 7.6, 5.3, 5.3 Hz, 1H), 3.81 (s, 3H), 3.64 (dd, J = 12.9, 5.3 
Hz, 1H), 3.58 (dd, J = 12.9, 5.3 Hz, 1H), 3.41 (dd, J = 10.6, 5.0 Hz, 1H), 3.27 (dd, J = 10.6, 5.0 Hz, 1H), 1.46 (s, 
O O
OMPMHO
O O
OMPMTsO
O O
OMPMI
10-210 10-3
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3H), 1.41 (s, 3H).  
13
C NMR (67.8 MHz, CDCl3) 159.3, 129.9, 129.3 (2C), 113.9 (2C), 109.8, 80.1, 77.8, 73.3, 
70.2, 55.3, 27.4, 27.3, 6.4.  MS (FAB) m/z 415 (M + Na)
+
.  HRMS (FAB) C15H21Na IO4 (M + Na)
+
 : 
calc.415.0382, found 415.0357 (-2.5 mmu). 
 
 
FAMSO 11 
To a solution of formaldehyde dimethyl dithioacetal S-Oxide (2.15 mL, 20.6 mmol) in THF (26 mL) at 0 °C was 
added n-butyllithium (13.6 mL, 1.51 M THF solution, 20.6 mmol).  10-3 (4.04 g, 10.3 mmol) in THF (13.0 mL) 
was added to the reaction mixture.  After stirred at room temperature for 12.5 h, the reaction mixture was 
quenched with saturated aqueous NH4Cl and extracted with EtOAc.  The organic layer was washed with brine 
and dried over MgSO4.  Concentration and column chromatography (silicagel, hexane/EtOAc, 1:1-1:5) gave 11 
(2.77 g) in 69% yield.  Diastereomer ratio of 11 was 3 : 3 : 2 : 2. 
Rf = 0.21 (1:5 hexane/EtOAc).  IR (CHCl3) ; 1615, 1515, 1460, 1375, 1245, 1080, 1040, 845 cm
-1
.  
1
H NMR 
(270 MHz, CDCl3)7.26 (br d, J = 8.6 Hz, 2H), 6.88 (br d, J = 8.6 Hz, 2H), 4.56-4.44 (m, 2H), 4.20 (m, 1H), 
3.96 (m, 1H), 3.80 (s, 3H), 3.77 (m, 1H), 3.65 (m, 1H), 3.52 (m, 1H), 2.70 (s, 0.9H), 2.56 (s, 0.6H), 2.53 (s, 0.9H), 
2.53 (s, 0.6H), 2.27 (s, 0.9H), 2.17 (s, 0.6H), 2.16 (s, 0.6H), 2.10 (s, 0.9H), 2.09-1.73 (m, 2H), 1.43-1.39 (m, 6H).  
MS (FAB) m/z 411 (M + Na)
+
.  HRMS (FAB) C18H28NaS2O5 (M + Na)
+
 calc. : 411.1276, found : 411.1269 
(-0.7 mmu). 
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Methyl acetal 12 
To a solution of 11 (638 mg, 1.64 mmol) in MeOH (33 mL) at 0 °C was added conc. HCl (2.6 mL).  After stirred 
at room temperature for 14 h, the reaction mixture was quenched by saturated aqueous NaHCO3 and extracted 
with EtOAc.  The organic layer was washed with brine and dried over MgSO4.  Concentration and column 
chromatography (silcagel, hexane/EtOAc, 3:1-2:1-1:1) gave 12 (182 mg) in 41% yield.  
Rf = 0.55 (1:5 hexane/EtOAc).  IR (CHCl3) ; 3500 (br), 1615, 1515, 1440, 1360, 1250, 1090, 1055, 830 cm
-1
.  
1
H NMR (270 MHz, CDCl3)  7.26 (br d, J = 8.6 Hz, H), 6.88 (br d, J = 8.6 Hz, 2H), 5.16 (dd, J = 5.0, 3.0 Hz, 
0.75H), 5.05 (br d, J = 3.3 Hz, 0.25H), 4.51 (s, 2H), 4.52-4.47 (m, 0.75H), 4.33-4.23 (m, 0.25H), 4.11 (dt, J = 5.0, 
4.6 Hz, 1H), 3.81 (s, 3H), 3.81 (m, 0.25H), 3.77 (d, J = 5.0 Hz, 1.5H), 3.64 (dd, J = 10.2, 6.9 Hz, 0.25H), 3.36 (s, 
3H), 2.87 (d, J = 10.6 Hz, 0.25H), 2.78 (d, J = 5.6 Hz, 0.75H), 2.14 (m, 2H).  MS (FAB) m/z 291 (M + Na)
+
.   
HRMS (FAB) C14H20NaO5 (M + Na)
+
 calc. : 291.1208, found : 291.1225 ( mmu). 
 
 
Hemiacetal 13 
To a solution of 12 (1.36 g, 5.07 mmol) in THF (46 mL) at room temperature was added 1M HCl (46 mL, 46 
mmol).  After stirred at room temperature for 4 h, the reaction mixture was quenched by saturated aqueous 
NaHCO3 and extracted with EtOAc.  The organic layer was washed with brine and dried over MgSO4.  
Concentration and column chromatography (silcagel, hexane/EtOAc, 5:1-3:1-2:1-1:1-1:5) gave 13 (1.27 g) in 
90% yield.  
Melting point; 70-73 °C.  Rf = 0.36 (1:2 hexane/EtOAc).  IR (CHCl3) 3590, 3360, 1615, 1515, 1460, 1440, 
1360, 1250, 1105, 1065, 1035 cm
-1
.  
1
H NMR (270 MHz, CDCl3)  7.27 (br d, J = 8.6 Hz, 2H), 6.89 (br d, J = 
8.6 Hz, 2H), 5.71 (dt, J = 4.0, 3.3 Hz, 0.3H), 5.44 (ddd, J = 8.6, 3.3, 1.7 Hz, 0.7H), 4.54 (s, 1.4H), 4.52 (s, 0.6H), 
4.49 (m, 0.3H), 4.42 (m, 0.7H), 4.27 (dd, J = 10.9, 5.0 Hz, 0.3H), 4.07 (dd, J = 9.6, 5.6 Hz, 0.7H), 3.84-3.80 (m, 
1H), 3.81 (s, 3H), 3.77 (d, J = 5.0 Hz, 0.6H), 3.63 (d, J = 8.6 Hz, 1.4H), 3.09 (d, J = 5.6 Hz, 0.7H), 2.71 (d, J = 5.6 
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Hz, 0.3H), 2.66 (d, J = 3.3 Hz, 0.3H), 2.17 (t, J = 4.3 Hz, 0.6H), 2.11 (m, 1.4H).  MS (FAB) m/z 277 (M + Na)
+
.  
HRMS (FAB) C13H18NaO5 (M + Na)
+
 calc.: 277.1052, found: 277.1074 (+2.2 mmu). 
 
 
unsaturated ester 14 
To a solution of 13 (113 mg, 0.446 mmol) in CH3CN (2.2 mL) at room temperature was added methyl 
(triphenylphosphoranylidene) acetate (247 mg, 0.738 mmol).  After stirred at room temperature for 2.5 h, the 
reaction mixture was evaporated and column chromatography (silcagel, hexane/acetone, 5:1-3:1-2:1-1:1 and 
silcagel FL60D, hexane/acetone, 5:1-2:1) gave 14 (128 mg) in 92% yield.  
Rf = 0.53 (1:1 hexane/acetone).  IR (CHCl3) ; 3560, 1715, 1660, 1615, 1515, 1305, 1280, 1250, 1120, 1035 cm
-1
.  
1
H NMR (270 MHz, CDCl3)  7.24 (br d, J = 8.8 Hz, 2H), 6.99 (dt, J = 15.6, 7.3 Hz, 0.75H), 6.89 (br d, J = 8.8, 
2H), 6.38 (dt, J = 11.5, 7.8 Hz, 0.25H), 5.91 (br d, J = 15.6 Hz, 1H), 4.51 (d, J = 11.5 Hz, 1H), 4.46 (d, J = 11.5 
Hz, 1H), 3.82 (s, 2.25H), 3.80 (s, 0.75H), 3.72 (s, 2.25H), 3.71 (s, 0.75H), 3.68-3.56 (m, 3H), 2.92 (m, 1H), 2.70 
(d, J = 6.1 Hz, 1H), 2.61 (d, J = 4.4 Hz, 1H), 2.45 (m, 2H).  MS (FAB) m/z 333 (M + Na)
+
.  HRMS (FAB) 
C16H22NaO6 (M + Na)
+
 calc. : 333.1314, found : 333.1307 -0.7 mmu).
 
 
 
Tetrahydrofurna 15 
To a solution of 14 (122 mg, 0.393 mmol) in MeOH (4.0 mL) at 0 °C was added sodium methoxide (28.2 mg, 
0.520 mmol).  After stirred at -20 °C for 38 h, the reaction mixture was quenched by saturated aqueous NH4Cl 
and extracted with Et2O.  The organic layer was washed with H2O and brine and dried over MgSO4.  
Concentration and column chromatography (silcagel, hexane/acetone, 5:1-4:1-1:1) gave 15 (68.3 mg) in 56% 
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yield.  
Rf = 0.44 (3:2 hexane/acetone).  IR (CHCl3) ; 3460, 1735, 1615, 1515, 1300, 1250, 1170, 1135, 825 cm
-1
.  
1
H 
NMR (270 MHz, CDCl3)  7.26 (br d, J = 8.6 Hz, 2H), 6.89 (br d, J = 8.6 Hz, 2H), 4.65 (m, 0.9H), 4.51 (s, 2H), 
4.51 (m, 0.1H), 4.49 (m, 0.9H), 4.39 (m, 0.1H), 4.27 (m, 0.1H), 4.09 (m, 0.9H), 3.81 (s, 3H), 3.75 (d, J = 5.3 Hz, 
2H), 3.67 (s, 3H), 2.93 (d, J = 4.0 Hz, 1H), 2.63 (dd, J = 15.2, 6.9 Hz, 0.9H), 2.72 (m, 0.1H), 2.50 (dd, J = 15.2, 
5.4 Hz, 0.9H), 2.39 (m, 0.1H), 2.18 (m, 1H), 1.82 (ddd, J = 13.9, 9.2, 5.0 Hz, 1H).  MS (FAB) m/z 447 (M + 
Na)
+
.
  
 HRMS (FAB) C16H22NaO6 (M + Na)
+
 calc. : 333.1314, found : 333.1331 (+1.7 mmu). 
 
 
TBS 16 
To a solution of 15 (444 mg, 1.43 mmol) and imidazole (390 mg, 5.78 mmol) in DMF (10.6 mL) at room 
temperature was added tert-butyldimethylsilyl chloride (431 mg, 2.8 mmol).  After stirred at room temperature 
for 10 h, the reaction mixture was quenched by H2O and extracted with Et2O.  The organic layer was washed 
with H2O and brine and dried over MgSO4.  Concentration and column chromatography (silcagel, hexane/acetone, 
5:1-3:1-1:3 and silcagel FL60D, hexane/acetone, 5:1-1:1) gave 16 (494 mg) in 81% yield and 17 (93 mg) in 15%.  
Rf = 0.65 (1:1 benzene/Et2O).  [] D
26
 +22.7°(c 0.42, CHCl3).  IR (CHCl3) ; 1735, 1615, 1515, 1300, 1250, 1170, 
835 cm
-1
.  
1
H NMR (270 MHz, CDCl3)   7.25 (br d, J = 8.5 Hz, 2H), 6.86 (br d, J = 8.5 Hz, 2H), 4.58 (m, 1H), 
4.50 (d, J = 11.7 Hz, 1H), 4.43 (d, J = 11.7 Hz, 1H), 4.38 (br t, J = 3.4 Hz, 1H), 4.07 (m, 1H), 3.80 (s, 3H), 3.68 (s, 
3H), 3.57 (m, 2H), 2.70 (dd, J = 15.4, 6.6 Hz, 1H), 2.47 (dd, J = 15.4, 6.6 Hz, 1H), 2.07 (ddd, J = 12.9, 5.6, 1.3 Hz, 
1H), 1.76 (ddd, J = 12.9, 9.8, 4.4 Hz, 1H), 0.88 (s, 9H), 0.05 (s, 3H), 0.03 (s, 3H).  
13
C NMR (67.8 MHz, CDCl3) 
 171.5, 159.1, 130.4, 129.6 (2C), 113.7 (2C), 81.8, 73.9, 73.1, 73.0, 68.8, 55.3, 51.6, 41.9, 40.4, 25.7 (3 C), 18.0, 
-4.7, -5.2  MS (FAB) m/z 447 (M + Na)
+ ; HRMS (FAB) C22H36NaO6Si(M + Na)
+
 calc.: 447.2179, found : 
447.2207 (+2.8 mmu). 
17  Rf = 0.59 (1:1 benzene/Et2O).  [] D
30
 +23.4° (c 0.42, CHCl3).  IR (CHCl3) ; 3500, 1615, 1515, 1460, 1440, 
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1360, 1250, 1180, 1070, 1035, 835 cm
-1
.  
1
H NMR (270 MHz, CDCl3)   7.26 (br d, J = 8.6 Hz, 2H), 6.86 (br d, 
J = 8.6 Hz, 2H), 4.51 (d, J = 11.5 Hz, 1H), 4.44 (d, J = 11.5 Hz, 1H), 4.42-4.30 (m, 2H), 3.90 (ddd, J = 6.6, 5.3, 
4.6 Hz, 1H), 3.80 (s, 3H), 3.68 (s, 3H), 3.63 (dd, J = 9.9, 5.3 Hz, 1H), 3.57 (dd, J = 9.9, 6.6 Hz, 1H), 2.83 (dd, J = 
15.5, 6.3 Hz, 1H), 2.59 (dd, J = 15.5, 7.6 Hz, 1H), 2.32 (ddd, J = 13.5, 7.9, 5.6 Hz, 1H), 1.67 (ddd, J = 13.5, 5.0, 
2.3 Hz, 1H), 0.88 (s, 9H), 0.05 (s, 3H), 0.03 (s, 3H).  
13
C NMR (67.8 MHz, CDCl3) 171.8, 159.1, 130.3, 129.5 
(2C), 113.7 (2C), 82.3, 74.2, 73.1, 72.6, 69.1, 55.3, 51.5, 41.5, 41.0, 25.7 (3 C), 18.0, -4.7, -5.3.  MS (FAB) m/z 
447 (M + Na)
+
 
 
 
Alcohol 16-2 
To a solution of 16 (491 mg, 1.16 mmol) in THF (7.2 mL) at room temperature was added lithiumaluminium 
hydride (1.0M, THF solution, 2.31 mL, 2.31 mmol).  After stirred at room tempareture for 50 min, the reaction 
mixture was quenched by MeOH and 0.5M potassium sodium tartartrate (30 mL).  After stirred at room 
temperature for 30 min, the mixture was extracted with Et2O.  The organic layer was washed with brine and 
dried over MgSO4.  Concentration and column chromatography (silcagel, hexane/acetone, 5:1-3:1-1:3 and 
silcagel FL60D, hexane/acetone, 3:1-2:1-1:1-1:3) gave 16-2 (458 mg) in 100% yield.  
Rf = 0.39 (1:1 hexane/EtOAc)  [] D
30
 +17.4° (c 0.34, CHCl3).  IR (CHCl3) ; 3500, 1615, 1515, 1460, 1440, 
1360, 1250, 1180, 1070, 1035, 835 cm
-1
.  
1
H NMR (270 MHz, CDCl3)  7.25 (br d, J = 8.6 Hz, 2H), 6.87 (br d, 
J = 8.6 Hz, 2H), 4.46 (s, 2H), 4.43-4.34 (m, 2H), 4.08 (m, 1H), 3.80 (s, 3H), 3.84-3.76 (m, 2H), 3.62 (dd, J = 9.9, 
5.3 Hz, 1H), 3.53 (dd, J = 9.9, 6.3 Hz, 1H), 2.65 (t, J = 5.6 Hz, 1H), 1.97 (ddd, J = 12.9, 5.6, 1.3 Hz, 1H), 
1.83-1.66 (m, 3H), 0.87 (s, 9H), 0.07 (s, 3H), 0.04 (s, 3H).  
13
C NMR (67.8 MHz, CDCl3)  159.2, 130.4, 129.5 
(2C), 113.7 (2C), 81.7, 77.7, 73.1, 72.6, 68.8, 61.5, 55.3, 42.4, 37.5, 25.7 (3C), 18.0, -4.7, -5.2  MS (FAB) m/z 
419 (M + Na)
+
 ; HRMS (FAB) C21H36NaO5Si (M + Na)
+
 calc.: 419.2230, found : 419.2207 (-2.3 mmu). 
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Bromide 7 
To a solution of 16-2 (48.1 mg, 0.121 mmol) in pyridine (0.6 mL) at 0 °C was added TsCl (46.9 g, 0.246 mmol).  
After stirred at 0 °C for 7h, the reaction mixture was quenched with H2O and extracted with Et2O.  The organic 
layer was washed with brine and dried over MgSO4.  Concentration gave 16-3 (69.0 mg) which was directly used 
in the next reaction. 
To a solution of 16-3 in DMF (1.0 mL) at room tempareture was added lithium bromide (52.5 m g, 0.605 mmol).  
After stirred for 1 h under reflux, the reaction mixture was dilluted with Et2O and washed with H2O and brine and 
dried over MgSO4.  Concentration and column chromatography (silicagel, hexane /Et2O 5:1-3:1) gave 7 (48.6 mg) 
in 87% yield in 2 steps. 
Rf = 0.60 (1:1 hexane/Et2O).  [] D
26
 +11.1°(c 0.43, CHCl3).  IR (CHCl3) ; 1610, 1515, 1460, 1440, 1360, 1250, 
1170, 1080, 935, 835 cm
-1
.  
1
H NMR (270 MHz, CDCl3)  7.26 (br d, J = 8.6 Hz, 2H), 6.87 (br d, J = 8.6 Hz, 
2H), 4.52 (d, J = 11.6 Hz, 1H), 4.44 (d, J = 11.6 Hz, 1H), 4.39-4.27 (m, 2H), 4.03 (ddd, J = 6.6, 5.0, 3.6 Hz, 1H), 
3.80 (s, 3H), 3.59 (dd, J = 9.9, 5.0 Hz, 1H), 3.59 (m, 1H), 3.55-3.47 (m, 2H), 2.19-1.79 (m, 3H), 1.67 (ddd, J = 
12.5, 9.9, 4.6 Hz, 1H), 0.88 (s, 9H), 0.15 (s, 3H), 0.05 (s, 3H),  
13
C NMR (67.8 MHz, CDCl3)  159.1, 129.6, 
129.6 (2C), 113.7 (2C), 81.6, 75.9, 73.1, 73.0, 68.9, 55.3, 41.8, 39.3, 30.0, 25.7 (3C), 18.0, -4.7, -5.2.  MS (FAB) 
m/z 481 (M + Na)
+
.  HRMS (FAB) C21H35
79
BrNaO4Si(M + Na)
+
 calc.: 481.1386, found : 81.1361 (-2.5 mmu). 
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 Synthesis of C5-C8 fragment 
 
THP 19 
To a mixture of 18 (9.71 g, 139 mmol) and p-toluenesulfonic acid (270 mg, 1.42 mmol) at 0 °C was added 
3,4-dihydro-2H-pyrane (15.2 mL, 166 mmol).  After stirred at room temperature for 30 min, the reaction mixture 
was quenched with saturated aqueous NaHCO3 and extracted with Et2O.  The organic layer was washed with 
brine and dried over MgSO4.  Concentration and distillation gave 19 (18.3 g) in 86% yeild. 
Rf = 0.61 (3:1 hexane/Et2O).  boiling point; 86-89 °C / 19 mmHg.  IR (CHCl3) ; 3310, 2120, 1455, 1440, 1350 , 
1130, 1030, 980, 905, 870, 815 cm
-1
.  
1
H NMR (270 MHz, CDCl3)  4.65 (t, J = 3.6 Hz, 1H), 3.91 (m, 1H), 3.84 
(dt, J = 9.9, 6.9 Hz, 1H), 3.58 (dt, J = 9.9, 6.9 Hz, 1H), 3.52 (m, 1H), 2.50 (dt, J = 2.6, 6.9 Hz, 2H), 1.98 (t, J = 2.6 
Hz, 1H), 1.91-1.48 (m, 6H).  
13
C NMR (67.8 MHz, CDCl3)  98.7, 81.4, 69.2, 65.5, 62.2, 30.5, 25.4, 19.9, 19.4.  
HRMS (ESI) C9H14NaO2 (M + Na)
+
 calc.: 177.0891, found : 177.0866 (-2.5 mmu). 
 
 
TMS 20 
To a solution of 19 (4.99 g, 32.4 mmol) in Et2O (32.0 mL) at -78 °C was added n-butyl lithium (1.58M, hexane 
solution, 24.6 mL, 38.8 mmol).  Trimethylsilyl chloride (4.93 mL, 38.8 mmol) was added to the reaction mixture.  
After stirred at room temperature for 2.5 h, the reaction mixture was quenched with saturated aqueous NH4Cl and 
extractedvwith Et2O. The organic layer was washed with H2O and brine and dried over MgSO4.  Concentration 
and column chromatography (silicagel, hexane /Et2O 59:1-39:1-1:1) gave 20 (4.90 g) in 67% yield. 
Rf = 0.52 (19:1 hexane/EtOAc)  IR (CHCl3) 2170, 1455, 1440, 1355, 1250, 1220, 1180, 1120, 1080, 1030, 905, 
845 cm
-1
.  
1
H NMR (270 MHz, CDCl3)  4.66 (t, J = 3.6 Hz, 1H), 3.91 (m, 1H), 3.82 (dt, J = 9.6, 7.3 Hz, 1H), 
3.55 (dt, J = 9.6, 7.3 Hz, 1H), 3.51 (m, 1H), 2.53 (t, J = 7.3 Hz, 2H), 1.90-1.47 (m, 6H), 0.13 (s, 9H).  
13
C NMR 
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(67.8 MHz, CDCl3)  104.0, 98.2, 85.1, 65.6, 60.3, 30.6, 25.7, 20.2, 19.4, 0.3 (3C)  HRMS (ESI) C12H22O2Si (M 
+ Na)
+
 calc. : 249.1278, found : 249.1259 (-1.9 mmu). 
 
 
Vinyl bromide 21 
To a solution of 20 (4.91 g, 21.6 mmol) in Et2O (47.2 mL) at 0 °C was added diisobutylaluminium hydride 
(0.95M, THF solution, 25.0 mL, 23.8 mmol).  After stirred at 40 °C for 3 h, the reaction mixture was cooled to 
0 °C and Et2O (22 mL) and pyridine (3.48 mL, 43.2 mmol) were added.  The reaction mixture was cooled to 
-78 °C and bromine (2.2 M, CH2Cl2 solution, 14.0 mL, 32.4 mmol) was added and stirred for 2 h.  The reaction 
mixture was quenched with 1M NaOH and H2O and extracted with hexane.  The organic layer was washed with 
1M HCl, saturated aqueous NaHCO3 and brine and dried over MgSO4.  Concentration and column 
chromatography (silicagel, hexane /Et2O, 99:1-49:1) gave 21 (6.07 g) in 91% yield. 
Rf = 0.19 (1:1 hexane/benzene)  IR (CHCl3) ; 1605, 1455, 1440, 1250, 1140, 1120, 1070, 1030, 985 905, 845 
cm
-1
.  
1
H NMR (270 MHz, CDCl3)  6.79 (t, J = 7.9 Hz, 1H), 4.60 (t, J = 4.0 Hz, 1H), 3.85 (m, 1H), 3.81 (dt, J = 
9.6, 6.6 Hz, 1H), 3.51 (m, 1H), 3.42 (dt, J = 9.6, 6.6 Hz, 1H), 2.41 (dt, J = 7.9, 6.6 Hz, 2H),1.90-1.47 (m, 6H), 
0.28 (s, 9H).  
13
C NMR (67.8 MHz, CDCl3)  144.3, 129.4, 98.8, 66.1, 62.1, 32.8, 30.6, 25.4, 19.4, 0.3 (3C)  
HRMS (ESI) C12H23
79
BrNaO2Si(M + Na)
+
 calc. : 329.0548, found : 329.0527 (-2.1 mmu). 
 
 
Z-alkenylsilane 8 
To a solution of 21 (10.5 g, 34.2 mmol) in Et2O (35.0 mL) at 20-30 °C was added pyridine (0.97 mL, 12.0 mmol) 
and bromine (1.92M, CH2Cl2 solution, 0.88 mL, 0.18 mmol).  The reaction mixture was stirred and irradiated at 
20-30 °C for 3 h, the reaction mixture was quenched with saturated aqueous Na2S2O3 and extracted with hexane.  
The organic layer was washed with H2O and brine and dried over MgSO4.  Concentration and column 
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chromatography (silicagel, hexane /benzene 1:1-1:2) gave 8 (10.6 g) in 100% yield. 
Rf = 0.65 (3:1 hexane/Et2O).  IR (CHCl3) ; 1615, 1455, 1440, 1350, 1250, 1135, 1120, 1075, 1030, 980 890, 840 
cm
-1
.  
1
H NMR (270 MHz, CDCl3)  6.33 (t, J = 6.6 Hz, 1H), 4.63 (t, J = 4.0 Hz, 1H), 3.81 (m, 1H), 3.81 (dt, J = 
9.6, 6.9 Hz, 1H), 3.72 (m, 1H), 3.51 (dt, J = 9.6, 6.9 Hz, 1H), 2.58 (dt, J = 6.6, 6.9, Hz, 2H), 1.90-1.46 (m, 6H), 
0.18 (s, 9H).  
13
C NMR (67.8 MHz, CDCl3)  149.6, 138.5, 98.6, 65.3, 62.1, 33.1, 30.6, 25.5, 19.4, -1.9 (3C) 
HRMS (FAB) C12H23
79
BrNaO2Si(M + Na)
+
 calc.: 329.0548, found : 329.0527 (-2.1 mmu). 
 
Synthesis of Z-chloroolefin 22 
 
Coupling product 6 
To a solution of 8 (1.28 g, 4.23 mmol) in Et2O (21.2 mL) at -78 °C was added sec-butyl lithium (1.01M, THF 
solution, 8.37 mL, 8.45 mmol).  After stirred at -78 °C for 2 h, 7 (485 mg, 1.06 mmol) in THF (4.5 mL) and 
hexamethylphosphoric triamide (1.47 mL, 8.45 mmol) were added at -78 °C.  After stirred at -78 °C for 20.5 h 
and the reaction mixture was quenched with saturated aqueous NH4Cl and extracted with Et2O.  The organic 
layer was washed with H2O and brine and dried over MgSO4.  Concentration and column chromatography 
(silicagel, hexane/Et2O, 23:2-11:1-9:1-7:1-5:1) gave 6 (435 mg) in 68% yield and 23 (115 mg) in 29%yield.  
6  Rf = 0.41 (2:1 hexane/Et2O)  []D
26
 +17.2° (c 0.23, CHCl3)  IR (CHCl3) ; 1610, 1585, 1515, 1465, 1440, 
1340, 1250, 1170, 1120, 1030, 835 cm
-1
.  
1
H NMR (270 MHz, CDCl3)  7.26 (br d, J = 8.9 Hz, 2H), 6.86 (br d, J 
= 8.9 Hz, 2H), 5.74 (t, J = 6.6 Hz, 1H), 4.61 (t, J = 4.0 Hz, 1H), 4.52 (d, J = 11.6 Hz, 1H), 4.44 (d, J = 11.6 Hz, 
1H), 4.36 (m, 1H), 4.17 (m, 1H), 4.04 (m, 1H), 3.80 (s, 3H), 3.90-3.69 (m, 2H), 3.65-3.37 (m, 4H), 2.42 (dt, J = 
6.8, 7.3 Hz, 2H), 2.29-2.03 (m, 2H), 1.95 (m, 1H), 1.82 (m, 1H), 1.71-1.47 (m, 7H), 1.43 (m, 1H), 0.88 (s, 9H), 
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0.15 (s, 3H), 0.05 (s, 12H).  
13
C NMR (67.8 MHz, CDCl3)  159.1, 142.6, 136.1, 130.5, 129.5 (2C), 113.7 (2C), 
98.6, 81.4, 73.2, 73.1, 69.0, 66.9, 62.1, 55.2, 42.0, 36.4, 30.7, 30.0, 29.0, 26.0, 25.8 (3 C), 25.5, 19.5, 18.0, -1.2 
(3C), -4.7, -5.2  MS (FAB) m/z 629 (M + Na)
+
.  HRMS (FAB) C33H58NaO6Si2(M + Na)
+
 calc. : 629.3670, 
found : 629.3667 (-0.3 mmu). 
23  Rf = 0.77 (2:1 hexane/Et2O)  ]D
26 
+15.2° (c 0.72, CHCl3).  
1
H NMR (270 MHz, CDCl3)  7.26 (br d, J = 
8.9 Hz, 2H), 6.86 (br d, J = 8.9 Hz, 2H), 5.85 (ddd, J = 17.2, 10.2, 6.6 Hz, 1H), 5.25 (ddd, J = 17.2, 1.7, 1.3 Hz, 
1H), 5.09 (ddd, J = 10.2, 1.7, 1.0 Hz, 1H), 4.63 (m, 1H), 4.52 (d, J = 11.6 Hz, 1H), 4.44 (d, J = 11.6 Hz, 1H), 4.39 
(m, 1H), 4.09 (m, 1H) , 3.81 (s, 3H), 3.59 (dd, J = 9.9, 5.0 Hz, 1H), 3.63 (m, 1H), 2.01 (ddd, J = 12.9, 5.6, 1.7 Hz, 
1H), 1.79 (m, 1H), 0.89 (s, 9H), 0.06 (s, 3H), 0.04 (s, 3H) 
 
 
Chloroolefin 22 
To a solution of 6 (970 mg, 1.60 mmol) in DMF (40 mL) was added H2O (16M, DMF solution, 0.02 mL, 0.272 
mmol) and N-chlorosuccinimide (427 mg, 3.20 mmol).  After stirred at 50 °C for 6 h under shading condition, 
the reaction mixture was quenched with saturated aqueous Na2S2O3 and extracted with Et2O.  The organic layer 
was washed with H2O and brine and dried over MgSO4.  Concentration and column chromatography FL60D 
(hexane /Et2O, 11:1-5:1-1:1) gave 22 (407 mg) in 45% yield.  
Rf = 0.51 (3:2 hexane/Et2O).  []D
26
 +15.1°(c 0.54, CHCl3)  IR (CHCl3) ; 1610, 1515, 1460, 1360, 1250, 1170, 
1140, 1120, 1030, 835 cm
-1
.  
1
H NMR (270 MHz, CDCl3)  7.26 (br d, J = 8.6 Hz, 2H), 6.87 (br d, J = 8.6 Hz, 
2H), 5.57 (t, J = 6.1 Hz, 1H), 4.60 (m, 1H), 4.52 (d, J = 11.6 Hz, 1H), 4.44 (d, J = 11.6 Hz, 1H), 4.36 (m, 1H), 
4.20 (m, 1H), 4.05 (m, 1H), 3.80 (s, 3H), 3.85 (m, 1H), 3.75 (m, 1H), 3.65-3.38 (m, 4H), 2.29-2.01 (m, 4H), 1.93 
(ddd, J = 12.7, 5.7, 1.7 Hz, 1H), 1.91-1.63 (m, 9H), 1.05 (s, 9H), 0.05 (s, 3H), 0.03 (s, 3H).  
13
C NMR (67.8 
MHz, CDCl3)  159.1, 135.9, 130.4, 129.5 (2C), 122.0, 113.7 (2C), 98.7, 81.4, 77.2, 73.1, 73.1, 69.0, 65.9, 62.3, 
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55.3, 42.0, 36.3, 33.9, 30.7, 29.7, 25.7 (3C), 25.4, 19.5, 18.0, -4.7, -5.2  MS (FAB) m/z 591 (M + Na)
+ ; 
HRMS(FAB) C30H49
35
ClNaO6Si(M + Na)
+
 calc. : 591.2885, found : 591.2864 (-2.1 mmu). 
 
+
Synthesis of seco acid 
 
Alcohol 24 
To a solution of 22 (150 mg, 0.263 mmol) in THF (2.8 mL) and H2O (1.4 mL) was added acetic acid (5.6 mL).  
After stirred at 45 °C for 3 h, the reaction mixture was quenched with saturated aqueous NaHCO3 and extracted 
with EtOAc.  The organic layer was washed with H2O and brine and dried over MgSO4.  Concentration and 
column chromatography FL60D (hexane /Et2O 7:1-5:1) gave 24 (102 mg) in 80% yield.  
Rf = 0.25 (2:1 hexane/EtOAc)  []D
26
 +18.0°(c 0.45, CHCl3).  IR (CHCl3) ; 3610, 3460, 1610, 1515, 1460, 1360, 
1250, 1170, 1080, 835 cm
-1
.  
1
H NMR (270 MHz, CDCl3)  7.26 (br d, J = 8.3 Hz, 2H), 6.87 (br d, J = 8.3 Hz, 
2H), 5.57 (br t, J = 6.9 Hz, 1H), 4.53 (d, J = 11.5 Hz, 1H), 4.44 (d, J = 11.5 Hz, 1H), 4.36 (m, 1H), 4.19 (m, 1H), 
4.03 (m, 1H), 3.80 (s, 3H), 3.71-3.50 (m, 4H), 2.61-2.30 (m, 5H), 1.93 (br dd, J = 12.5, 5.6 Hz, 1H), 1.84-1.54 (m, 
3H), 0.87 (s, 9H), 0.05 (s, 3H), 0.03 (s, 3H).  
13
C NMR (67.8 MHz, CDCl3)  159.1, 136.8, 130.4, 129.6 (2C), 
121.6, 113.7 (2C), 81.4, 76.7, 76.5, 73.1, 69.0, 61.6, 55.3, 41.9, 36.4, 33.8, 32.1, 25.7 (3C), 18.0, -4.7, -5.1  MS 
(FAB) m/z 507 (M + Na)
+
 ; HRMS(FAB) C25H41
35
ClNaO5Si(M + Na)
+
 calc. : 507.2310, found : 507.2296 (-1.4 
mmu). 
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unsaturated ester 25 
To a solution of 24 (277 mg, 0.572 mmol) in CH2Cl2 (0.6 mL) at 0 °C was added Dess-Martin periodinane (364 g, 
0.858 mmol).  After stirred at room temperature for 30 min, the reaction mixture was quenched with saturated 
aqueous Na2S2O3 and extracted with EtOAc.  The organic layer was washed with brine and dried over MgSO4.  
Concentration gave 24-2 (299 mg) which was directly used in the next reaction. 
To a solution of 30 (284 mg, 0.858 mmol) and 18-crown-6 ether (226 mg, 2.86 mmol) in THF (1.0 mL) at room 
tempareture was added potassium hexamethylphosphorictriamide (0.5 M, toluene solution, 1.72 mL, 0.858 mmol).  
After stirred for 10 min, 24-2 in THF (5.0 mL) was added to the reaction mixture.  After stirred at -78 °C for 3h, 
the reaction mixture was quenched with saturated aqueous NH4Cl and extracted with EtOAc.  The organic layer 
was washed with brine and dried over MgSO4.  Concentration and column chromatography (silicagel, hexane 
/Et2O, 5:1-4:1-3:1-1:1) gave 25 (243 mg) in 77% yield in 2 steps. 
Rf = 0.60 (1:1 hexane/Et2O)  []D
28
 +13.0°(c 0.11, CHCl3)  IR (CHCl3) ; 1710, 1615, 1515, 1460, 1250, 1135, 
1075, 1035, 835 cm
-1
.  
1
H NMR (270 MHz, CDCl3) 7.26 (br d, J = 8.6 Hz, 2H), 6.86 (br d, J = 8.6 Hz, 2H), 
5.88 (dt, J = 7.6, 1.7 Hz, 1H), 5.51 (t, J = 7.6 Hz, 1H), 4.51 (d, J = 11.6 Hz, 1H), 4.43 (d, J = 11.6 Hz, 1H), 4.35 
(m, 1H), 4.19 (m, 1H), 4.04 (m, 1H), 3.80 (s, 3H), 3.75 (s, 3H), 3.59 (dd, J = 16.8, 9.3 Hz, 1H), 3.52 (dd, J = 16.8, 
9.3 Hz, 1H), 3.32 (dd, J = 7.6, 7.6 Hz, 2H), 2.47 (m, 1H), 2.36 (m, 1H), 1.89 (d, J = 1.7 Hz, 3H), 1.97-1.56 (m, 
4H), 0.87 (s, 9H), 0.05 (s, 3H), 0.03 (s, 3H).  MS (FAB) m/z 575 (M + Na)
+
 ; HRMS (FAB) C29H45
35
ClNaO6Si 
(M + Na)
+
 calcu: 527.2572, found : 527.2549 (-2.3 mmu). 
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Alcohol 26 
To a solution of 25 (23.3 mg, 42.1 μmol) in toluene (0.86 mL) at-78 °C was added diisobutylaluminium hydride 
(1.0M, hexane solution, 0.126 mL, 0.126 mmol).  After stirred at -78 °C for 1.5 h, the reaction mixture was 
quenched by MeOH.  0.5M potassium sodium tartartrate (4.9 mL) was added to the reaction mixture and stirred 
at room temperature for 1h and extracted with Et2O.  The organic layer was washed with brine and dried over 
MgSO4.  Concentration and column chromatography (silcagel, hexane/acetone, 5:1-3:1-1:1) gave 26 (24.3 mg) in 
100% yield.  
Rf = 0.28 (1:1 hexane/Et2O).  []D
29
 +16.9° (c 0.20, CHCl3).  IR (CHCl3) ; 3600, 3480, 1615, 1585 1515, 1460, 
1250, 1070, 1035, 835 cm
-1
.  
1
H NMR (270 MHz, CDCl3)  7.26 (br d, J = 8.9 Hz, 2H), 6.86 (br d, J = 8.9 Hz, 
2H), 5.45 (t, J = 6.9 Hz, 1H), 5.27 (br t, J = 6.9 Hz, 1H), 4.52 (d, J = 11.6 Hz, 1H), 4.44 (d, J = 11.6 Hz, 1H), 4.36 
(m, 1H), 4.18 (m, 1H), 4.16 (s, 2H), 4.03 (m, 1H), 3.80 (s, 3H), 3.57 (dd, J = 16.5, 9.9 Hz, 1H), 3.54 (dd, J = 16.5, 
9.6 Hz, 1H), 2.92 (br t, J = 6.9 Hz, 2H), 2.29-2.54 (m, 2H), 1.93 (ddd, J = 12.9, 5.6, 1.3 Hz, 1H), 1.80 (d, J = 1.3 
Hz, 3H), 1.82-1.56 (m, 4H), 0.87 (s, 9H), 0.05 (s, 3H), 0.03 (s, 3H).  
13
C NMR (67.8 MHz, CDCl3)  159.1, 
135.6, 134.7, 130.4, 129.5, 129.5 (2C), 123.7, 113.7 (2C), 81.4, 77.3, 77.2, 73.1, 69.0, 61.5, 55.3, 41.9, 36.1, 33.8, 
27.3, 25.7 (3C), 21.2, 18.0, -4.7, -5.2 MS (FAB) m/z 547 (M + Na)
+
.  HRMS (FAB) C28H45
35
ClNaO5Si(M + Na)
+
 
calc. : 547.2623, found : 547.2596 (-2.7 mmu). 
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Sulfoxide 27 
To a solution of 26 (24.6 mg, 46.8 μmol) in CH2Cl2 (0.94 mL) at 0 °C was added Dess-Martin periodinane (29.6 
mg, 698 μmol).  After stirred at room temperature for 30 min, the reaction mixture was quenched with saturated 
aqueous Na2S2O3 and extracted with Et2O.  The organic layer was washed with brine, dried over MgSO4.  
Concentration gave 26-2 which was directly used in the next reaction. 
To a solution of 31 (59.4 mg, 0.234 mmol) in THF (1.2 mL) at -78 °C was added tert- butyl magnesium (0.93 M, 
THF solution, 0.25 mL, 0.234 mmol).  26-2 in THF (0.8 mL) was dropwised to the reaction mixture at -78 °C.  
After stirred at -78 °C for 3 h, the reaction mixture was quenched with saturated aqueous NH4Cl and extracted 
with CH2Cl2.  The organic layer was washed with brine and dried over MgSO4.  Concentration and column 
chromatography (silicagel, hexane /EtOAc 11:1-7:1-5:1-1:1) gave 27 (20.9 mg) in 57% yield in 2 steps. 
Rf = 0.56 (3:2 hexane/EtOAc).  []D
28
 +105° (c 0.33, CHCl3).  IR (CHCl3) ; 3595, 3480, 1720, 1515, 1460, 
1370, 1250, 1145, 1060, 1035, 835 cm
-1
.  
1
H NMR (270 MHz, CDCl3)  7.53 (br d, J = 8.3 Hz, 2H), 7.34 (br d, J 
= 8.3 Hz, 2H), 7.25 (br d, J = 8.6 Hz, 2H), 6.86 (br d, J = 8.6 Hz, 2H), 5.45 (t, J = 6.9 Hz, 1H), 5.38 (br t, J = 6.9 
Hz, 1H), 5.12 (dd, J = 7.6, 5.9 Hz, 1H), 4.51 (d, J = 11.5 Hz, 1H), 4.43 (d, J = 11.5 Hz, 1H), 4.35 (m, 1H), 4.18 (m, 
1H), 4.03 (m, 1H), 3.80 (s, 3H), 3.63-3.51 (m, 2H), 3.47 (d, J = 7.6 Hz, 1H), 3.07 (d, J = 5.9 Hz, 1H), 2.92 (m, 
1H), 2.83 (m, 1H), 2.42 (s, 3H), 2.53-2.27 (m, 2H), 1.93 (ddd, J = 12.9, 5.6, 1.3 Hz, 1H), 1.77 (br s, 3H), 
1.83-1.58 (m, 3H), 1.31 (s, 9H), 0.87 (s, 9H), 0.05 (s, 3H), 0.03 (s, 3H).  
13
C NMR (67.8 MHz, CDCl3)  165.8, 
159.2, 141.9, 138.7, 135.3, 133.1, 130.5, 129.5, 129.8 (2C), 129.8 (2C) 127.7 (2C), 124.7, 123.0, 113.7 (2C), 83.4, 
81.4, 77.3, 76.7, 73.1, 73.1, 72.4, 69.0, 67.7, 55.3, 41.9, 36.1, 33.9, 27.9 (3C), 27.2, 25.7 (3C), 21.4, 18.0, -4.7, 
-5.2.  MS (FAB) m/z 799 (M + Na)
+
. 
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t-butyl ester 28 
To a solution of 27 (19.4 mg, 0.0250 mmol) in THF (1.8 mL) and H2O (0.2 mL) at room temperature was added 
aluminium amalgam (80 mg).  The reaction mixture was sonicated for 1.5h and stirred at room temperature for 
14 h.  The reaction mixture was filterated though celite pad and washed with CHCl3.  Concentration of filtarate 
and column chromatography (silicagel, hexane /Et2O 5:1-2:1-1:1) gave 28 (13.7 mg) in 86% yield.. 
Rf = 0.51 (3:2 hexane/EtOAc).  []D
28
 +9.2° (c 0.056, CHCl3)  IR (CHCl3) ; 3520, 1715, 1595, 1515, 1460, 
1370, 1250, 1150, 1075, 1030, 835 cm
-1
.  
1
H NMR (270 MHz, CDCl3)  7.25 (br d, J = 8.9 Hz, 2H), 6.85 (br d, J 
= 8.9 Hz, 2H), 5.45 (t, J = 7.3 Hz, 1H), 5.21 (br t, J = 6.9 Hz, 1H), 4.99 (dd, J = 9.9, 3.3 Hz, 1H), 4.51 (d, J = 11.6 
Hz, 1H), 4.43 (d, J = 11.6 Hz, 1H), 4.35 (m, 1H), 4.17 (m, 1H), 4.03 (m, 1H), 3.79 (s, 3H), 3.57 (dd, J = 17.2, 9.9 
Hz, 1H), 3.55 (dd, J = 17.2, 9.9 Hz, 1H), 2.98-2.83 (m, 2H), 2.57 (dd, J = 16.2, 9.8 Hz, 1H), 2.41 (dd, J = 16.2, 
3.3 Hz, 1H), 2.57-2.28 (m, 2H), 1.93 (ddd, J = 11.6, 5.6, 1.3 Hz, 1H), 1.87-1.67 (m, 4H), 1.71 (br s, 3H), 1.47 (s, 
9H), 0.87 (s, 9H), 0.05 (s, 3H), 0.03 (s, 3H)  MS (FAB) m/z 661 (M + Na)
+
 
 
 
 
Acetate 28-2 
To a solution of 28 (7.0 mg, 11.0 mol) in pyridine (0.60 mL) at room temperature was added acetic anhydride 
(0.30 mL, 0.32 mmol).  After stirred at room temperature for 7.5 h, the reaction mixture was concentrated with 
toluene.  Column chromatography (silicagel, hexane /Et2O, 7:1-3:1-1:1) gave 28-2 (7.4 mg) in 99% yield.. 
Rf = 0.38 (3:1 hexane/EtOAc).  []D
30
 -31.7° (c 0.011, CHCl3)  IR (CHCl3) ; 1735, 1590, 1515, 1460, 1370, 
1230, 1150, 1080, 1030, 835 cm
-1
.  
1
H NMR (270 MHz, CDCl3)  7.25 (br d, J = 8.6 Hz, 2H), 6.88 (br d, J = 8.6 
Hz, 2H), 5.95 (dd, J = 9.6, 5.3 Hz, 1H), 5.47 (t, J = 6.9 Hz, 1H), 5.25 (br t, J = 6.3 Hz, 1H), 4.51 (d, J = 11.6 Hz, 
1H), 4.43 (d, J = 11.6 Hz, 1H), 4.35 (m, 1H), 4.18 (m, 1H), 4.03 (m, 1H), 3.80 (s, 3H), 3.57 (dd, J = 17.5, 9.6 Hz, 
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1H), 3.55 (dd, J = 17.5, 9.6 Hz, 1H), 3.05 (m, 2H), 2.69 (dd, J = 15.2, 9.6 Hz, 1H), 2.41 (dd, J = 15.2, 5.3 Hz, 1H), 
2.53-2.35 (m, 2H), 2.20 (s, 3H), 1.93 (ddd, J = 11.6, 5.6, 1.2 Hz, 1H), 1.85-1.70 (m, 3H), 1.66 (br s, 3H), 1.43 (s, 
9H), 0.87 (s, 9H), 0.05 (s, 3H), 0.03 (s, 3H)  MS (FAB) m/z 703 (M + Na)+ 
 
 
Secondary alcohol 28-3  
To a solution of 28-2 (10.9 mg, 16.0 mol) in THF (0.80 mL) and pyridine (0.30 mL) at 0 °C was added 
70%HF-pyridiene (0.50 mL).  After stirred at room temperature for 3 h, the reaction mixture was diluted with 
EtOAc and poured into saturated aqueous NaHCO3 and extracted with EtOAc.  The organic layer was washed 
with H2O and brine and dried over MgSO4.  Concentration and column chromatography (silicagel, hexane/EtOAc, 
3:1-2:1-1:1-1:2) gave 28-3 (8.4 mg) in 93% yield. 
Rf = 0.33 (1:1 hexane/EtOAc).  []D
29
 +11.3° (c 0.043, CHCl3)  IR (CHCl3) ; 3480, 1730, 1610, 1510, 1370, 
1250, 1160, 1100, 1035, 835 cm
-1
.  
1
H NMR (270 MHz, CDCl3)  7.25 (br d, J = 8.9 Hz, 2H), 6.88 (br d, J = 8.9 
Hz, 2H), 5.95 (dd, J = 9.4, 5.3 Hz, 1H), 5.47 (t, J = 6.9 Hz, 1H), 5.27 (dt, J = 6.3, 1.3 Hz, 1H), 4.51 (s, 2H), 4.46 
(m, 1H), 4.23 (m, 1H), 4.04 (m, 1H), 3.81 (s, 3H), 3.73 (d, J = 5.6 Hz, 2H) 3.07 (m, 2H), 2.93 (d, J = 4.0 Hz, 1H), 
2.69 (dd, J = 15.2, 9.4 Hz, 1H), 2.51-2.25 (m, 2H), 2.41 (dd, J = 15.2, 5.3 Hz, 1H), 2.07 (ddd, J = 12.9, 5.6, 1.0 Hz, 
1H), 2.02 (s, 3H), 1.67 (d, J = 1.3 Hz, 3H), 1.82-1.65 (m, 3H), 1.45 (s, 9H)  MS (FAB) m/z 589 (M + Na)
+
 
 
 
Seco acid 29 
To a solution of 28-3 (2.1 mg, 3.8 mol) in THF (0.50 mL) at 0 °C was added trimethylsilyl 
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trifuluoromethanesulfonate (20 μL, 0.010 mmol).  After stirred at 0 °C for 2 h, the reaction mixture was 
quenched with 1M HCl and extracted with EtOAc.  The organic layer was washed with brine and dried over 
MgSO4.  Concentration and column chromatography (ODS, MeOH /H2O 7:1, and silicagel , CHCl3/MeOH 
39:1-29:1) gave 29 (1.3 mg) in 90% yeild. 
Rf = 0.30 (5:1 CHCl3/MeOH).  []D
28
 +13.8° (c 0.058, CHCl3).  IR (CHCl3) ; 3680, 3420, 1730, 1610, 1460, 
1280, 1170, 970 cm
-1
.  
1
H NMR (400 MHz, CDCl3)  6.01 (dd, J = 10.3, 5.9 Hz, 1H), 5.69 (dd, J = 7.6, 7.6 Hz, 
1H), 5.65 (br t, J = 7.6 Hz, 1H), 4.45 (m, 1H), 4.25 (m, 1H), 3.96 (d, J = 3.7 Hz, 2H), 3.91 (m, 1H), 3.15 (m, 1H), 
2.93-2.80 (m, 2H), 2.86 (m, 1H), 2.67 (dd, J = 12.9, 10.3 Hz, 1H), 2.57 (m, 1H), 2.33 (m, 1H), 2.20 (ddd, J = 13.4, 
6.8, 1.7 Hz, 1H), 2.08 (s, 3H), 1.75 (s, 3H), 1.89-1.63 (m, 3H) Peaks of CO2H and OH were not found.  MS 
(FAB) m/z 413 (M + Na)
+
 
 
Synthesis of macrolactone 34 
 
 
MMTr 32 
To a solution of 26 (182 mg, 0.347 mmol) in pyridine (9.70 mL) at room temperature was added 
4-methoxytriphenylmethyl chloride (1.49 g, 4.82 mmol).  After stirred at 50 °C for 15 min, the reaction mixture 
was quenched with H2O and extracted with Et2O.  The organic layer was washed with H2O and brine and dried 
over MgSO4.  Concentration and column chromatography (ODS, MeOH/H2O/Et3N 80:20:1-1:0:0) gave 32 (261 
mg) in 94% yield.. 
Rf = 0.31 (1:1 hexane/Et2O).  []D
29
 +11.4° (c 0.090, CHCl3)  IR (CHCl3) ; 1615, 1515 cm
-1
.  
1
H NMR (600 
MHz, CDCl3)  7.47 (br d, J = 7.3 Hz, 4H), 7.35 (br d, J = 9.0 Hz, 2H), 7.28 (br dd, J = 7.9, 7.3 Hz, 4H), 7.25 (br 
d, J = 8.6 Hz, 2H), 7.21 (br d, J = 7.3 Hz, 2H), 6.86 (br d, J = 8.6 Hz, 2H), 6.83 (br d, J = 9.0 Hz, 2H), 5.33 (br t, J 
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= 7.0 Hz, 1H), 5.21 (br t, J = 7.3 Hz, 1H), 4.50 (d, J = 11.5 Hz, 1H), 4.44 (d, J = 11.5 Hz, 1H), 4.34 (m, 1H), 4.16 
(m, 1H), 4.02 (m, 1H), 3.79 (s, 3H), 3.79 (s, 3H), 3.59 (br s, 2H), 3.58 (dd, J = 9.7, 5.3 Hz, 1H), 3.53 (dd, J = 9.7, 
6.6 Hz, 1H), 2.68 (br dd, J = 7.3, 7.0 Hz, 2H), 2.40 (m, 1H), 2.38 (m, 1H), 1.93 (br dd, J = 11.7, 5.5 Hz, 1H), 1.85 
(br s, 3H), 1.75 (m, 1H), 1.69 (m, 1H), 1.62 (m, 1H), 0.87 (s, 9H), 0.04 (s, 3H), 0.02 (s, 3H).  MS (FAB) m/z 547 
(M + Na)
+
 ; HRMS (ESI) C48H61
35
ClNaO6Si(M + Na)
+
 calc. : 819.3824, found : 819.3814 (-1.0 mmu). 
 
 
Alcohol 33 
To a solution of 32 (299 mg, 0.375 mmol) in THF (10.8 mL) at room temperature was added tetrabutylammonium 
fluoride (1.0M, THF solution, 0.75 mL, 0.75 mmol).  After stirred at room temperature for 2 h, the reaction 
mixture was quenched with saturated aqueous NH4Cl and extracted with EtOAc.  The organic layer was washed 
with brine and dried over MgSO4.  Concentration and column chromatography (silicagel, hexane/EtOAc, 
3:1-2:1-1:1) gave 33 (251 mg) in 98% yield. 
Rf = 0.13 (1:1 hexane/Et2O).  []D
31
 +0.0° (c 0.19, CHCl3).  IR (CHCl3) ; 1615, 1515 cm
-1
.  
1
H NMR (600 
MHz, CDCl3)  7.47 (br d, J = 7.3 Hz, 4H), 7.35 (br d, J = 8.8 Hz, 2H), 7.28 (br dd, J = 8.0, 7.3 Hz, 4H), 7.24 (br 
d, J = 8.6 Hz, 2H), 7.21 (br d, J = 7.3 Hz, 2H), 6.87 (br d, J = 8.6 Hz, 2H), 6.83 (br d, J = 8.8 Hz, 2H), 5.34 (br t, J 
= 7.0 Hz, 1H), 5.22 (br t, J = 8.3 Hz, 1H), 4.51 (d, J = 11.5 Hz, 1H), 4.48 (d, J = 11.5 Hz, 1H), 4.45 (m, 1H), 4.20 
(m, 1H), 4.03 (br dd, J = 9.2, 5.3, 1H), 3.80 (s, 3H), 3.79 (s, 3H), 3.73 (d, J = 5.3 Hz, 2H), 3.59 (br s, 2H), 2.90 (d, 
J = 4.0 Hz, 1H), 2.68 (br dd, J = 8.3, 7.0 Hz, 2H), 2.39 (m, 1H), 2.29 (m, 1 H), 2.05 (br dd, J = 13.4, 5.7 Hz, 1H), 
1.85 (br s, 3H), 1.76-1.67 (m, 3H).  MS (FAB) m/z 547 (M + Na)
+.
 HRMS (ESI) C42H47
35
ClNaO6 (M + Na)
+
 
calc. : 705.2959, found : 705.2975 (+1.6 mmu). 
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Bromoacetate 34-2 
To a solution of 33 (14.7 mg, 21.5 μmol) in pyridine (0.30 mL) at 0 °C was added bromoacetyl bromide (20 μL, 
0.230 mmol).  After stirred at room temperature for 1 h, the reaction mixture was quenched with H2O and 
extractedvwith EtOAc.  The organic layer was washed with H2O, saturated aqueous NaHCO3 and brine and dried 
over MgSO4.  Concentration gave 34 which was directly used in the next reaction. 
A solution of 34 (20.0 mg) in acetic acid (1.6 mL) and H2O (0.40 mL) stirred at room temperature for 4 h, the 
reaction mixture was evaporated and extracted with Et2O.  The organic layer was washed with H2O, saturated 
aqueous NaHCO3 and brine and dried over MgSO4.  Concentration and column chromatography (silicagel, 
hexane/EtOAc 5:1-3:1-2:1) gave 34-2 (8.7 mg) in 89% yield in 2 steps. 
Rf = 0.28 (1:1 hexane/Et2O).  []D
32
 +53.4° (c 0.027, CHCl3).  IR (CHCl3) ; 1735, 1615, 1515 cm
-1
.  
1
H NMR 
(600 MHz, CDCl3)  7.24 (br d, J = 8.8 Hz, 2H), 6.87 (br d, J = 8.8 Hz, 2H), 5.46 (m, 2H), 5.27 (br dd, J = 9.0, 
6.2 Hz, 1H), 4.52 (d, J = 11.7 Hz, 1H), 4.41 (d, J = 11.7 Hz, 1H), 4.21 (m, 1H), 4.16 (m, 2H), 4.16 (s, 2H), 3.81 (s, 
3H), 3.72 (s, 2H), 3.59 (m, 2H), 2.92 (br t, J = 7.3 Hz, 2H), 2.47 (m, 1H), 2.38 (m, 1H), 2.14 (br dd, J = 13.9, 5.9 
Hz, 1H), 1.88-1.75(m, 3H), 1.81 (d, J = 1.3 Hz, 3H)  MS (FAB) m/z 547 (M + Na)+ ; HRMS (ESI) 
C24H32
79
Br
35
ClO5 (M + Na)
+
 calc. : 553.0968, found : 553.0967 (-0.1 mmu). 
 
 
Aldehyde 5 
To a solution of 34-2 (1.8 mg, 3.4 μmol) in CH2Cl2 (0.5 mL) at 0 °C was added Dess-Martin periodinane (2.9 mg, 
6.8 μmol).  After stirred at room temperature for 30 min, the reaction mixture was quenched with saturated 
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aqueous Na2S2O3 and extracted with Et2O.  The organic layer was washed with brine and dried over MgSO4.  
Concentration and column chromatography (silicagel, hexane/Et2O, 1:1-1:2) gave 5 (1.7 mg) in 95% yield. 
Rf = 0.28 (1:1 hexane/Et2O).  []D
32
 +21.0° (c 0.053, CHCl3).  IR (CHCl3) ; 1740, 1685, 1615, 1515 cm
-1
.  
1
H 
NMR (600 MHz, CDCl3)  9.40 (s, 1H), 7.24 (br d, J = 8.4 Hz, 2H), 6.87 (br d, J = 8.4 Hz, 2H), 6.41 (br dd, J = 
6.8, 6.4 Hz, 1H), 5.56 (br t, J = 6.8 Hz, 1H), 5.46 (br t, J = 4.2 Hz, 1H), 4.52 (d, J = 11.5 Hz, 1H), 4.46 (d, J = 
11.5 Hz, 1H), 4.22 (m, 1H), 4.18 (m, 1H), 3.80 (s, 3H), 3.72 (br s, 2H), 3.58 (dd, J = 6.1, 2.6 Hz, 1H), 3.49 (dd, J 
= 13.9, 7.0 Hz, 1H), 3.21 (br t, J = 6.4 Hz, 2H), 2.52 (m, 1H), 2.42 (m, 1H), 2.15 (m, 1H), 1.88-1.78(m, 3H), 1.79 
(br s, 3H).  MS (FAB) m/z 547 (M + Na)
+ 
; HRMS (ESI) C24H30
79
Br
35
ClNaO6 (M + Na)
+
 calc. : 551.0812, 
found : 551.0814 (+0.2 mmu). 
 
 
Regioisomer 38-1, 38-2 
To a solution of samarium iodide (0.10 M, THF solution, 4.8 mL, 0.48 mmol) at 0 °C was dropwised 5 (4.1 mg, 
0.108 mol) in THF (9.6 mL) for 3.5h.  After stirred at room temperature for 30 min, and the reaction mixture 
was quenched in the air and evaporated.  Saturated aqueous NaHCO3 was added to the reaction mixture and 
extracted with EtOAc.  The organic layer was washed with saturated aqueous NaHCO3 and brine and dried over 
MgSO4.  Concentration and column chromatography (silicagel, hexane/EtOAc 3:1-2:1-1:1-1:2-0:1) , preparative 
TLC (hexane / EtOAc 1:2) gave 38-1 (1.52 mg) in 44% yield and 38-2 (1.48 mg) in 42% yield. 
38-1  Rf = 0.57 (1:1 hexane/EtOAc).  
1
H NMR (400 MHz, CDCl3)  7.24 (br d, J = 8.5 Hz, 2H), 6.87 (br d, J = 
8.5 Hz, 2H), 5.53 (br t, J = 7.6 Hz, 1H), 5.33 (dd, J = 10.7, 4.9 Hz, 1H), 5.14 (br t, J = 3.7 Hz, 1H), 4.57 (d, J = 
11.7 Hz, 1H), 4.39 (d, J = 11.7 Hz, 1H), 4.25 (m, 1H), 4.19 (m, 1H), 3.82 (m, 1H), 3.80 (s, 3H), 3.58 (m, 2H), 
3.56 (m, 1H), 3.23 (m, 1H), 2.69 (dd, J = 14.2, 3.7 Hz, 1H), 2.63 (dd, J = 14.2, 6.6 Hz, 1H), 2.59 (m, 1H), 
2.52-2.40 (m, 2H), 2.20 (m, 1H), 1.67 (br s, 3H), 1.54 (m, 1H), 1.43 (m, 1H) Peak of OH was not found.  MS 
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(ESI) m/z 473 (M + Na)
+
 
38-2  Rf = 0.57 (1:1 hexane/EtOAc).  
1
H NMR (400 MHz, CDCl3)  7.24 (br d, J = 8.5 Hz, 2H), 6.87 (br d, J = 
8.5 Hz, 2H), 5.49 (m, 1H), 5.28 (dd, J = 11.0, 3.4, 1H), 5.15 (br t, J = 3.9 Hz, 1H), 4.58 (d, J = 12.0 Hz, 1H), 4.44 
(m, 1H), 4.41 (d, J = 12.0 Hz, 1H), 4.24 (m, 2H), 3.85 (m, 1H), 3.80 (s, 3H), 3.59 (m, 2H), 3.56 (m, 1H), 3.30 (m, 
1H), 2.52-2.46 (m, 3H), 2.18 (m, 1H), 2.12 (m, 1H), 1.73 (br s, 3H),1.69 (m, 1H), 1.40 (m, 2H).  MS (ESI) m/z 
473 (M + Na)
+
 
 
 
Macrolide 35 
To a solution of Wilkinson's catalyst (5.37 mg, 5.38 mol) in THF (4.0 mL) at 0 °C was added diethyl zinc (1.0M, 
hexane solution, 2.37 mL, 2.37 mmol).  5 (57.1 mg, 0.108 mmol) in THF (18 mL) was dropwised to the reaction 
mixture at 0 °C for 4 h then acetic acid anhydride (0.1 mL, 5.29 mmol) was added.  After stirred at 0 °C for 1 h, 
the reaction mixture was quenched with saturated aqueous NaHCO3 and filterated though celite pad with Et2O.  
The organic layer was washed with brine and dried over MgSO4.  Concentration and column chromatography 
(silicagel, hexane/EtOAc 11:1-9:1-7:1-5:1-3:1-0:1) , preparative TLC (hexane / Et2O 1:3) gave 35 (4.5 mg) in 9% 
and 37 and 38 (18.4 mg) in 33% yield.. 
35  Rf = 0.58 (1:1 hexane/EtOAc).  []D
33
 +43.7° (c 0.016, CHCl3).  IR (CHCl3) ; 1740, 1615, 1515 cm
-1
.  
1
H 
NMR (400 MHz, CD3OD)  7.24 (br d, J = 8.8 Hz, 2H), 6.87 (br d, J = 8.8 Hz, 2H), 5.70 (dd, J = 11.5, 4.4 Hz, 
1H), 5.69 (m, 1H), 5.30 (br d, J = 6.8 Hz, 1H), 5.24 (br t, J = 3.4 Hz, 1H), 4.52 (d, J = 11.7 Hz, 1H), 4.38 (d, J = 
11.7 Hz, 1H), 4.25 (dt, J = 6.3, 3.9 Hz, 1H), 3.95 (m, 1H), 3.77 (s, 3H), 3.59 (dd, J = 6.3, 2.0 Hz, 2H), 3.47 (m, 
1H), 2.68 (dd, J = 11.7, 11.5 Hz, 1H), 2.53 (dd, J = 11.7, 4.4 Hz, 1H), 2.45 (m, 2H), 2.30 (m, 2H), 2.12 (m, 1H), 
2.01 (s, 3H), 1.85 (br s, 3H), 1.52 (m, 1H), 1.42 (m, 1H).  MS (FAB) m/z 547 (M + Na)
+. HRMS (ESI) 
C26H33
35
ClNaO7 (M + Na)
+
 calc. : 515.1812, found : 515.1817 (+0.5 mmu). 
37  Rf = 0.57 (1:1 hexane/EtOAc).  
1
H NMR (400 MHz, CD3OD) 7.25 (br d, J = 8.3 Hz, 2H), 6.89 (br d, J = 
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8.3 Hz, 2H), 5.76 (m, 2H), 5.54 (br t, J = 7.3 Hz, 1H), 5.16 (br t, J = 4.2 Hz, 1H), 4.53 (d, J = 11.7 Hz, 1H), 4.43 
(d, J = 11.7 Hz, 1H), 4.30 (m, 1H), 4.08 (dt, J = 7.3, 7.1 Hz, 1H), 3.77 (s, 3H), 3.52 (m, 2H), 2.97 (m, 1H), 2.81 
(dd, J = 12.2, 10.5 Hz, 1H), 2.76 (m, 1H), 2.47 (dd, J = 12.2, 3.7 Hz, 1H), 2.39-2.26 (m, 3H), 2.17 (m, 1H), 2.00 
(s, 3H), 1.65 (br s, 3H), 1.49 (m, 1H), 1.42 (m, 1H).  
 
 
Secondary alcohol 37-2 
To a solution of 37 (5.3 mg, 11 μmol) in MeOH (1.8 mL) and H2O (0.2 mL) at 0 °C was added K2CO3 (20 mg, 
0.189 mmol).  After stirred at 0 °C for 1 h, H2O and NaCl were added to the reaction mixture and extracted with 
EtOAc.  The organic layer was washed with brine and dried over MgSO4.  Concentration and preparative TLC 
(hexane / EtOAc 1:1) gave 37-2 (2.2 mg) in 45% yield. 
Rf = 0.58 (1:1 hexane/EtOAc).  
1
H NMR (400 MHz, CD3OD)  7.27 (br d, J = 8.8 Hz, 2H), 6.88 (br d, J = 8.8 
Hz, 2H), 5.53 (br t, J = 7.1 Hz, 1H), 5.21 (br t, J = 6.6 Hz, 1H), 5.03 (br dd, J = 8.3, 5.5 Hz, 1H), 4.51 (d, J = 11.5 
Hz, 1H), 4.46 (d, J = 11.5 Hz, 1H), 4.33 (br t, J = 3.9 Hz, 1H), 4.19 (m, 1 H), 4.01 (m, 1H), 3.77 (s, 3H), 3.67 (dd, 
J = 10.2, 4.6 Hz, 1H), 3.65 (m, 1H), 3.57 (dd, J = 10.2, 7.0 Hz, 1H), 2.93 (m, 2H), 2.63 (dd, J = 14.6, 8.5 Hz, 1H), 
2.41 (dd, J = 14.6, 5.4 Hz, 1H), 2.42 (m, 2H), 2.01 (ddd, J = 13.2, 5.9, 1.2 Hz, 1H),1.75 (m, 2H), 1.69 (br s, 3H) 
Peak of OH was not found. 
 
Synthesis of Haterumalide NA Methyl ester 
 
Vinyl iodide 18-2 
To a solution of zirconocene dichloride (4.82 g, 16.5 mmol) in 1,2-dichloroethane (130 mL).  
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Trimethylaluminum (2.0M, touluene solution, 99.0 mL, 198 mmol) was added to the reaction mixture.  A 
solution of 3-butyn-1-ol 18 (4.63 g, 66.0 mmol) in 1,2-dichloroethane (35 mL) was also dropwised to the reaction 
mixture.  After stirred at room temperature for 14 h, the reaction mixture was cooled to 0 °C ans iodine (20.0 g, 
79.2 mmol) in THF (65 mL) was added.  After stirred at room temperature for 40 min, the reaction mixture was 
quenched with saturated aqueous K2CO3 and filterated with celite pad and washed with Et2O.  The organic layer 
was concentrated and column chromatography (silicagel, hexane/EtOAc 5:1-3:1) gave 18-2 (8.7 mg) in 89% 
yield. 
Rf = 0.41 (1:1 hexane/Et2O).  
1
H NMR (400 MHz, CDCl3)  6.18 (br s, 1H), 3.74 (m, 1H), 3.70 (br t, J = 6.3 Hz, 
2H), 2.47 (br t, J = 6.3 Hz, 2H), 1.88 (br s, 3H). 
 
 
Carboxylic acid 18-3 
To a solution of chromic acid (2.61 g, 26.2 mmol) in 1.5M sulfuric acid (43 mL) at 5-10 °C was dropwised 18-2 
(1.46 g, 6.88 mmol) in acetone (80 mL) for 30 min.  After stirred at room temperature for 4 h, the reaction 
mixture was extracted with Et2O and dried over MgSO4.  Concentration gave crude mixture and diluted with 
Et2O (30 mL) and extracted with 1M NaOH.  Aqueous layer was acidified with 6.0 M HCl and extracted with 
Et2O.  The organic layer was washed with brine and dried over MgSO4.  Concentration and column 
chromatography (silicagel, hexane/Et2O 1:0-1:1) gave 18-3 (1.06 g) in 68% yield. 
Rf = 0.23 (1:1 hexane/Et2O).  
1
H NMR (270 MHz, CDCl3)  6.22 (br s, 1H) , 3.25 (br s, 2H), 1.96 (br s, 3H). 
Peak of CO2H was not found.  
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C16-19 fragment 3 
To a solution of 18-3 (1.06 g, 5.25 mmol) in benzene (50 mL) and MeOH (10 mL) was added (trimethylsilyl) 
diazomethane (12.0 mL, 6.93 mmol).  After stirred at room temperature for 5 min, the reaction mixture was 
concentrated and column chromatography (silicagel, hexane/Et2O, 49:1-9:1) gave 3 (0.930 g) in 74%  yield. 
Rf = 0.79 (1:2 hexane/Et2O).  1H NMR (270 MHz, CDCl3)  6.18 (br s, 1H), 3.70 (s, 3H), 3.21 (br s, 2H), 1.94 
(br s, 3H). 
 
 
Alcohol 39 
To a solution of 35 (1.1 mg, 2.2 μmol) in CH2Cl2 (1.0 mL), tert-butyl alcohol (0.1 mL) and 1.0M phosphate buffer 
(pH=5.91) at 0 °C was added 2,3-dichloro-5,6-dicyanoquinone (4.0 mg, 17.8 μmol).  After stirred at room 
temperature for 1.5 h, 2,3-dichloro-5,6-dicyanoquinone (4.0 mg, 17.8 μmol) was added again.  After stirred at 
room temperature for 1 h, the reaction mixture was quenched with saturated aqueous NaHCO3 and extracted with 
CH2Cl2.  The organic layer was washed with brine and dried over MgSO4.  Concentration and column 
chromatography (silicagel, hexane/acetone, 5:1-3:1-1:1) gave 39 (1.10 mg) in 100%. 
Rf = 0.17 (1:1 hexane/EtOAc).  []D33 +7.7° (c 0.019, CHCl3).  IR (CHCl3) ; 3500 (br), 1730 cm-
-1
.  
1
H NMR 
(400 MHz, CD3OD)  5.76 (dd, J = 10.1, 6.0 Hz, 1H), 5.70 (m, 1H), 5.30 (br d, J = 7.4 Hz, 1H), 5.26 (br t, J = 3.4 
Hz, 1H), 4.15 (m, 1H), 3.91 (m, 1H), 3.68 (m, 2H), 3.48 (m, 1H), 2.76 (m, 2H), 2.68 (m, 1H), 2.47 (m, 2H), 2.30 
(m, 2H), 2.02 (s, 3H), 1.87 (br s, 3H), 1.52 (m, 1H), 1.43 (m, 1H) Peak of OH was not found.  HRMS (ESI) 
C18H25
35
ClNaO6 (M + Na)
+
 calc. : 395.1237, found : 395.1251 (+1.4 mmu). 
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15-epi-haterumalideNA menthyl ester 41 
To a solution of 39 (0.80 mg, 2.15 μmol) in CH2Cl2 (1.0 mL) at 0 °C was added Dess-Martin periodinane (5.20 
mg, 12.3 μmol).  After stirred at room temperature for 30 min, the reaction mixture was quenched with saturated 
aqueous Na2S2O3 and extracted with Et2O.  The organic layer was washed with brine and dried over MgSO4.  
Concentration gave 40 (0.90 mg) which was directly used in the next reaction. 
A solution of 40 (0.90 mg) and 3 (41.0 mg, 0.170 mmol) in DMSO (0.50 mL) was degassed by freeze-pump-thaw.  
To a reaction mixture was added CrCl2 (58.0 mg, 0.472 mmol) and catalytic amount of NiCl2.  After stirred at 
room temperature for 20 h, the reaction mixture was quenched with H2O and extractedvwith Et2O.  The organic 
layer was washed with saturated aqueous NaHCO3 and brine and dried over MgSO4.  Concentration and column 
chromatography (silicagel, hexane / Et2O, 5:1-EtOAc), preparative TLC (hexane/EtOAc, 1:2) gave 41 (15R : 15S 
= 11 : 1).  41 (15R : 15S = 11 : 1) was purified by HPLC (Develosil ODS HG-5 φ4.6 × 250 mm), MeOH : H2O 
= 3 : 2) and 40 (0.59 mg) was obtained in 57% yield in 2 steps. 
Rf = 0.38 (1:2 hexane/EtOAc).  1H NMR (800 MHz, CD3OD)  5.79 (dd, J = 11.4, 4.6, 1H), 5.70 (br dd, J = 9.2, 
7.4, 1H), 5.37 (br d, J = 8.7 Hz, 1H), 5.31 (br d, J = 7.3 Hz, 1H), 5.30 (br t, J = 3.4 Hz, 1H), 4.53 (br t, J = 8.5 Hz, 
1H), 3.93 (br tt, J = 11.4, 3.6 Hz , 1H), 3.90 (dd, J = 8.7, 3.7 1H), 3.67 (s, 3H), 3.49 (m, 1H), 3.08 (s, 2H), 2.82 
(dd, J = 11.5, 4.2 Hz, 1H), 2.77 (dd, J = 11.5, 11.4 Hz, 1H), 2.47 (m, 2H), 2.29 (m, 2H), 2.10 (br dd, J = 12.8, 3.2, 
1H), 2.02 (s, 3H), 1.88 (br s, 3H), 1.81 (d, J = 1.4 Hz, 3H), 1.52 (br dt, J = 12.8, 3.2, 1H), 1.39 (m, 1H)  HRMS 
(ESI) C24H33
35
ClNaO8 (M + Na)
+
 calc. : 507.1762, found : 507.1753 (-0.9 mmu).  CD (MeOH) ext220 nm ( 
-0.72) 
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Chapter 5 
Summary 
 
In conclusion, the author identified G protein-biased and highly subtype selective EP2 receptor agonists and 
reported the first total synthesis of resolvin E2 and haterumalide NA methyl ester.  
As described in Chapter 2, the author discovered G protein-biased and highly subtype selective novel EP2 
agonist 27a by hybridization of a thiazole moiety and a bicyclic scaffold of prostacyclin.  Optimization of α 
chain, 11-hydroxyl group and ω-chain led the author to identify compound 9 with 100-fold increase in G protein 
signaling without increase of β arrestin activity relative to 27a.  Furthermore, structure functional selectivity 
relationship studies revealed that the combination of meta and para substituents on the phenyl moiety was crucial 
to regulate its functional selectivity (Figure 5-1). 
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Figure 5-1. Outline of discovery of G protein-biased EP2 agonists. 
 
The author reported the efficient total synthesis of resolvin E2 by using its intrinsic pseudoenantiomeric 
substructure as shown in Chapter 3 (Figure 5-2).  Moreover, biological evaluation in the acute peritonitis model 
revealed that resolvin E2 exerts potent activity in blocking neutrophil infiltration and reducing proinflammatory 
cytokines.  
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Figure 5-2. Outline of the first total synthesis of Resolvin E2 
 
As described in Chapter 4, the author also reported the first total synthesis of haterumalide NA methyl ester.  
14-membered macrolide and Z-chloroolefin moieties of haterumalide NA were synthesized by the intramolecular 
Reformatsky-type reaction and the stereoselective taransformation from E-vinylsilane moiety.  The author 
revised the absolute stereochemistry of haterumalide NA.   
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Figure 5-3. Outline of the total synthesis of 15-epi-Haterumalide NA methyl ester. 
 
Overall, the author identified the first examples of G protein-biased EP2 receptor agonists and these compounds 
would be a good tool compounds to investigate the biological role of G protein- and β arrestin-mediated signaling 
for EP2 receptor.  And efficient synthetic routes of lipid mediators (resolvin E2 and haterumalide NA) should be 
helpful strategy for further investigation of resolvins and haterumalides.   
 
  
O OMPM
OTBS
Br
OEt
O
O
EtO
OH
OH O OMPM
OTBS
TMS
THPO
HO THPO
TMS
Br
O OMPM
OH
Cl
OH
O O
O
Cl
OAc
O
H
O OMPM
O
Cl
H
O
Br
O
I
COOMe
O
O
Cl
OAc
O
OH
COOMe
1
7
3 4
5
2
9
10
6
14 steps
5 steps
5 steps
5 steps
8
3 steps
160 
 
Acknowledgments 
 
The studies in this thesis have been performed under the direction of Professor Hideo Kigoshi at Department of 
Chemistry, Graduate School of Pure and Applied Sciences, University of Tsukuba.   
First of all, I am deeply grateful to Professor Kigoshi for his valuable advices and helpful encouragement for 
carrying out this work and giving me pleasure of organic chemistry when I was a graduate student at Nagoya 
University.  I would like to express my sincere thanks to Professor Daisuke Uemura for his hearty 
encouragement and teaching me an importance of organic chemistry at Nagoya University.  I also appreciate 
Associate Professor Masaki Kita for his proper advice for this studies and giving me experimental skills of organic 
chemistry.  I would like to offer my heartfelt thanks to Professor Masayuki Inoue for his excellent suggestion and 
giving me strategies for rational synthesis when I was a visiting researcher at Tokyo University and thank 
Assistant Professor Daisuke Urabe for his valuable suggestion.   
The investigations at ONO Pharmaceutical described in this thesis were performed under the direction of Dr. 
Kazuhito Kawabata, general manager of research department, Dr Takuya Seko, a former manager of medicinal 
chemistry research laboratory.  I would like to offer them my sincere thanks for their kind direction and 
encouragement.  The collaborations of Dr Toshihide Watanabe, Mr Isamu Sugimoto, Ms Kazumi Moriyuki, Dr 
Yoshikazu Goto, Mr Shinsaku Yamane, Dr. Akio Watanabe, Mr Kzuma Tsuboi, Dr Atsushi Kinoshita, Dr Kousuke 
Tani and Dr Toru Maruyama and other members in “EP2 agonist project” are greatly acknowledged.  Particularly, 
I wish to thank to Dr Maruyama and Dr Tani for their kind and excellent suggestion for these studies.   
Finally, I would like to dedicate this doctoral dissertation to all my family, my wife Hitomi for her hearty 
encouragement, my son Hiroya and daughter Sumire for giving power to perform these works.     
 
 
 
 
161 
 
List of publications and patents included in this thesis 
 
1) Ogawa, S.; Watanabe, T.; Sugimoto, I.; Moriyuki, K.; Goto, Y.; Yamane, S.; Watanabe, A.; Tsuboi, K.; 
Kinoshita, A.; Kigoshi, H.; Tani, K.; Maruyama, T. Discovery of G protein-biased EP2 receptor agonists. ACS 
Med.Chem. Lett. DOI; 10.1021/acsmedchemlett.5b00455 (in press) 
 
2) Ogawa, S.; Urabe, D.; Yokokura, Y.; Arai, H.; Arita, M.; Inoue, M. Total synthesis and bioactivity of resolvin 
E2. Org. Lett. 2009, 11, 3602-3605. 
 
3) Kigoshi, H.; Kita, M.; Ogawa, S.; Itoh, M.; Uemura, D. Enantioselective synthesis of 15-epi-haterumalide NA 
methyl ester and revised structure of haterumalide NA. Org. Lett. 2003, 5, 957-960. 
 
4) Ogawa, S.; Watanabe, T.; Sugimoto, I.; Tani, K.; Moriyuki, K.; Goto, Y.; Yamane, S. Compound exhibiting 
selective EP2 agonist activity. PCT Int. Appl., WO 201515129782, 2015  
  
162 
 
List of publications and patents not included in this thesis 
 
1) Kambe, T.; Maruyama, T.; Nagase, T.; Ogawa, S.; Minamoto, C.; Sakata, K.; Maruyama, T.; Nakai, H.; Toda, 
M. Synthesis and evaluation of novel modified γ-lactam prostanoids as EP4 subtype-selective agonists. 
Bioorg Med Chem. 2012, 20, 702-713 
 
2) Iwahashi, M.; Naganawa, A.; Kinoshita, A.; Shimabukuro, A.; Nishiyama, T.; Ogawa, S.; Matsunaga, Y.; 
Tsukamoto, K.; Okada, Y.; Matsumoto, R.; Nambu, F.; Oumi, R.; Odagaki, Y.; Katagi, J.; Yano, K.; Tani, K.; 
Nakai, H.; Toda M. Discovery of new orally active prostaglandin D2 receptor antagonists. Bioorg Med Chem. 
2011, 19, 6935-6948. 
 
3) Iwahashi, M.; Kawauchi, S.; Kinoshita, A.; Kishida, Y.; Kobayashi, K.; Matsunaga, Y.; Naganawa, A.; Nambu, 
F.; Ogawa, S.; Okada, Y.; Shimabukuro, A.; Tsukamoto, K.; Yano, K. Carboxylic acid compounds and 
medicinal compositions containing the same as the active ingredient. PCT Int. Appl., WO 2005028455, 2005 
